var title_f16_22_16736="Eye manifestations HSV 1";
var content_f16_22_16736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eye manifestations of HSV-1 infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Different eye manifestations of herpes simplex virus-1 infection. Panel A: Corneal epithelial disease with damaged epithelial cells observed as \"dendrites\" after staining with dyes. Panel B: Corneal stromal disease or \"disciform keratitis;\" this reflects severe damage to infected epithelial cells, producing stromal edema with corneal clouding. Panel C: Necrotizing stromal disease in which infiltration of inflammatory cells and neovascularization results in destruction of the cornea, glaucoma, and dense scarring. Panel D: Keratouveitis in which mononuclear cell clusters, termed \"keratic precipitates,\" can be seen in the corneal epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Immunology Today, 18(9), Streilein, JW, Dana, MR, Ksander, BR, HSV-1 Infections: Clinical presentation and diagnosis, 443-9, 1997, with permission from Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16736=[""].join("\n");
var outline_f16_22_16736=null;
var title_f16_22_16737="Molgramostim: International drug information";
var content_f16_22_16737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Molgramostim: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gramal (MX);",
"     </li>",
"     <li>",
"      Growgen-GM (AR);",
"     </li>",
"     <li>",
"      Leucomax (AR, AT, BE, BR, CH, CZ, DE, DK, ES, FI, FR, GB, HR, HU, IE, IT, LU, MX, NL, NO, PT, SE);",
"     </li>",
"     <li>",
"      Mielogen (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      rHu-GM-CSF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Colony Stimulating Factor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of neutropenia in patients receiving myelosuppressive therapy; acceleration of myeloid recovery following bone marrow transplantation",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose varies by indication, maximum dose: 10 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cancer chemotherapy: SubQ: 5-10 mcg/kg/day; starting 24 hours after last dose of chemotherapy, continued for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Bone marrow transplantation: I.V.: 10 mcg/kg/day infused over 4-6 hours, starting day after transplantation, continued until absolute neutrophil count is in desirable range; maximum duration of treatment: 30 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 150 mcg (1.67 million units); 300 mcg (3.33 million units); 400 mcg (4.4 million units)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10418 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AC7BEB5723-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16737=[""].join("\n");
var outline_f16_22_16737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979631\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979624\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979626\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979629\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979625\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821126\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979628\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10418\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10418|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_22_16738="Subcostal coronal view tetralogy of Fallot";
var content_f16_22_16738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Subcostal coronal view of tetralogy of Fallot (TOF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 342px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFWAegDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopaAEoop8cbyNtjRnb0UZoAZRWlHoupOpYWUyqOpddn86tweF9SmciOIMP7wOR+dAGFRXTSeFJraNWvJfLJ/hABP8AOqh0mNZMhbhk7blxmgDEoroYNKt3JEitGR/efNQT2FtG+P4e5GaAMWit6PSrRlz574/65k4q1DpVlgMjRTL3Dh1x+tAHL0V089haAfJaQnP9yR+PzNLDpWnyD95tiPoJCTQBy9FdVJoliCApm+qqTTbrQLYRhoHmX/fFAHL0V0WneGZNRkZILmFGHaVsZqzeeA9btkZzAsiDoY23Z/KgDlKK0JNIvY32NAwk67DwR+dV5bO5hwZYJUBGRlSKAK9FLRigBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKUAk4Ayam+zyAfMNue3f8AKgCCnKjMcIC30Gasw2pZsNx9a6LSoLW3TfcyIBnhMbv0FAGFBpF9N/q7aQj1x0rYs/CrEK1/dRQDrtyCa7Wyi/tJECicxjoWwoH0HSp73R7WCArCjySsOcP/AIUAUtG8PeHogHnhWTGeZpMlvotdPb6lplkgitoJLdMYxaQBTj/exWR4ahjs5MwaILmXP+tmf5V/CvQgqG3Vrh4kkI/1UMYwPxoA59f7MmUMulrI/wDz1vJyzfrWfd6YtyGFpcSM/wDzztICwX8SMV6Bp2m27R+ZMzqPvbQQv596zdcghLjCXXHI2yMVx9eFoA87i0OfTZvNml8l25HnRqzn9Tiortb55Sy20d0h/ikcAD8BXU6leWscexkWVsYwAshH61y2pLcSRlrVVWPv5oChfwFAGbqAtkUnNpHMOojQkiqtrMzAmf7NInYOBk1B9jEk25ZHeXvtiIH51KTMrAS28joOwiIB/E0AWVYkFpU8lB0ESAg02SJLiLJSbb6/Z9o/nTfIe6TjyoYx1Dr0qWCK8gO20uA6d/mJX8jQBnpbCQlEgkK/3lGKQWKQHcwnT/eAYfrW5ZqkdyDJYJczevCrW7Lq1wsYjm8O28sf+y+aAOJgMYlAlXevbZ1/Sr6w2VzmNZJon9DIB+jV0WzQ5U3T2FxZOeuWG0fjtrNuUs/m+zJ9qUdiRJj+RoAo2qLYMUBST/ejB/kajvriaOVWsrxIWznCk4/LNEnlOv8Ax5hfccYP0phF5uX5LdCPuPkigDTOpS39n9nm1GzaT/bBBB/EcVmSaZfPHhrm3KjuG61bKTzr+9Wzjn6Byev1qyiXdtAftsFuYjxviywP5HigCjb+HLK6jLM9vM/G5W+U/gRVW78HWkmTbQahHwRmPEqg/wAyKsWtzaW16RHbXCSseNrED9a6SwvruyuBcMZ7RPVkBjb646UAcLd/DzVwpksNl5F1G35GPttPQ1zep6PqGlymPULOaBhn7y8HHoehr6Fg8QWksqmaGIE9XhuAM/hTfEmsWK2m37KLpGH8JVsfUUAfNuOKSvQNT0iwu5nlW0ECnJ+TKn8q5TVNMjt3/wBGeRk9JFwR+I4NAGVRTmUjqKbQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFT29rNcsFhjZyfQVqro624H2yQeZ18tOSPrQBjJG7nCKT9KnjtGPMjBR+ZrVW3Qt85EMX5sfoKknaxt49sYJY9FHLN9T2oAowpFHnYGyP4j1p2w4LBti92PU0+3jklbIixjt2X6k1cSyRzmR2lcdk+6v40AQWsAY4jXryXJx+ZPStO3tY2YBZPOkHQIuQKdbWtkE/elm9lB2j/GuhsLIJBm3hdEI4Zvkz/WgCPSrG681Q10kAHOH5x9RXZ2sdhFDuubyTUJR0QfLGD+g/nXEyWUwuFAIjdj94gsfwFdvo0EVhbR7Ll5bk/wByHzZCfYDp+NAFvRfDep6zcm4dvLh/gWNTtUfU4H866WDw3HaDas091cH/AJZxSDr7sBxWhaaVPqWnp9uvLu0DAYWWQBz/AMAXmum8L2f9iIfLaRxnJlnRc/huJoAwLPw5q/k/aDHZ2CAZJaRpCPf/APXWHq1ppzRsmpavDeTjO1Uzk+wwDj8K9F8Ua7ay6c5Z55ccr5jHb+CjGa83tZYRI097aOqE/K11cLAv4DrQBmWekzXcLxWSRWEPTe7CPP1J5NV7rwPA8B+2arPJJ1AtZQR+ZrQ1lbTVE22cel4BzuNy2P0HNctcRX0DPEdYs/KxgrFOfyoAhutGa3HlXGp3EVsOkbFWc1nTyeShj067mVRwWnjx+XNT28dpGGllvb1Qp5Nqw+b8WJNSyXKX8IFnCZol6G9cbjQBn6fbvczFXvbmBSOWiUOW/DNTR6bZ2twxuZrueLuXgIY/gDTrSOeSdlntpDj7qDG0fQ8VBfWctlIZZEVUJzn7Qdy/gCaANSzl0t3MdvPf2iD+7E6k/mDV02Fg8TSSaheREdDK+8H8Kg025t7i2/d6mLeYDiTzWH58VDPK8kTJdatZ6lzwH4x+OM0AVb+3YxBraWC7gB5aAbZR9RVlRqUCRtDFJdQkcxzwY4+oqeyngtowj2+kBz0KytG5/HGK1H024vIllhtSePux34Vvwx1oAwrrUIriTZ/ZrIyjDPEznafcVY0yGKQGHUZ/9FbozIGA+vANPltDPIF+y6vBOhwSk6vj8cZq29nezQoHgkvYD97cFWQfiKAKV54XgjuUNjqzQK33HKiSL8e4qLUdL1fSZE3rZyiQYWSNC6P9cdPxrTl0S3toDLbRXUGfvAwiUfjtINU7X7cYpGtJWuYBw0SkjH58j8aAKJa2twYdYsLi1c/daPDxk+oB6VTuLyeJvLs7gSW7fwXcZAA/z3rdt4zd4YNMbfpIh2zY/wCA/wD6qo3dnax3O3T1tbmE8lY2KFf+AE/pQBDYaXDeRs66esdyuSDbXAZW/wCAn+VNtLn7LdMkulqpU4IRMN+KNwfwNMW3tLG6Dz+Xas/9wkD8R2+tdHaSalChaCO21C1Izsmbacf7L80Acnrt5pl0Ttja0nHSWAMnPuprmLi4lKFZQswH/LSMA59yK6zxPrC+YUurKaI/887iINj/AHZV6/jXIlba8k3wSmOUdUcUAZr2LXQJjVGI/u9fyqibFd/lvuifoGxwa2L2OSAgFypPTIyKoXF1cFdk+1wP739DQBlXNu9u+18exHeoKnuZjNJkk4HAye1QUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA+ONpDhBk1uafpER2vNmVj/AOBTNCa1ZW+1H5kxtjUcvW7tcx+dcFLO1zgDHLewHVj+lACW8e3EcTiInj92Msf8AD8KcYoY/3drEZZ2PzO54H+JpDdjaRBA0UB45+/J/vH+grodE0mOW3+16ldC0tDwNg+aT2UdT+GB70AclfWkFuxEshuLs/wAC8BPr6VHZ2qeYVcBT1IHB/wDrV6dDp9lHbNJbWcVna9ppz87f59BXK6ncWaSMun2zPGh+eRhsXP8An8aAILO0UR74LTzsf8tZ/kiX6L1b6mpJLGe5h866uo2iHSOMBEz/AF/CqLXd5fuu8kQLwI06D8K1IL+0tiGvJEVk6Rqm9v8ABaALukaddsokjtVkYfcym4L+HAH410VrpFy4MupXdvAAOWml3YHsi8frXONr814P9Ft5mjHQzPtQe5ArN1LVJZGETziVupjjXYg/qaAOj1RbGZvKsrya5fvIVwv4L6fWtrwvbakSsUd08Fr/ABTEAH8MYArzS3vAk4aaVwR0Hb8FH8zXdeFp5Jplla8llYYwJRiNB/n0FAHtXhqw0a2IFtI9xcMPmkdi5P1PQV0k9vG4AS5ZQP8Alnbwgn/vpqwfClvG1ust7dqy4yWlk2J+QxWn4k8Q6PZWDImvCJjkBNPgDH/vrt9c0AYGrHTDMyalKIHUfKJ5xuI9h2/KuJOo6Lb6jI8txAwz+7V4g35swpIRZTXTXF5PciNmJBeQSSv7ljwv607V7uynhNro9pbq2MFnCuc+7E0AYXiaWPVkP2W8sGQdI490h/8AHRgVyMjXFojxtaQmPHJwiA/rmt2bRtVtEaWe4tU3dIxI7DH0GBXM32nCdjNdFpCOyMoQUAMa88uFwYrEKegRix/nin6ZdwR2/wC/txLk/wATgfpSafElsoMIeRD3YAIv+NaBsppHEouWlj77IsKKAJrK8tt221WLzCeUkjVv5mpbq6upZljuPL8r+5AkcbfnVaayNyVWyiRsdZGtyAPxp88KWUWLnSt0mObhX/xoAv2+mpFKZ/7QS3jx/qppkbP606zvRPcPFDaWN4V/i81FP5E1R0yDTpjvurqGOM9VlQs36cVZTRdNGoLLbRrNb98RAA/ixoA2bWWfUJfLu4vKjj6KkIlX8cCtR5NCnTyLyOxkccbFhCNn6ZBqlYW08FyywxyRWBH+rWAMf8/SpoLCZmkcaLFcAfcLRje35nIoApzWWjxBpbG31KzuU+6m98N9OTS2195sRYapcW9wePJaYZJ+jCq8t5rC3DxTmSwj7QurLt+h5FTzaje3tn9mLaffS9AxOyQfiRQAy6vhJA/my3cV6OAjAEP+IrEhtrq/y9sDBMOf3kmCfoeoq7p0E1v5iapBDsHRpJiCp/A/yqjeW968+bTz3jPRobjeP15oAo3W61nBvjeQXp4W4iAYN7Ejr+NS2FxJqV2DLZ+dcp/y1jOxm99p4NaES3FrbyLPbhnYchsgn8OlUY7tbco0/wBtt0LfwncPwoAvagIWCGMNHdIceXImR/8AW/Sta2j1CeyzYywGTGTErAOD/u96dZRRX9xDd6Jqcc9yvHlyMPmPpg8g/nW7rctre2pg1nRWtb5B8sirsOfY8UAeUa9f3JlkttREYcfeUgqw9yDWCtq7DfCwP0IDfgDwfzrstQsJpZRudpUU/Kbgb+PTd1FYGsxw2TDNqbVyfmUjdE3uD2oAwbya7t18uYrLAfUcj8KyL2TEWFb5W6ANnFdGsYurmK2kltYIpMnzrhyqJgE8kA9en1IrkblleUlF2qOAM0AQ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBNbTyW06SwsVkU8Gu10rbqAS5VGkduCz8kHuB6CuFFb/g6S/k1QWWnYL3AOScfIFBYuMnHABoA7I6UjSq99MseB8sY5P5d/0FWLef7RcYswsdtHw9xKdwHtk8fgKzre4iMTG1ie6zy00zbQ/ux649hS+TLqDj7ZIZIYxkRxrtjUey/wCNAF/VtYsWbYtw85Awz56+w9vYVRWT7YivPCIbNPuqeAfw71Gzwqu+0ggigXrPKcj8PX8Kqm4WecOxku2B+VRwCfXHYfWgDWZppbfbblbeEjAKr8zfQUujaXapIZJrczMP+ezYUfXufpTPL1CYqpUwx45VRyf/AK3vWjp1/p8Evkf8fUw6gHKr9SeKAJb26i2fvQphQfLHEmfyA4H1OTWdFZuA15e2wsrQ8pCvEj+7Mf5CulluWuIN9pJFbxDrLHHvOf8AZJ4/KuY1RF37mkEkufv3k24j32jigCxbTwsweGwiCt0aRto/xrpdJ8y5xFb+QoHLeV+7QfV2+Y/hXHwQRSvm8mku3HJ3EQQr+A5NbmjNG8yxWjxzKTgpEpEY+p7/AJ0AdpprRm9RLmWPUGQ8Rxr+6T8WPP5V1WtyLc6bsa1S3iAx5kkfH/ARj+lW/C8sGkWMbCwtvNYcFgF/Ida2L7ULq/gOVtozjIMuAq++DQB5/Y2WnRJ5sti12/aW4ZiB9ExgVg6lEpvGkubELEn3RE5QD8AK7W9sYLyJ9upSX92OpjO2JPYEVy9/aXEcQ23LQsh6wyhM/iQT/KgDEu9Rswig295ErdHMe7P4tVC+FuoDWttJcOR9+dOB9O1at3dzwQrLOqz88GWYSP8AX5v6CqV1f2c0YGoXtzDnnaIy+PwGBQBlWOm3szSNHqFmnqjrwPpSwi/kV7ZXGF4LMh2H6YpZo7W6hZdOjvpwOchViH4gVVgFzZ27OImD/wB3zxn8QaANm2s5pIjBNJO2eNsN0yD/AL5Iq3bWFraoLe3H2eUHJaRmZz+fFYNvqNwwBhuHhcdVluBj9BV6CVuJ7m4t7o9ozLvX8+DQBpaldSxqiWGy6ZfvCZVLH6DFWNNXUVXzbiSNUPJgOwkfRQKqwyteSg3GhRqB9wwTsD9cCr1lpOmK8kw024nlXllNyVcfQ9aANiGP9z5rNqqQMPmMUG1f0PFPsr7SYEMdpdarGufmkldsD/vof1rAkv7KQGOHUb20t84eCc+a4Pt60j3cFj5YtJ7x2k6B/lVvwNAE+tbb6YQf27C0bfd82Rhu+hAxVaCTyD9kj1RfPQcQzkHI/wBlxVe+tLXUIzJcwyW6A53xTqMH6AVDDqq2MsUX2iS8ZT8okiB3j3Yj9aAFv/tFuTJcWME7HhZkbJX/AHgB/Slhv9QhtR5jRxNnh40XC1qB21mcE2DKBwQZCjr9Cv3hVHVo7OKfaY5Q4GCBID+jDrQAy8lu7yJJLq7stRWM8iMbJB9cVF/ZdpPlWsprYN8w8uRifqPWo7eWztiXtpkWQjlnXZj2Ixir1tFb3zpFBfRRzsM5hkwM+uAcfiPyoAxXjkW4K21o18Y+GYQ+VMB/JvxrrLPxBdxaWEstSE8SDEmm6lDv2D2/iH4VUvtO1TRWiuZp71ojx5qxrOn58GrV0yuqXV5ZxXCf891jIx9f4loA57UmkkzdaZBFBHLxLbtLvhY/7Dfw/SuW1Fr2yBeNCIW62853Y/3T0IrrtZg0+8RjYXosblx9yU/LJ7Buh/HmuRuYr6xUxXIWWP8A2GGG/A8GgDmtTvIXtJXEXlSD5VQdCT/LFcyTmtPxDcLNfFI8bIxtGBjnvWXQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUoPtmkooA6/wvfC6QW91KEWEZ3E8lfQDua3Lq+a7K20FuFt+qxnq/8AtNXnVrO9tOksRAdDkZGa7vS3fUbfzIpltreTiVx99j/dz/QUANl0+S/mEkzKsKHAaRtsa+wHU1pQ3UGnSLDZREMR81zKmD/wFew96uW8UNugFmqLKo/18/zFB6gdBWY1uqTGaaaaWRzwz/ec/wCyo6D3NAG5cSzzWDsmy3jI5lm5dvovYfWsGD7PYLvlT7U5Pyq3yr9TnrVvUZJre0D3KCIL9yE8n6kev1rJ083F1NvdQGY/ekGSfZR0oA6OK/bU4lSQpDAg5IO0fQf/AFqnMCxRY06C3toTw93KpZ29kHU1JpNjai5UXJ+13Q+7BF8236noK606JfXQBM9tbIvXjKp/8UaAOEbT45HWKBHdzyWkGAPdv8K1PD7XNtqgtrGGCQg/NO/Y+ijpWx4gtHitBDF9qMX8UgQIZD7k9B9KoaPbxWCx3Aabdn5QF/QHr+NAHc2WmyTX8UM1yto0n35gxLH+ZNdDqXh7w5p0Qf8AtJpLgfMzTEYJ+jGrHhG3ur8QvcSrY2ZxyU2F/bJ5NdB4rTQLa1VYY3mnTvbxK7f99HgUAcDOt/qBVYRd/ZRgRo7BY2HqEUDP41W1PTLqJo7ZDZMW5eFJBlR6sFP8zU+pSyxqbx3FhF0xJiSZx9WIUfgKoWtvd3J+26dFYmIj5pJsb2+pHH5UAULrT7O0m2pbQ3twOojiBC/rj865u70fVbq/N013HaWqnmOR049gq1ueI31qeJo1uXtIF6paRgb/AKnOawrnS7+TTBOmiyuic+fc5TPvgcn8aAIdW1GOGERxx267fvSMvJ/KsaHXIpHCxSyoM8nyyFP5ir0+oTxWaxyBXmf7qgbMfiOafpniAWDCPWdLuLpW6GKViB/SgCa28SpbDZLZWsi/89GhL5/Srb6u2qIDYqUKchVtlVT+XNQ3MsOqOTpWlSWyd98xw3tjjmpEsHsrRnj028snI5kMnyn6d6ANe2vHuIFe4hmWSL+4mOR7jmrEd/b6wQZbgWc8XTKb2I/HBrJ07UY2iW2Ku7MfneV/N/wxXSrFC9mJ47qOJI+oZhEze2McigCtGYdYlEFvNiWDnMykK31A/rVi813WYSIILCwZF43bFkU/pxWQbr7XPIdO09rhoxyM5OPoCMin6cniWQtLaWdhFB3hyY931HrQBLp72M8ryz3SWjyf6yLy3C59h0qxAkC3qyaa0UiL6QsoP4jI/OucmkntdYdrvS7m1cjLxqGlib3B7GriJavcrf2t4Ip1+9A+VYD2K/1oA09fmjiidr6dVlX5lXv+YAqjHqseqfZzNcpIsXIEgww+uRyKQTJZ6qJZJp7uN1z84Lun0/8Ar1iatIksklzEsk9ujZYbDC6/l/OgDpFXT3uZZEeJkxyYnbj6/wD16xX0yxvr1hp0Vut4OdkoCbx6gjg1V0/ZDbm8sLm5Cn7+4Kzp9R3FdOPCn9qWEV5HcQNG43M0Qxn3we/0oAzotW1DSLpbW3kFtO/Bjly0b+3oa1/7ZmNq6XMttZyEYZTnyvyI4/lUEMGp6NMlvbmG5s26pckPH+IblfzqLxLcXGl26PHpMaWknLKsnmRr9M8r+eKAMB9Lng33UtnDJbufmMREkLe/t+lc14nvdOs7CV4I2huAMLA3zxsT0KntjriulvL61jsvNsfMsblhysZKg/h0P615j45vYZdUNtZSyy28eGZ5VVWaQgbuF4656UAc0xJJJOSeppKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArY8PaktldbZcmCTgjONp7NWPSjGeaAPS4pJoykCW5VW5Jc8v/wDWq1Opss3FzLsfHyxRcO31J+6P1rH0XXLae4uUsLOWKUt+4jkl81ljx03kDOOecdMVq2umNeObi+bztp+WJOVz6erGgCG2S4vz5pVMdFzyF+nqfeormz+z3Y89pJ5P+eURwB/vN/QV2VlprxH/AEhNsu3iEEZRffsv481Euk3d+5SzEaR/xTYwgHcjufrxQBS8P2MsDm9kgKQp0iD7V/Gu88MXb69PtjmKIpx+6XCD6Hqf0FVYPDkQ00BissKdXmbCMfYDrXW+DtAvLkqZ7djajhI0QRxj6jgE/XNAFPXdHsIFXfdidyfmJO8j2AHH6muq8LzkWfl6Bo21kGGu7iMEr7/N0+ldvb+GIfKWNLaHcRhmzkqPrjj/AICKtXY8PeErYXWp3kVsqr8gllxn/dXqTQBneHNInuZmutVsZ7qVek92459kQdB9azvHN3bW9sYbrU7fTgeFtbJVeZ/6CuN8T/Gi6v7iWw8O2xt42yvnspd8evoK8vurrVNOu3uIXRrqbq/lh5f6mgDtb9tGgeJ7TQRc3ZOfOv5FlP4gnArdunnvdD2Xs9oibf8AVWZT5R6Z6CvJ2sG1FluNS1C4nlzkQLEev+0zEAU8WlnaobjUr7T4baM7hHbuZJW/XGfwoA3YI7fTZw+nTTTXG4tmZt6p+OMUmqXesantTUmN1ZtwCZyi5+g61zuoeNZtUt/sHhbQb66YcCabBx747Vgta+JRKGu/OnuBysbTAhPouaAOxTRJ45ClxCrRAfKsahiPxJFW4NN1ZrOYGa0sYB9398u8j3C5xXn1r4j1i2kltmjJb+I7en61S/tpBOVuiyPnOFk2hvrigDum0S8HM2pTsD0EUY/m1Os9LubaTybzUmuYpeAsyo+0f99Vymm6qt1Izx2ULy9EaQ7x+Wa7jwxb6i84ju9OtTGwyHniBXPttHFAEdppo0l5U0+K1uI35dZHEf5LmrrWM0tiZLXT0tP75vU3xD6HPFJr3g2Wa7S51C5s4rVuAsSuVT+oqjqNi2m23l6dqAkiUZYxsdpHptagCKONLBCGaCKZv+Wtu3y/gVOfzqe0u7yVdtvfQyyqcbgMN+IbrXMXcha3DaeZY4W/1u2NN5PqCKqae6m8Xz7hpB/CfkbP+9nkUAej239pzrn7fqVzGww8ccKlE+lYWr6VY2ztJbaion6uXfyXX/vmqF1crHcJPYyS2jnhzEGCn8siqc2mpc3Hm/2k/mAbzMZGKt7HPIoAt2uorBMAt/cSXy8xOWDq3tnj8jU6eIpFlzqscRkc7THLCcfUNTNK06eVlJuLaN85VZFG5sehPWnM91a3UguVzATteNGVmHvtPGPpQBceOxWTabdo0n6PACNpPqG7e4NVtQspdHZLeyl1OJZuQsx2xN64bp+FWlhuEjS2Yx3mnseHnBjKexx0+tRapBcR2R06EXDQP8ypJciRP+AP/Q0AV7fTpZ87J41uQMhGlySPoetTWFyt1ZXFpc3TxiPKuI13op/2kPI/CktG0abTyrxKmqRDBjkO0tjuOxP0qpHHa3Dmd4HgucY3xvgN7bvX2NAHN6tdHTbK5BuYbm3QEoyggqewx9a8wkYuxZjlmOSfU11fj6/V7tbGF2ZYjulZl2sWPY44OB3965KgBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAsWVzJaXKTxHDocj39j7Gvd9AeTWNGtbrRZIbK3cYkmY5kDfxKP7uD36kdK8Artfhf4ii0TXo4dQfGmXJAkJPEb/AML/AId/Y+1AHstvptlp1vund7kE5aSbKxk+y9XNblrBBciNbwyQ7sMkCr82P7z9h7Dmur0nR7CDbeai0MtwMYaTiKHPpnv+prprP7G8hksh5oBG+5ZMAH0Uev60AcjY+CZNTdZ4xKsaHia6JCj2VOp+pr0TQPCAtniuL64luJoxiFX4jj9wg4z7nJrRtzcqyS3QjtLOMfIGO6SQ/Tt/Ok1q/u7W0luzLHa2yKSZLn92qj/dHJP5UAQ+K/E0Og2wjZw1wRwq9R7nsK+e/GfiC0udVM9wILeY/MZpU8xgPq3T6AVzvj/x9Pd6nctplzLcYJHnsmFP+6v9TXkV9dX2oXbTXc0kjMc7mOfyAoA9R1nx1p9snkWQupEH3pFVUL/QdvxrmJfGNxcI62UbWNuT85Q7pH+rn+lcq0T7eGVT1Jbt+HWoJGTOFeWQjvjAH0FAG5d+IJJiAschVecyt/Sp7HxP5RDJp0eAeXKBjj6Vzf2hUYKsUYcjln5NPhjEhPlysx7gjAFAHp8XxKZtONlYSLpiEYZooFUt9SBXPw3tw92ZIQLiQ9ChKn/69c2GkRdiWg3dPMLcj8K6nSi2nW48rZ50g7L5sn+AoApXlrcSSn7T5sTt/wA9XCj/ABNdj4a8H6V4gsDZTXUmneJvNzYyXQ22N6hUYhD7cxyZBwTnOe+cKugaVc3eXuLgyI/GJ4QT+B7V3f8AwjqxaGbSSyub6KQf6p2LA/geAKAIfBPhCNbie2vLS1tb+zO2ezuFzNGexPYg9mGVPYmus1fxD4c0VBY3MEMN9tG0xXIBXOcE+nQ1ykWq3X2JbXxrb6lbWFtlLHX4pN95p4P8Ln700PTIOTgc5wCul4n+E89p4Cu9fu1tdT1u0ne5eWDLi5sdihgM85ABlA5wcqCc5oA5jXdZ1OWF7m206a7gU4+0NdCSMD1w39K8u168vBcCSe3YBznlunuBXQXekW8OkLcQvcGLOY5UdgrA/wCz0x7itD4QItv8SNPlWW4RxbXjGWNizp/ok3IyRyOwyOe4oA85hvW84ok05Vjleg5rT0i8eGWVLq0SYtzg7kY/iOCa9RvdfittQ8CXl3eXes6JdxXFjfazeLiaVJzskglGWwYgdwBZvvZBxirXhTR18La7oHhHVI0e/ur65vpoph8snlLJFaKe2GdXOD1Eg9aAPN7O6KXW60a+tFfoiqrZPpV21vls9ZgmvminlDjapfB+hXtXoOhaxr2p6H4mn167vDJYRrJFLIWWSzvBKoVYj/Bld+UGPu9BTfH2s6xPoPhm3uJ9V1CK603ddQi8fE/7+TllJwzcDkjPA9KALd1qFtc3VrLrMcKadjCKyKwU+5HzCs6/s9E1K4eQwTWyQnpvLZHqhPX6GuR0hJNUv2t7OQCOAZFtf7geO2RXSC+1WERxeTYQZO1fMbzoifTP3loAh1TSzBIlxZXUeoWmOIgDDMv4Hr9K5y+djcZt4GZCcsjSCKSM+o9fpXU61PLqNg1vrcdtYzDoEuCAPdcjBH41yr6GLdY5WnW+gQ/663mBkT6qeaAHwXFx5nlG5tr21fny7mNdyH6jkfUVK+oQaRBc3okQwohMtswDBvYMOvPHIqrpN/FYX8rXtk7WTHa7iPH4lT0/Csb4xXWmRLpdho6x/PGbidwPnfJ+QMenTPp70AecX1y15dzXEgAeVy5A6DJzVeiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApe2KSigD6j+DHjiHVfBdpp/iJoGu7FmhtXkmRVaFQMsyg7y4zjOORjng16hpkn9s3ts63FxHp8RxGiL5YkPsPT/JNfDWi6jcaTqtrf2ZAnt5BImehx2PqD0NfWPgnxHd+OLOB9JbyYmQG6mf5fKPdOOw7DjNAHrmu+JYNItStgn2i4Ubfl5wfQt6+wrxX4h+IZ7yMjxBcXE0h+5Y23RfZyOB9Otb/ibW49Ht/K0uB52j+X7Q/3nb0jXsPfrXD6rbpPpb3viq/XSrUj/j3hIa4m9uPug0AeM6w7z3MsiKEQHhW6IPpWObgLkPLgngleprb8TX1ncMY9Hs2tbNT8u45Zvck10fwgsbabRvGlzM2jxXdva2xt7zV7NbqG3ZrlFJKmOTGQSuQpxnnA5ABwgTcgkYnyV5weM/WntcIybQqr7AV7DceHY7v4wX0dloAuY9D00XlxZW1mGhvbhYlAMcK5HlSSshCjjYc47Vxfxf0mPw/43lcaW1hbajBFqMFnLEYjCJV3NHsIG3Y+9cdttAHNW9u/DRjfI3ZedtXBBNGvlypEisezAE/1rOinaeRQE2r2CEgfjV+3svNniETxSybuI14H4k9aANAW89uIol2xrJ/tDpXoXhLwpmONpAxhfl5JXbn6ADNWfh34RS/u45ZpbQSL96KZ1CL7kn+le1z6HaaNY/btS16GCJB8qxhVQ+gyetAHP6P4W0mwj3JbW8TEfLKysQT9XNZGqyaToN/Lc6pcRksuA1s7MVP0PyimXvj+aKGQqk93GxIR3UKuPUGuE1jxI0rBvt7wQyZLJKPNLH6YoAG8V3djrsN7Z387JC2baO6s47iEnPDbTg7vRgQRXqmk/G3X7Ty08ReF4ryJxnz9Om8psf8AXKQkf+P18+anqLTyKbFRclTk7mOB+Ham3c920kN5MbePYOizZP02k0AdNNqNjP4j1HTNHS7h0iR/MsoryMxvAr8mHqRhTnGCRjFM1zTr3QI45jZ31hcMrKl1b3LgOGBBHHIyCQeeQTVTTJLnUI0dprUsxwvnOFC/TnrWr4hutV06wQajcXU8OMYM37o+mOTQB5nLdXEVp/Z0Ek7WTyiV7YSt5bOAQGK5wWAJGevNGr397eXP266vbm7uQAhe6mZ5ABwAGJzx29Kr6pcwXEskqxmJmPQSk5rNVbmRt2GGB/Ec5oA7uz8TalqunpFreqatdGE/It5dvKqjH8IYnFXMT6nJBG97eu9un+jA3AeNVyTtwTlRkk4HrXD2M8yckIVbj5SFx9a6i00e5azkuYpSkicOIgWOPw4oA6m3smnlhlnlEDZAeQZYofqeR+dX7iwvY9Ua3kZ54pI9ylR5iuvrjOQfcVz+m3n9nRrHOZ4UkHEu7gn3DZFa/hjxAW1FIwIDNbnMUsaEOB7AHH5UAadnfxWMElreWz3yr90SEOGHoGOCD9az9Zu7S1MF9aW8qxD/AJZsfmX2Pr9DXof9mW/imza8822cgfvY3Ty2z64I/WuFvtNaG6eKKEbF53l1eM/4UAUhrektH/aADRLAhkdHG5WA/hI9+nBrxDW9Sl1bVru/mAR7iQvsHRR2UewGB+Fd58ULzSIbWG10yzFpqE5zeCGXdC6D7pC9mJ/lXmp68UAJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUtJRQBuBE4+RenpWNL/AKx/qa7FIIsL+7U8DtXIXIAuZQOAHP8AOgCKiiigAooooAKKKKACiiigAooooAWvS/gj44fwvrv9nX1wY9E1J1ScknbE/RZOOeOh9j7V5nS0AfXnxK1zStJha2t8zXm35mQjKj2PRRXz/q2vTavMYrWMKO8snIUew9fc1W0vXG1HR0069mSJLcZLY+aVe2T3xWYczSulpu8snlumaAIpWjhlKmQy46v6/SrVtrmpWem6jZWbiCx1BEjuU2rmRUcOoyRkYZQeMdPSpbOxtgWkmkDso4C9F+prMvmDTYhYyAf3RhRQBq3fjHXLzQV0i5vfN09Io4FQwoXEcbMyIZNu8qpYkAnA49BVKbU7zU7DTrG9nM1rp6vHaKUUGNXcuwzjJG4k8k4ycYqpvZE/eYVR2x1pIrmWR9saFU74HJ/GgDWtfJhlVVYyZ++7Hha39MgF7eRf2d5zSBgDiMudvqOOK5qycpKm7dtz9wjqa9O8FW8qI19d/aGgH/Lvajdn6t0FAHrPhqex8L6dEx0l9U1KVcqs8mNvuc9KzPFfieI25vNTEbTyfKI2KpFH9ASSawNX8R6TZWcUurBDI4PlQOWdwPQnAUVxup+MfDh0iaGHQEe9fP7+SYkL9FHWgDbtNZ0RmmOoa6+HXAiggd9vsDwK5SR9JW/ZhfPbIGyskq72Ye4zXKT6i89qbZQqr1JYc1mSf6OCRKdx6Bh0oA63Wr7TWuS8FwksKfxhShc+mK4/ULi3nvS1usqIT91jVUs+Sz8j0PSgFZWAVCh/2e9AF5pEU/Ngj+6DmkuLycx/flZP7p4H5VUaN4Dzg5/hzzUamQHqUB7GgCwkwk4lLqvtVy3t4J22LKqHqSSQKzxExB35KgdR0qW0uHjcKzER9Pl60AddpPhX+0LhUslkl+X5iGGAfxqxDFqui3skTyNaxR8MQ4wR7qetW/Ci6Zd+TG2prbyOCGjYsu/6noDWxq+lt5NgtxqDR2Ec+y9kSEXXkRHgSEBgWA7jOcUAQaZNp99bz3FxZxtdopwv2hofMHqob5TWVY2zWs76hDE6QZ5IYOUr2mf4D6/Jo8UejaxoV5bOokhlJlhUg8hhxKMY9K8l8deHdX8FapFpes/2Y93Ou9o7W5EhA45YYUrnPGRzzigDpfB+qT2ckkaXhMUg8xdiHd+H+TXSawbOeIXkl80PlLuaYw+XtOCcOAMc4NeY6Bq5mlit2iQyxnMfz+Wy/Q074jeNdaTQptElkMdveNlo5U/ehFPc9CCe/fFAHmWt3x1LVbq8ZFTzXLBEGAo7AVQoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClpKUUAelR20OE+TsO9ed3wAvbgDoJG/nXrcVpFiPO7ovf2rybUhjUboDoJXH6mgCtRRRQAUUUUAFFFFABRRRQAUUUUAFaWhaWdX1BLRLq1tXfAV7lyqkk4AGAeazasWN1NZXcN1bNsmhcSI2AcMOQeaAOzms7L4feI7qy12003xDMbRozEkrhbaRuhJwMsPTtn1rnvtqvD8qopI5z0H4VlXE8lxNJNO7SSyMXd2OSxJySTUlg8SXC+eu5D+h7UAXPPVotru7knoOAKbhzypKIOc5qe4tgvzSOqD0ohKFcBsj1P9BQBTaMSNlt3sWPWpIldI8q469R0/OrE8WMsvzE9z1/8ArVVaJSQZXCjsBQBq6UtzdzpBbo8krHAWMZJ/HtXr0OmPoOk2kWpBjK/3YI23MnvjPH1xXm3g6GMP9oicQtHwGJ+Zj7AV113d3VhCHhghN833mLea6L6nPAP1oAwPHuoTyP5EMTImeHk5Y/TsK423MYICGRpP4vat3WNRur4yT3CsZM7Q0hGR+VYclvHbfvWlQ56rjmgCZZssUVWZT0JGM1RuA3mkMCGPrVwmMRCWKVUlHRQOtQzzPKo3gbgOvegCrKgDDzGPrSs0eRsZgo9B1qT7K7Lk/Nnpt5/On2+myyK24FdvXIwKAK4BfJY5X1J5pGbcQsa5Pr1r07wB8P7HX/Cg1ObSPEGq3B1ddPZNKuEjWCIxhjM5aF+ATjkqPcVQ13wbpdroer3fh/UZNQm0rWW0+WRCGSSBwfIlUAZGWR1PJB+XFAHAGRo2wcqfQ96c0gJycqexrpvH2hRaF4kuNLtnlmaySOK6kkZW/wBICDzguAPlD7lA5Py9a5fAfgjI7HFAGrpd9cW5K+WJY5OM4xj6H1roLS+u7aaFbKRoJpOrnCbh754JrltOjndiIeOOef8APNdhosVr5VvFfDz5nkG2ME5B9f8AJoA9l+DXxSufCOhal4c8ROqpb2k91pE0hyoZEZzASOxxlfxX+6K5G7/4RL4mXJu7to/B/jCdy7SysX0y+kP+31hYn14/3ia1bvw9oNpapLrKAS7d8cc4YD8Af6GvNtSubeK5uHt1iniOWwpO3HoQaALvirStU8GXcVh4p0hombPlydVkHqkg4YfQ5HcCvOte1E6nqMkxaUxKAkSyPuKIOgz6V3+k/FLVNF0dtIu7Sy1nw9OCP7K1FTLDHxw0ZzujI7AHHoAea8uoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApR1pKUUAe6w2aERfO3Kr/IV4pqwxqt4B2mcf+PGvoG3ssiH5/wCFe3sK8A1obdYvx6TyD/x40AUqKKKACiiigAooooAKKKKACiiigAooooAKKKKANOxkSSLyym6cdGJ4x/jU7QiNlaQjrkqOSfr6VjqxUgqSCO4rpU0SRrh7aKaK5CkAy20nmIxwDw3pzj65oAgl2yrlicDoi/1PYVVhgkkYN5RaIHlscf8A167u08INLZlYwfMxzk/nnsBV7wx4Yu7y/j09DFKGGW2HaET1J7D3oAueCnlj0yR4tttbKMFo4VEjn03t90VQurTTvtEs95fwROeRBFN5jfVj610PinSrSxaKztgbyJfl8pH2oT7dz9a871VbaKV/sdpAJhwUh6J9T3NAFDWLiB7hktIJCinG9u/0FZWB5TEyR7vQck/U1ZnNwUKiHjqx3f1rO8smXBAIHYGgCaNQZB5Sh8dQO9XLVW+1J5oR1PYdh6VRdAuXJSMngIpyavaVfXFs+YHMa5zkDnP1oA6qIfZLHzomAtZOGRXDfngZFPsb3RpdOlS7EsZGQuyRo/wwBg/iaw7jWrieYM8ah85ygBZjVpdZkaB4SkSxyD51aIZ+v1oA6iXxLpug+GrPT/DVzcQXtvqa6vHdFskOI9mzbjn+XbFUtF+IWnaF4t1PVrXwzCdO1GNDPpbXJ8kTpIkqyKdvCiRAwTnAJXOK5ZtOiutjWySGIff7lPfB7VLb+Fru6hmmjkS4SIbv3DCQfiO1AHP3d9cXFzcXM0plknkaSRm5LMxyT+ZojlZ1Bi5b+JcVu2miJJamW6l8li2Fwu4Z9DjkVRubZ4mJgx1wGHf8KALWlidleVLWXyU5dkG4A+px2r0TwzZ3Tac0kFiLmEAPEysBhu4Ge341wmjyGFSPJljc/eaCTBx3wO49q7aw1u58tU0u/wDtNkyeXNb58psfT19xQBX8Yz3EiLaB3Td87WssnmNEe5XJ6VydvoU0l8scJ3GQMyYcICACTksccAHiuj1UWaalGk4kijCgs/lneh9z3rl/GEH2WMf6UsyycKuCp9clen40AcvfSrLcu0YAXPG3ofeq9KetJQAUUUUAFFFFABRRRQAUUUUAFFLSUAFFFLQAlFFFABRRRQAUUUuKAEooooAKKKKAClHWkpR1oA+n7ezfbB86/dTt7Cvm7Xht1zUR6XEg/wDHjX1Na2kmLf7v3U7+wr5b8RDHiDUweoupf/QzQBnUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdB4O1WLTdUQXeTaSkK43YAPZjjsPSufpQaAPoBbu2m02eKzkaWTHSOPduPYemPQVZ8NW75W31G8+w7WDXBYb5JD2XA6n26Cua+B09prUraLdKzXUZ82Ieb5fmoO2fUfy+lew30NhBdlNPtIrm5VdspiZvLT0Bbv+lAHkHxIkK68qW0kgRxsCtIN7f7wH3R7VxTxC0MwQjB4JXBAPtXonj7Qp57+V7G1E+0ZdoRiKI9wT3NedGZvtAWVFGxsIHGB9cd6AFttBl1kA6ZHFHGn32kk2At7Z61mahax6fIYbhi0w4+Vsr+FdhFF9rYRSiMgDPmyfIce23oKWysPD0tvcJfQ3U94G+RYcLEo/wBpzk4oA86cIoDjPJ9aV7gyqAF2ge9a9/BaG5MdpLC+TjeoJA9gT1rMv7JrSQKXVye69qALGk3otpUYmPcrZBIya6Nrs6lKkZPmNKcKCAoB/CuSitmaAuwZf+A9a2LC4aKFYWiEZHzA4wT+PWgDotGsZYb7Of3jHY+4EhR9Txit+ytLK3vXm+0FVCESMuQEPsy8c1yS3c4KRhriO1kb73LL+Zq1bzJ5cglcrao/3lTBJ7E80AdZp2ntBp66o11bSK+5G8xBnB6EHsfrWA+iMtz58bpKjHIEpy5PsR2qTUdQla0tZTJ5TDhNybkl9sDIH41m6lq9/Inlv8kca5dLeMKMH1I6GgDqrKLQIlLXEkWnSqMsAjGRT6gdDmqm6ytQJ5bkA3BIiEMQjP1I965bRPE11o2rmS2n3RTLtkMyiQMvphq3IbzSNRt5DdXFvDKSVBnUkhc/wlehoAxr+W3nZjPqk/mbsGMjPy9seprk9Yuzc3AUP5kUI2I2MZHrWv4o01dOcPbXQntmP7p0JIJ+tcyaAEooooAKKKKACiiigAooooAK6LwAl7J4rs10rTotTvPn2W0luLgMNpyRGSA5AyQvcgVztdL8OUhl8aaXDcadc6kssnlra21x5EruQQu2TI2kNg59qAPetPvdDtb7TG1PRdA1DRhp15d3eoW+lJCSYnCjdEw3I65Csg4y4xxk1pprPhOS9tdMj+GynXp5/I/strWBZUzGJEYsfl2snOe2DmuET4oeB7Vbe3fwlqsn2QXER86+EhmE3+tEpP8ArNx557gEdKbo3xT8DaLc2Nzp/hbWFubOV5op5L8O7MyeWd7EZYBeAD0oA9H0LVfh9rXi2TQLXwxpYn3SJFMbWIiV4/8AWAqBuTHOC3DYOKyLvX/COkatrVlfeC7a/FndTlpILCBFt4I3jQ5HVgC45PJzjFZq+PtD8O3S+KB4R1WzF8omjUarH5Tebu/eLB2LbGyccHPTNZOu+OvCFvcXNzq3g/WY5NetmncjUUIlhmkVywwPly0Q46jHvQB6T4ubwj4Z1OOzl8DWt8DZPqE0trZREQQI4V3YHnAznj6Vnxav4Mmt9Ru4PAUEtha3QsYblLSEre3LECOKMdcsGzkjA7815t4n+LHhjxN4pstQ1jw/qM1jb2LW32dbsIzOZQ+SR1QgEFT1zV9vi/4KfR9Q0pvCepGwvrlryWP7WoKytj5ozj5MYGMdKAO0u/EXgaGzkkg8Bx3N5bRTzX9lHYxCSwWFtjmQngjdgcfWnHXPBUek3+qT+A7WDT7W4FmlxLbwBLi4JwI0PbjksflGOea8e8Y+PfDWqaXpmm6H4dn0+3h8xLi5kn33Do7At8wIDk8n58jODXVD4u+C/wCwJtFbwxqz2E05um3Xi+YsxwfMVsZVsjIx0oA7fTvEPgDUbzS7a08HWTm9ilkZ/ssIWJoyQ0a5/wBc2R0TOQQe9eS/G6+0XV9L8L6p4f0W30iGdblXiiEe5irJjd5fQ4P3TyK3F+KnggNpTSeGtdmOmOZbcTanvHmEk73B+8wzweMVwPxF8SaDrsWnxeHNLvrFIXmmuHvLnz5J5JCvzFuvAUCgDiaKKKACiiigApR1pKUdRQB9jWkMu22/dt91P5CvkrxLx4j1XP8Az9y/+hmvsi0Rttt8rfcj7ewr458U/wDIzav/ANfk3/oZoAy6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC7o2oXGk6nbX9m5Se3cOpBIz6g47EcH2NfYfhfXNP8AGnhnT76KUWdtN8r2kAUSNMPvRoo+6oP8R5Ir4vr0r4PeOo/Dd8ulakRb6Jfy4vbqAYnUEYUhv7o54GPvGgD27xrpDXUX2O3L/ZYASbe3k2xofWR/4j7V4rq1zY6bDLbQ2f2ifOZLp1JOfQD0rtPFviO3tYLm30aC8NuGwrbt+F9SenPrXnMqz3cshtyYywztkck59h1JoAdDqEFnFBO8AklJ+RWJYD6qK1ta1bT5tPtYbOEtM5HmLuESn1+Uf1rnbfS7kzrE81s8rnlSSCv1qnqunSQTsBLGiJ/Ep/rQB0mt3GmG3WK1sbW1eMfMSGZmb6n+lc0YLlWZTECkvOAMk/4VSMl5bYaNWZT0Zvmp8eqsAM+Yr4wDn+lAGlZXVssyx3ayNGpG5E4OB6E8Vo6vY6Zrknm6N9os1VMsb2YNvPtgcfjXIySMzfvSxB5JBxirltqLW1vJFDKQr8FTzQAqJq1ksi2s07QD5WaIFk/Gqct9dSSgSTGQ5+mfr611fhXVvJMqNr0ulxyLsZFi3q49D6VR1bw+v2rzbTUoLqJ/mEiDHH0oAZc67FNYxQiCW31EfK8qyZjfHT5exqew1WeEEzO0UnH7wHch/wB4dKox+HJZzuhuIpFJAznBU+hHX8qsQeHNTjgkaLEoJ2NGsgyD6EGgDN1WZJZGLiJZyxJaLhTT9H8qa6toDMsQdwNzjI696o39hdWMhS7t5IGBwVkUg1CQ8JVzwcZXNAGl4tVbfXbu0gnE8NvIYxIgIVyP4gD0zWJSkkkk8mkoAKKKKACiiigAooooAKKKKACuk+HOp2mjeO9C1LUpDFZ2t2ksrhSxVQeTgcmubooA9k0/4j6bpug6ZBEYbmTT7W3ljge1Hz3S3js+Xxn/AFLcEnHOK0NE8ceEdN1ua1sbyWz02yFpDZ6hNp63Mt1axyM8sLqQNpZnyGx0QA14XS0Ae/XHxD8HvJZNLIZjHPGVY2Zf7OR9oxKAwwwRpI229/wrzz4w69ZeIPEOn3FhqZ1UwadDbT3htzB5sqltx2EDHUVwlJQAUUUUAFFFFABRRRQAUUUUAFFFFABSjqKSlHUUAfdlkTttOv3I/wCQr4n8Wf8AI1az/wBfs3/oZr7tsfu2n+5H/wCgivhTxh/yNut/9f0//oxqAMiiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKUUlFAHrPgL4gXKaTBpV1b2cv2JSYWlUDcO2R3IP44+lOF5Z31/dXmqzeRIQS5j++49M9FH05ryu0ne2uY54j+8Q7h/gfavRILu31N7WXT7KB0K7pFcBUiYdQfX/CgCeOys5XF1FIsdkerP8o9lXPLH1rMWy0+8uXVRcuxbCgEKB9B/U1ute3kxkaTT7fy4lOHC9R6gnG0U3SNNguGMuoW/lQx4YSFiqv6KFHWgCjfQWUFh9iETxXwO0OPndh14ArGuNBhSztpzNI0rHPl7OAo6kmu9eews3Sa5iiFwcrDAsXlIY/7zfxH61DBeaTdy3D6itq0Tnd5cRYrE3T5cct9DQB5v5FskkwA3KTxuBDA/Wo4bG1kt2lkuEjOcfMDuB969CksVnuIAibrO4yiu4UyjHToeM1DJ4T3CKWRFcSybETIJY57/AIelAHDWFjB5m95OD8uf4c+oNa1tcQWc0duYESJsgyFeSPY108nhO9lAtra2u2nRmWOEwgDHZj71R1Hwv4ng04xrpl3LaLwZFtmKp69utAGRdJpdtfI9jcGNY8M0qqxG760+51qe9uVh+1uwYZjfYMhvXJ6/WsGe1u5J447hJhEW2Z2kHI9qWR2t2iAbaeVyhJxQBveKtWTUbSzjv5JZpoEKGWUfeP171x2pPGZVSEkoFGc9j3rXvXnsWR5TvBX5Qy7hn6GueYliSeSeaAG0UUUAFFFFABRRRQAUUUUAFFFFABSgZOBSVZ025NlqNrdhFkMEqyhG6NtIOD+VAHWy/DrU4NVtdOuL3TortrU3l6jSn/iXRDBzOQvBwynC7jzjrVa18Aa5deKv7CghWWXCP9qjDPAInXckpcDhGGCCQOtdxq3xP0fU72QXcOqXEGoxXEV5eTBDcWsc23MMPOGjQrkbiM5PSrOg/FfRba7ZbqDWbW0tHjNs1m6B7tI4PJVLkEgEYAbAyASw96AOC8U+Ab/w7osWpT32n3MbNEksUEjGSFpI/MQMCozlcnjOO9cea9X8cePtF13we+nw/wBq3F40drHDFdpGILExKA7xEEtl8EHIHX6V5Q3WgDqf+EKu18Hw+IJ9Q02COdWkt7SWfbPNGsnls6AjBw3bOcAnGKq+K/Cl/wCGtUs9PvJLa4ubq3juI/skolUiTO0BhwTx2yPet+w8U6LB8NLvRLlNTutQlUrFBP5b2tvIZA3nxMfnjbaCpUcNnJqxbeLdGGsaTq8kc32nRNEitrSGWMFZb1MqrHHRVLb+euzHegDjPEujy6Brl3pVzNBNPasElaBiyh8AsuSBypJU+4Na2veB9T0TRxf3UlrIYzGt5bxSEy2TSDMYlGMAsASME9OcGuZnkeaaSWV2eR2LMzHJYnkk16rP428N6vMV1GC9hTVbi1uNXVlDRxi2jZUjhwdx8zOCW+7noaAOdsvhxqdwtu017p1mktrFcF7mRlEbTbvJhbCn944XcB0wckisW08MX8x10XHl2n9jRs9355xtcOEEYxnLljgDpwea6vR/Hlpc32tP4niu/J1C9h1FXsgpaOSEt5cWGIGzDbc9QFHBrP8AF/ii11HRfs2nKUm1O9m1bVDtIHms7eXCpPVUUk57mQ+lAGXZeDdWuvBmoeKPKSHSLN0i8yUlTM7MFxGO+M8noPrXOV6LZ/EZpPh7qPhvUrC1lf7HFZ2Myw/MqibzG3nd2ySCB1xXnR60AJRRRQAUq9RSUo6igD9FNPVdtn8q/cj7f7Ir4D8Z/wDI4a7/ANf8/wD6Mav0O0+KPbZZRf8AVxdv9kV+efjfjxpr+P8AoIXH/oxqAMSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACt7wpOYJbuQX1taGOHepnVmLtkAKgAPzc55wMA1g0ueMUAejzHUZ5Ui1SOaaMncsSHDN/tHtj61YmeMyGaNfJAXJeMklfYf41yWj6o7osVzP8A6oBV3seV9BXUw6iiWc8OFe1dM+ZG21i3170ACaVLq9u1yssgjfku5+9jt/8AWrK1CL7PMVtizRqgBKLgE98j0rRXW9Rh077LePCbfAYrDgui9t3oPasuXC2aiyNyLyWT5nPKuh6Y70AXrG+eO6dL91tgxDBUj4c49PerkV/PJewyyvBOkH7wKXIUexA61l2aXJVJb0pNFE2dzj5vTkGrVpdrHeXMRNvZl4j5WRkMPQ/X1oA7G58f2bWX2eTRkM5mDyS7irKPRT2rqfB3joTzNBH4m1zTGDZVZCskTLjgY9a8UuL7z7bbKFzn55XOcDPaor9JPM3PKJo3AQGJ/mPofagD2TVdc+ya1I19aad4ggUhW3jyZUU5JGOmT6iuch0jQfErzyaXfQ6bduSXsJxypHTaT1/OvN/tEx86Gd2klAC7d3JA6U+S7W1h86RAznkYIOPbNAB8RLaHT9eawhjkjlgiRbndKHDy45YY4AII47VytSzytNLJI5JZ2LEnmoqACiiigAooooAKKKKACiiigAooooAK6r4X2lje+OdNg1OOGaBjIUhmICSyiNjGjZ4wzhQc+tcrS0Ae73ng+TX/ALFd+Jo5bm/XTpJzpun6clhfO4dE2sDwyxg7g23lV/GtbV/hz4dtoks79dUksLC4a3t1haNZMyXccXzNt5+/k9cY4r57e/u5Ln7RJdTtcbdvmmQltuMYznOMcfSlbUr5hhry5POeZWPIOfX1ANAHoWpeFdG0/wAM60xghl1CyuLiBJ31qKOQ7JSoJtdu8nA6Z561weiW1hdagkOrag2nWhBLXCwGYg44G0EE5PHWqLyNJIzuxZ2OWYnJJ9c0080Ae7+Dh5PguTT/AA5Jdm3S4uWXXpNKga0f90p2TmTc8QGCAfVuM10/w68G6bounWpttOurtp5rGRtSnjjlguy8Ur4txg/dJ2kEnJAzjpXzRFeXMNvLbwzyxwS48yNXIV8dMjofxqSLU7+GGOKG9uo4ozuREmYKp9QM8GgDufjPbOut6ZqL2j2R1CxRzDPbLbXBKMYy80a/KrMV3fLgYIrzqp7q7uLyUy3c8s8pABeVyzY+pqCgDo/h/wCG5/Fnim00u3jkdGzLOY1LMsKDc5AHU4BAHckDvXbL4D07TPHGpadqtoz6c8Ed5YC+1JNLk8mQ5XcZFOWA+UrwQQa8ttbq4s5PMtJ5YJcY3xOVOPTIpbu8ubyQPdzy3EgGA0rlyB9TQB6FdiA/CvxBbw2FlGtjrsUcdxFtklZWE3ytMB84GBgjAPWvNj1qQTyCJohIwiYhigY7SR0JHryajoASiiigApV6ikpV6igD9N9Pgj8qzO3/AJZx9/8AZFfnH46GPG/iEDp/aNx/6Nav0q0+BPsdq3OREnf0Ar81/Hwx468RgdBqVz/6NagDBooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAcrFWBHauz028s57WKK3i8srt3My7jn0x0riq1PD999i1CIySMkBYbyBnHvQB1VjPaoZUWERsSVaQjg+xPaqk91dwH/AEFOACP3XGwemewrTlkF7cG0gEhQkyOX2hcY7cVXuyNOu1+0SLBFMgXyfMyQPUt2OPWgCrMLn7JHLciKIXQKDAy24dMn0zVOKyvW+dreeaNBsZl+ZVx1H0qzcajFYyyxJdwTBk+RgPNVQeoyehxVqy8TW8FuUV1RVOGRWZGlU9c4GDQAzVdNuFcExtGxXJXIIA9B61RtWJjmJgzD03cjbjtn0rTn1nS59iwzmLYGCo2WAOOCGI9fWoLq9guU8pHXEqhJTG24Mcc/h04oAyUZ1iMqgFeQMnnHTiqF/wDubaKAMCW/eMM5Kn0rUiG61MM7LH5OZHZ+AQOir71z8rmSRnOck55oAjor3jT9Hl0fwr4bvfD/AIGh8RpeWS3FzPLbmUJJgbgTg981zfxumsbm38L3dlo2m6RLd2X2ieCxiEahmxwe/FcdPF88+Tl0bavddL/5HRLD8sea/S/9feeVUUp60ldhzhRRRQAUUUUAFFFFABRRRQAU5VLMFUEsTgAdTTakgkeGVJImZJEIZWU4II6EUATzabfQAmezuYwASd8TLwOp5FNSxu3WQpazsI1DuRGTtUjIJ9BjnNe1W3ia4+0+HvCuv6297HqtnKdQvrm58xYnu4wI1DknaqARlvcsK1fDGsapeeK7650vUoU8LWUrWSp/aEcXk+VAI47iZDgzxYU/KeG56UAfPFJXpnj3R9FsvA2j3WjWunyJL5Z/tNb/ADc3EhQmZGt/4VVwADgYGOu7jzTHFACUUUUAFFLjjNAoAtjTL8xpILK68t8bG8psNnpg45zTZ7C8twTcWlxEAMkvGVwM4zz716BF4p1fSfhjHv1u9mutRuFgtIvtRYWUFuQxZVz8jlyoHT5VPrXZ6hr8EOja9o/iW5l1+LStLtkn3X2Hup5LhJH2S8kqmVAAB4Q9M0AeCyxSRSGOVGSReqsMEfhTa+hviLpel3GjeMtal0vS9Su5bh0s7mG9AngUBd0sg34KjhVVVJPJNfPLdaAEooooAKcvWm0UAfQ0P7VPiqKKONdE0MhFCg7Zew/368G1rUJNW1i+1GdUSW7nkuHVPuhnYsQPbmqVFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU+N2jkV0OGUgg+hFMooA0dR1rUdRuJ57y7kkknYvIeF3E+w4rPZixyxJPqaSigBc0ZpKKAFzQCQcjg+1JRQBdXVLxdMl04Tt9iklWZ4yAcuoIBz16E1TzSUUAdFYeNPElhpkenWet30NhHnZbrKdi59BWXqGq32orAt7cPMsK7Iw2PlHoKo0VCpQUuZJXL9pK1r6C0lFFWQFFFFABRRRQAUUUUAFFFFABXa/BzSbPXPiLpWnalbxXNtN5oMUudjMInK7sEHG4DpXFV3PwTv/AOy/ibot4LK8vvKaQ/Z7OLzJX/dsPlXIz1z9KAPZ9H8GaHBq3iO18QeGNAu4NFsFupZtLNwg80gv5J8x/vbFz7ZGa5q7t9Dsv7Mjk8B6Ne3eoLaXkMNpNOCbacORF8zf65dn3h8p9K6K6+IfhDQFvNG1FPFNnLNfyX1/DcWsayXPmfehkyeYypA45wBg1maD4l8DXV/ZyacnjDU73TJYLmEmBJGhghyscPB4iBk69ckc0AULeXwaniNYNX8DW+maS0rqBIs8l0qeR5kTMiMcFjjIxwD+NW2g8BS+ErMXfg+W01vVdMlubWWGKT7PvCMcoxkJwuBnI4NXJ/iL4Dt/H0/iGc+JYdXWR1ktzboFR/J8hlI3ZyB79axJdX8J6VeXNhptz4yh1v7AdHTT7i3iAfKlVif+JQWIJC45NAHhFFS3EMlvPLDOhjliYo6N1VgcEGtTw74Y1vxI066Dpd1fmDaZPIjLbM5xn0zg0AQeH7mG01izmurW1u4Vkw8N2W8pgePm2kHAzng9q97n0bw6ngy61e08IeH7/wCx6hHZzX0FxOLWdGZB5kCltzEF9pBPB556V4r4JsoJfGWn22p22oSwxzFpobGMPP8AICxCqeDjbz7A17Td/En4dXGma3p4bX4LPVr5L+SOKBAsMisrERjdgBmUE/U0AX9a0HwhpniK+B8IaY2hWOqJo8/72b7S0rRl/NX5tuwDjaeT60ls/wAHrjywvhy5TfggyWsyjDIXQk7sYbaQvqQe3NUNX+I3w41TWbu+uG8RLFdSG4mskjTyHudhRbjG7O8A+uMgcVnT+MfhpNam3a58ThCLRciGPP8Ao0LxJ37q5J98YoA15x8J77T7qLTvDtzDeS27iB5raZFR2hZ4mLFsANg7fUg9ua+bzXut940+HjabcR21x4jacRW/kiSGPaXtrd4It3PQhst+leFGgBKKKKACiiigAooooAUClxV7QZLaHW9Pkv0WSzS4jadHGQyBhuBHpjNe7XniL4VaZZ3LWGn6ddzQs0MKPZs/mmI5Rzns+4jP+yM1UYp9TCrWdOyUW/Q+e8D1oIr6G/t34SWMErR2Nhc+WTEqNaOxkz+9z9A37vPp7VDp2sfCm2tZPtNvZyMGMnzWrMxFxyyLj/nlgD2zxVci7mX1qX/Pt/cfP+BRjivfrPxF8KzBFdXWm2KXJVbqWFLVtquxMRiA9Av7wjpnkc06z174VyW/2u50/TlnKvL5AtWC/uGIjXHYyKcn1xzRyLuDxUl/y7Z8/wCB60Yr3S08R/C+4gjaXRreAySvCUMBVo4Y/wB4khwSCzMNnB6HnirsHiH4VahcyNcafp9rGZBbx4s3XCSLveRh/sMCo9M8cUci7jeJkv8Al2z5+xSYr6Bj1r4U/anjax08W8XlmJhbOS5mysm71EYII9McVT13VPhemn6jb6baWLSR2bz28ywOHe4yY1jyf4cYejkXcFim3bkf3HhQApcD1rd8Cz6ba+LdNuNdSOTTYZPNmjlXcrhQSFI75IA/GvYrLW/hVLM0M2n2UEZAi814WYfOPOc/8BceWD6HpipjG/U0q1nTekW/Q+f+KXAr6ETXPhTc6gVNlYxRylX8w27BVa44kGOyxBQR6FuKmXxB8JvtLyfYdN3ECbabRtu7/U7B/wAB/eHt361Xs13Rk8XJf8u5HzpgUcV9GPrPwltbpwltp03krnP2Vijm3OFA9TJuJz3xzUVzqnwi8xYDDZFQrReZHbOBhP3wb6s37vPpkHij2a7oX1t/8+5fcfPOKTivoW+1v4USJAEsrAmdxE4jt2TyknG53J9YsYGORniku/EHwpktY5106wM7lZfIW3ZNpl/dMrHp8ijzPrjHNHs13Q/rUv8An2z58xxSYr3g6z8K0eC5Wwtg1lKxWHyWb7UiHyl3f7wPmYPp68VZ1a/+E3lRm2WyaSxkBUR2zqblYfmCnPB8wnbz6UcnmP607/A/uPn/AAKMD1r6Ft9X+E1zaeRPaWFv5g8tj5DFk3jziVYf3W/dj8ulS/2z8I7iAGS102LzQGZRauDGZ+GAI/557c+2eKPZruiXi5L/AJdy+4+deKMDPWvoiDXfhI1usrWOmqxXzjE9o+c58nYfw/efrT7fWfhLDEQltpsnkgkebasTIIOF57mQH8cc0ezXdB9bf/PuX3HzpxSYFfRcGq/CNN0Ah0/ajGBXe1cllX98Hz7t+79cDHSo18Q/CWOOd/sFgcdFNm5J84b2wPRCoUemTij2a7oPrcv+fcvuPnkjmjAr6D07XfhVNCJrqx06G4lRZpYzattR5R5bonoEHz+gJ4pbPX/hNEQ62NlmNBMFltWYM0R8tV+rqd57cDvR7Nd0P63Jf8u2fPZHvRX0Hbav8IreQKlraOI96BpbZ23iE71Y+8hO36Dmqr618Kprl7cabbLA8nkef5bLhJAZXkA6jYwCL3544o9mu41ipP8A5ds8GwKMCvoWLW/hLK4drKyiMrKWU2zYTz1w4+kWAfYk4oOu/CUXDziysi67Zgv2VgpYHydgHpt/eH3560ez80L63L/n3L7j56wMdaMV9F3XiH4UQQ/Z0tNPmjgPmKUtD+8aDAQZ6/vATnPBxzVcXPwlg1Z2X7BLBMnlf6h9iFP3u/HqxIj/AAxR7NdwWLfWnL7j58wPWjFfQEmofCWbUUn8uySK6iNvIiW7hYTL85kx2MeNoI6Zps2q/CeW6sb8W9mu4ETWwtnAHmDy/mHT5AC/Hc0ez80H1t/yS+48BxRgV75c6n8JwtndxW9oWtHLGAW75nCZjVW7ENkOfp+FWJtX+EcFpLElrZzGAskZFs++Xyf3iNn/AKaE7Oew5o9n5oPrb/59y+4+e8D1owK97kvfhRqOmeU0dpYTllOVhfcpbEr4YdlIMY+tWLLXfhRd27PdafYWb3IDPH5DN5Rn+VgpHTywobjoW4o5F3H9af8Az7Z894pK9y8V+IPht/wiN8NF0+xOrXMBFuPsjbonH7rk9Ado3/U+teHVMo26m1Kq6iu4teoldl8JNQstK8d2d5qc0cNpHBch2kYqGzBIAuRyNxIXPvXG10XgHRLfxD4qtNPvZJI7VllmlMWN5SONpCq5/iIXA9zUmp6V4F8UeGNav7n+3bOysjbW8Vpp0N5MGiS1DO0sZkkVsuxf72N2MgEYrY8H6z4QsfDlzHZXuh2NnJE0NxbXCMbySY3KnIkI+aHygOOOhyM1ysfw5/4SibTrnSNM/sPTprM3Ukkd4NQUruVV2qvzh9xwyk8H0xiqc3wh1CLT5WfVbA6qnnbbBcsXEcqRsQ4+XHzqQfwoA6fUdU8HR6BrEuky+H/PWO4aGKW2LXT3n2kNvRiNvlGPbtHsRgHNTeK/FWgza5BPHP4fvP7Q8Qb7i6FupeKxIgIySvy9G3HrlT755rUfg9d6ZdFdR1q0tLSK1lnmuJYWHlvEyiRNoyxHz/KwGG6cU3wx8MILy5sJr3WLV0kWO++wBHWWayadYlcEcKWyeM5UYz1oAf47u/Ds3ggroVxoI/0lt8H2djftP5r7pFkHAhKbMA8Y4wDzVX4U3ViPDHivTru70OC5uzamBNYkdIW2s+5gU53LkEVwfiK3is9f1O1t1KwQ3MsaKTkhVcgDP0FZ1AHuvhfVvDOl2nhma3vfD8UNsGF1HLE32xrnypRI7Sj/AJYvlQBnoQAAcmpNF1TwPK0lzfDw9BJNaWcuoxyWxKvD5JE0NsF+5Pvx0wehz1rweigCS5MZuJTAGWEsSgbqFzxn8KioooAKKKKACiiigAooooAKKKKAClpKKACiiigBaSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClzSUUAFFFFABRRRQAUUUUAFWtNvrrTL+C90+eS3u4HEkUsZwyMOhBqrRQB2H/CxPEf9pRXn2uHMcbRC3FrELcq2C2YguwksAxJHXmoH8d+IHjdPtiqrRTQ/JEi7VldZHAwOPmVSMdMcVy1LQB1Wo+Pdf1GKSO6uICJbZrWUpbRo0iMVLFiACzEqPmPNP0f4h+JdI0mLTbLUdtlFwiPEjkLvDhdxGdoZQQM4BJ9a5GloAmvbmW9vJ7q4bdNPI0jsBjLMck/magpaSgAoqe0tZ7y4WC0glnnfO2OJCzHAycAc9Aamm0u/ggkmmsbqOGN/LeR4mCq3Hyk4wDyOPepc4p2b1ApUVNbwS3Mnl28UksmC21FLHAGScDsACfwp9nY3d6ZBZ2s9wY13uIoy+1R1JwOB703JLdgVqKsXNnc20cMlzbzQpMu6NpEKhx6qT1HI6VXoTTV0AUUUUwCuh8EgHVZiVVsW7kblDYOR61z1aGi6kdLunmEQl3xmMqTjrjn9KcXZgz0EEY+5H/37X/CjI/uR/wDftf8ACuV/4Sxv+fMf9/P/AK1H/CWN/wA+Y/7+f/WrbniRZnVZH9yP/v2v+FGR/cj/AO/a/wCFcr/wljf8+Y/7+f8A1qP+Esb/AJ8x/wB/P/rUc8QszquP7kf/AH7X/CtDw9bw3niDTLa4hjeGa4RJF2KNyk8jpXC/8JY3/PmP+/n/ANapbXxnPaXUNzbWwjnhYOjb84I6HpS50FmeqSaHZa5rVzZaNJpVtJbLu2QK7o6BjvYswyGQfw9D2obRtKXQLu5LQMy6eJ4JVt8Fz55QOQehIAGOwNcBN8VNcldnysbttLNCFjLbTuGSqjv+dQS/EnVJTJ5iKfNha3cAgAxs24jG3+8Sc9qXN5jsa+RgfJH/AN+1/wAKOP7kf/ftf8K5UeK2A/481/7+f/Wo/wCEsb/nzH/fz/61VzxFZnVcf3I/+/a/4UZH9yP/AL9r/hXK/wDCWN/z5j/v5/8AWo/4Sxv+fMf9/P8A61HPELM6rI/uR/8Aftf8KMj+5H/37X/CuV/4Sxv+fMf9/P8A61H/AAljf8+Y/wC/n/1qOeIWZ1WR/cj/AO/a/wCFGR/cj/79r/hXK/8ACWN/z5j/AL+f/Wo/4Sxv+fMf9/P/AK1HPELM6rI/uR/9+1/woyP7kf8A37X/AArlf+Esb/nzH/fz/wCtR/wljf8APmP+/n/1qOeIWZ1WR/cj/wC/a/4UZH9yP/v2v+Fcr/wljf8APmP+/n/1qP8AhLG/58x/38/+tRzxCzOqyP7kf/ftf8KMj+5H/wB+1/wrlf8AhLG/58x/38/+tR/wljf8+Y/7+f8A1qOeIWZ1WR/cj/79r/hRkf3I/wDv2v8AhXK/8JY3/PmP+/n/ANaj/hLG/wCfMf8Afz/61HPELM6rI/uR/wDftf8ACjI/uR/9+1/wrlf+Esb/AJ8x/wB/P/rUf8JY3/PmP+/n/wBajniFmdVkf3I/+/a/4UZH9yP/AL9r/hXK/wDCWN/z5j/v5/8AWo/4Sxv+fMf9/P8A61HPELM6rI/uR/8Aftf8KMj+5H/37X/CuV/4Sxv+fMf9/P8A61H/AAljf8+Y/wC/n/1qOeIWZ1WR/cj/AO/a/wCFGR/cj/79r/hXK/8ACWN/z5j/AL+f/Wo/4Sxv+fMf9/P/AK1HPELM6rI/uR/9+1/woyP7kf8A37X/AArlf+Esb/nzH/fz/wCtR/wljf8APmP+/n/1qOeIWZ1WR/cj/wC/a/4UZH9yP/v2v+Fcr/wljf8APmP+/n/1qP8AhLG/58x/38/+tRzxCzOqyP7kf/ftf8KMj+5H/wB+1/wrlf8AhLG/58x/38/+tR/wljf8+Y/7+f8A1qOeIWZ1WR/cj/79r/hRkf3I/wDv2v8AhXK/8JY3/PmP+/n/ANaj/hLG/wCfMf8Afz/61HPELM6rI/uR/wDftf8ACjI/uR/9+1/wrlf+Esb/AJ8x/wB/P/rUf8JY3/PmP+/n/wBajniFmdVkf3I/+/a/4UZH9yP/AL9r/hXK/wDCWN/z5j/v5/8AWo/4Sxv+fMf9/P8A61HPELM6rI/uR/8Aftf8KOP7kf8A37X/AArlf+Esb/nzH/fz/wCtR/wljf8APmP+/n/1qOeIWZ1WR/cj/wC/a/4VqeFraC+8Saba3UMUlvLMFkXYo3DB4ziuB/4Sxv8AnzH/AH8/+tU1l41uLK8hurW2Ec8TbkffnafxHvS50Fmeu3HhFL69h+zxW1gv2fz7hYALiNQXKxlCcbt2OeeKxdU8Nyado8l7LPbSSx3BgeKGFXVMHGS/YnqBj8a4m0+JGq2gt1gUBLdWSNGYMoVjuIIK4PPIz07VHP8AEPUp7CWzljBt5ZfOkUELubryQucZ7dBSUvMdj1GfQbG78PWUWm2lodZkt7ec7Th8OxVmcEbdnIxjmqf/AAiHnX0FtZahaTtc+ZFAxt9oe4jI3xHI4AHIboa4B/ibq76Yun4C2qosYCEKwVTkDcF3Yz7064+KGt3EzTTSOZWh+z7w4UhM5IGBwSRyRye9HN5hY0tQM+heN7e60mV7iO1imt2uYbRWyXR0YeWxAP3iOSOOab4i1GO40HUNO8PaZqenxXdyzG3lAkjWDcjLGhL/ALsF13sADkhBnC1gah44udRvJLq8t1kuJMF33Y3EDGeB14qv/wAJW3/PmP8Av5/9auSrg6Naqq091b8NVfvbp26FKUkrI7ew8Q2un6MlvZeHru3vG0yaxkkjijHzPbeUTu6srSfvDnkdBmsbwFfHQtL1mw1fR726gvzC22LA5jEnGcgqcuCHHIx0Oawf+Esb/nzX/v5/9aj/AISxv+fNf+/n/wBasf7Mw3JKGvvWvq76O619R88tzutT186za2UDWV1A8I8yRrlVK7vs9vDtXrx+4LZ4+9jHGT5n4mOdbuOAOnQAD7o9K0v+Esb/AJ8x/wB/P/rVhand/br2S42bN+PlznHGK6aNCnhqSo0tkJtt3ZVoooqwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This still frame from an echocardiographic video clip of a subcostal coronal view highlights the infundibular hypertrophy in this patient with TOF. The arrows identify the muscle bundles in the right ventricle outflow tract (RVOT).",
"    <div class=\"footnotes\">",
"     RV: right ventricle; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16738=[""].join("\n");
var outline_f16_22_16738=null;
var title_f16_22_16739="Basal cell carcinoma eyelid";
var content_f16_22_16739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16739=[""].join("\n");
var outline_f16_22_16739=null;
var title_f16_22_16740="Dicyclomine (dicycloverine): Pediatric drug information";
var content_f16_22_16740=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dicyclomine (dicycloverine): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/6/27749?source=see_link\">",
"    see \"Dicyclomine (dicycloverine): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/8/32900?source=see_link\">",
"    see \"Dicyclomine (dicycloverine): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bentyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bentylol&reg;;",
"     </li>",
"     <li>",
"      Dicyclomine Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Formulex&reg;;",
"     </li>",
"     <li>",
"      Jamp-Dicyclomine;",
"     </li>",
"     <li>",
"      Protylol;",
"     </li>",
"     <li>",
"      Riva-Dicyclomine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/6/27749?source=see_link\">",
"      see \"Dicyclomine (dicycloverine): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &gt;6 months: Oral: 5 mg/dose 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Oral: 10 mg/dose 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 20 mg 4 times/day, then increase up to 40 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 20 mg/dose 4 times/day; oral therapy should replace I.M. therapy as soon as possible",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 10 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 10 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 10 mg/5 mL (480 mL [DSC]) [contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer 30 minutes before eating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M. only; not for I.V. use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of functional bowel/irritable bowel syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dicyclomine may be confused with diphenhydrAMINE, doxycycline, dyclonine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bentyl&reg; may be confused with Aventyl&reg;, Benadryl&reg;, Bontril&reg;, Cantil&reg;, Proventil&reg;, TRENtal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F159596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports with dicyclomine: Abdominal distension, abdominal pain, anaphylactic shock, angioedema, confusional state, constipation, cycloplegia, delirium, dermatitis (allergic), hypersensitivity, dyspepsia, dyspnea, erythema, facial edema, fatigue, hallucinations, headache, insomnia, lactation suppressed, malaise, mydriasis, nasal congestion, palpitation, rash, syncope, tachyarrhythmias, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports with similar anticholinergic drugs: Anorexia, apnea, diaphoresis decreased, diplopia, focal coagulation necrosis (I.M. injection), dyskinesia, hypertension, impotence, itching, lightheadedness (transient), numbness, ocular tension increased, sneezing, speech disorder, throat congestion, tingling, urinary hesitancy, urinary retention (in patients with prostatic hypertrophy), urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dicyclomine or any component; narrow-angle glaucoma, tachycardia, GI obstruction, obstruction of the urinary tract, severe ulcerative colitis, myasthenia gravis; should not be used in infants &lt;6 months of age (due to reports of respiratory distress, seizures, syncope, asphyxia, pulse rate fluctuations, muscular hypotonia, and coma), nursing mothers",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in children with Down&rsquo;s syndrome, spastic paralysis, or brain damage; increased sensitivity to toxic effects compared to adults has been reported. Use with caution in patients with hepatic or renal disease, mild-moderate ulcerative colitis, hyperthyroidism, coronary heart disease, CHF, cardiac tachyarrhythmias, hypertension, hiatal hernia, autonomic neuropathy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4801568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heat prostration may occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise. Psychosis has been reported in patients with an extreme sensitivity to anticholinergic effects. Injectable formulation is for I.M. administration only; inadvertent I.V. administration may cause thrombosis/thrombophlebitis and injection site reactions (eg, pain, edema, skin color change, reflex sympathetic dystrophy).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4370436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. In epidemiologic studies, birth defects were not observed in pregnant women taking doses up to 40 mg daily; information has not been located when used in pregnant women at recommended doses (80-160 mg daily). Use for the treatment of irritable bowel syndrome (IBS) is not recommended during pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands and the CNS",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.65 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 67%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial phase: 1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal phase: 9-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% in urine; 10% in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/8/32900?source=see_link\">",
"      see \"Dicyclomine (dicycloverine): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol; may cause dry mouth; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13228 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B3B70EFBF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16740=[""].join("\n");
var outline_f16_22_16740=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159572\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159573\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057828\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057822\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159552\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159537\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057832\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057825\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057831\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159598\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159596\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057836\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057821\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801568\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299186\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159548\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370436\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057820\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057834\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057835\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057827\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13228|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/6/27749?source=related_link\">",
"      Dicyclomine (dicycloverine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/8/32900?source=related_link\">",
"      Dicyclomine (dicycloverine): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_22_16741="Mevalonate kinase active site";
var content_f16_22_16741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    The putative mevalonate binding site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rat MVK active sites with ATP, motif II \"phosphate binding loop\" (light-blue cord), mevalonate (MEV) and significant residues highlighted. A) Overall tertiary structure. B) Electron-density surface of the active site enclosed by the red box in A. Blue represents positive, red represents negative, and white represents neutral electrostatic potential due to amino acid side chains.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fu, Z, Wang, M, Potter, D, et al. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. J Biol Chem 2002; 277:18134. Copyright &copy;2002 American Society for Biochemistry and Molecular Biology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16741=[""].join("\n");
var outline_f16_22_16741=null;
var title_f16_22_16742="Gastrointestinal Chagas disease";
var content_f16_22_16742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastrointestinal Chagas disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16742/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16742/contributors\">",
"     Rogelio Lopez-Velez, MD, DTMH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16742/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16742/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16742/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16742/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/22/16742/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H86302849\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi, most commonly transmitted by triatomine bugs. The major manifestations are Chagas cardiomyopathy and gastrointestinal disease.",
"   </p>",
"   <p>",
"    Issues related to Chagas gastrointestinal disease will be reviewed here. Other issues related to Chagas disease, including cardiac disease, epidemiology, diagnosis, and treatment, are discussed in detail separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3660898\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal manifestations of Chagas disease are the second most common cause of complications due to Chagas disease. The mortality is low, but symptoms can have a considerable impact on quality of life. The digestive form is seen more frequently in the countries of the Southern Cone (a high prevalence has been observed in the central region of Brazil) and is rare in northern South America, Central America, and Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among individuals with the chronic indeterminate form of Chagas disease, approximately 20 to 30 percent progress over a period of 10 to 30 years to clinically evident cardiac involvement, digestive involvement, or both. The likelihood of cardiac or digestive involvement may vary by region [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302856\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both parasite and host factors are thought to influence the development of gastrointestinal manifestations and the severity of disease. Molecular techniques have demonstrated the presence of parasite DNA in digestive tissues, which correlates with inflammatory infiltrate and degree of denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/3\">",
"     3",
"    </a>",
"    ]. The occurrence of the gastrointestinal manifestations in areas south of the Amazon basin has been attributed to variations in parasite strains [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of disease consists of destruction of the neurons of the enteric nervous system. Both sympathetic and parasympathetic nerves are involved, and denervation occurs in both the submucosal (Meissner) and myenteric (Auerbach) plexuses. A significant reduction in the number of interstitial cells of Cajal has been demonstrated; these cells play an important role in the modulation of digestive tube motility.",
"   </p>",
"   <p>",
"    Histologically, neuronal reduction and focal areas of fibrosis in the smooth muscle and myenteric plexuses are have been described, along with lymphocytic infiltrates at the submucosal, myenteric plexus, and smooth muscle levels. In addition, the muscularis mucosa can become hypertrophic, likely a compensatory mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/5\">",
"     5",
"    </a>",
"    ]. Denervation occurs to variable degrees; it is irregular and non-continuous. The esophagus and the distal colon are the most frequently involved segments.",
"   </p>",
"   <p>",
"    The digestive form of Chagas disease is characterized by alterations in the motor, secretory, and absorptive functions of the gastrointestinal tract. Uncoordinated motor activity of the sphincters occurs as a result of denervation. In the esophagus, there is hypercontractility and increased muscular tone, and often there is failure of sphincter relaxation with swallowing. In the large intestine, there is abnormal basal colonic motility and impaired relaxation of the anal sphincter. Progressive dilation of the esophagus and colon occurs, with reduction of contractility and subsequent difficulty with emptying semisolid material in these segments [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302863\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The digestive form of Chagas disease is observed only in the chronic phase of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link\">",
"     \"Chagas disease: Natural history and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In Brazil, gastrointestinal Chagas disease develops in about 10 to 15 percent of patients with chronic infection. The onset of symptoms is most common between the ages of 20 and 40 years but can occur at any age. Any part of the digestive system may be affected; the esophagus and colon (particularly the rectum, sigmoid colon, and descending colon) are the most frequently involved sites. Esophageal involvement is more common than colonic involvement; megacolon is the final manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 118 Latin American immigrants to Spain with T. cruzi infection who underwent clinical evaluation, gastrointestinal involvement was observed in 11 percent of patients and was generally mild; manifestations included incomplete relaxation of the lower esophageal sphincter, colonic elongation, and dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/9\">",
"     9",
"    </a>",
"    ]. Gastrointestinal symptoms (mainly constipation) were observed in approximately half of these patients. Concomitant gastrointestinal and cardiac involvement was observed in 2 percent of patients.",
"   </p>",
"   <p>",
"    Gastrointestinal manifestations are relatively rare in the setting of reactivation of chronic T. cruzi infection among organ transplant recipients or in patients with HIV infection, although there are reports of parasitic invasion of the peritoneum, stomach, or intestine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302870\">",
"    <span class=\"h2\">",
"     Esophageal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal manifestations range from asymptomatic motility disorders, to mild achalasia, to severe megaesophagus. The most common symptom of megaesophagus is dysphagia that occurs initially with solids, but eventually also develops with liquids. Esophageal pain may be spontaneous or associated with food ingestion that typically starts in the lower substernal area and radiates superiorly. Regurgitation of undigested food can also occur. In severe cases, intermittent aspiration can develop, resulting in cough and pneumonia. As the disease progresses, food may become lodged in the esophagus and cause local irritation, ulceration, bleeding, perforation, and fistulas. In end-stage disease, malnutrition can develop [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with megaesophagus also have an increased risk of esophageal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302877\">",
"    <span class=\"h2\">",
"     Colonic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical presenting symptom of megacolon is slowly progressive constipation. As the disease progresses patients may be unable to pass stool for weeks. This may be accompanied by bloating, colonic dysmotility, and, less often, colicky abdominal pain. Prolonged stool retention leads to fecalith formation; this can be diagnosed by abdominal palpation and rectal examination. Recurrent volvulus is common and can lead to secondary bowel ischemia. Anorexia and malnutrition can also develop.",
"   </p>",
"   <p>",
"    The prevalence of megacolon is not known because of diagnostic difficulties in remote areas. Symptoms may be absent in 25 to 30 percent of individuals with radiographic evidence of colonic dilatation. Most cases of megacolon are associated with megaesophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/2\">",
"     2",
"    </a>",
"    ]. Increased frequency of colorectal cancer has not been reported in patients with megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302884\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other parts of the digestive tract can be involved including the stomach, small bowel, biliary tree, and salivary glands.",
"   </p>",
"   <p>",
"    Nearly 20 percent of patients with megaesophagus have gastric involvement. Gastric manifestations may include altered myoelectrical activity (gastric dysrhythmias), alterations in gastric emptying, distension, hypoperistalsis, hypochlorhydria, and eventually pyloric hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Involvement of the small bowel (Chagas enteropathy) has also been described, with or without dilatation. Bacterial overgrowth, pseudoobstructive syndromes, and dyspeptic syndrome may develop [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholecystomegaly and choledochodilation are rare. An increased prevalence of cholelithiasis has been reported among patients with Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertrophy of the salivary and parotid glands develops in up to 25 percent of individuals with megaesophagus; the oesophageal salivary reflex produces hypersalivation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302891\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two steps in the diagnosis of gastrointestinal Chagas disease: confirmation of T. cruzi infection, usually by serologic testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polymerase chain reaction, and detection of organ involvement. Laboratory evaluation for Chagas disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link&amp;anchor=H541206387#H541206387\">",
"     \"Chagas disease: Natural history and diagnosis\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following laboratory diagnosis of T. cruzi infection, evaluation for presence of cardiovascular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal involvement must be performed. The approach to cardiac evaluation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13928168\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with no gastrointestinal tract symptoms do not require further evaluation. These individuals should be followed-up every 12 months; each year approximately 2 percent of patients develop clinical manifestations of the disease. There are no known markers of disease progression.",
"   </p>",
"   <p>",
"    Symptoms suggestive of upper gastrointestinal involvement include longer time to eat than others, dysphagia, odynophagia, esophageal reflux, weight loss, aspiration, cough, and regurgitation. These symptoms should prompt evaluation for esophageal involvement as outlined below. (See",
"    <a class=\"local\" href=\"#H86302898\">",
"     'Esophageal involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptoms suggestive of lower gastrointestinal involvement include prolonged constipation, fecaloma (hard mass of accumulated feces), and acute abdominal pain (volvulus and bowel ischemia). These symptoms should prompt evaluation for colonic involvement as outlined below [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H86302928\">",
"     'Colonic involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical evaluation should also include evaluation for HIV infection and other causes of immunosuppression, since management of Chagas disease is unique for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link&amp;anchor=H107060914#H107060914\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302898\">",
"    <span class=\"h2\">",
"     Esophageal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tools for evaluation for esophageal involvement due to Chagas disease include radiography, manometry, and endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302907\">",
"    <span class=\"h3\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain chest radiography may demonstrate an air-fluid level in the dilated esophagus.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    contrast studies are essential to confirm the diagnosis and to stage the disease. Radiographic examination should be combined with fluoroscopy to assess esophageal motility and emptying. Four stages of disease have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I (delayed emptying): normal diameter of esophagus (&lt;10 cm); minimal contrast retention; presence of a residual air column above the contrast",
"     </li>",
"     <li>",
"      Stage II (moderate esophageal enlargement with motor incoordination): moderate dilatation, with some contrast retention; increase in uncoordinated motor activity; relative hypertonicity of the inferior third of the esophagus",
"     </li>",
"     <li>",
"      Stage III (hypotonic and large achalasic esophagus): large increase in diameter and substantial contrast retention; hypotonic esophagus with weak or absent motor activity",
"     </li>",
"     <li>",
"      Stage IV (atonic esophagus): large increase in volume, atonic, elongated esophagus lying on the right diaphragmatic dome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302914\">",
"    <span class=\"h3\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal manometry may be useful for patients with suggestive symptoms but inconclusive findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow. Manometry can provide quantitative information regarding esophageal function, but cannot distinguish between Chagas megaesophagus and idiopathic achalasia. Manometry can demonstrate loss of peristaltic activity at the body of the esophagus (aperistalsis), with synchronic waves and failure or incomplete aperture of the lower esophageal sphincter with ingestion (achalasia). In stages III and IV, contractions are of low amplitude.",
"   </p>",
"   <p>",
"    In one study of gastrointestinal Chagas disease in Spain, esophageal manometry revealed mild abnormalities not detected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, even in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302921\">",
"    <span class=\"h3\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with megaesophagus may be at increased risk for esophageal cancer. Patients with symptoms suggestive of gastrointestinal Chagas disease or achalasia should undergo upper endoscopy to rule out malignancy, which may cause identical symptoms and is not necessarily visualized with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/16\">",
"     16",
"    </a>",
"    ]. Histologic sections demonstrate chronic inflammatory infiltrates, but parasites are rarely seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302928\">",
"    <span class=\"h2\">",
"     Colonic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for colonic involvement due to Chagas disease consists of radiography and manometry.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema is the primary diagnostic tool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302937\">",
"    <span class=\"h3\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncontrast abdominal radiography may demonstrate increased intestinal air; fecaloma can also be visualized, if present.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema may demonstrate decreased bowel haustra and a dilated, atonic colon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/17\">",
"     17",
"    </a>",
"    ]. Dilatation usually occurs in the distal colon, including sigmoid and rectum; rarely dilatation occurs in other segments or in the entire colon. Dilatation is frequently associated with an increase in colon length, known as dolichomegacolon.",
"   </p>",
"   <p>",
"    A sigmoid colon or descending colon diameter &gt;6.5 cm is considered pathologic and is radiographically definitive for megacolon. Three radiographic stages have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 0 &mdash; No alterations in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema",
"     </li>",
"     <li>",
"      Stage 1 &mdash; Dolichocolon",
"     </li>",
"     <li>",
"      Stage 2 &mdash; Dolichomegacolon: descending colon &gt;6.5 cm in diameter; ascending colon &gt;8 cm in diameter; cecum &gt;12 cm in diameter in diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302944\">",
"    <span class=\"h3\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of the colonic pathology in the absence of dilation requires alternative methods such as manometry and pharmacological tests of denervation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10007003\">",
"    <span class=\"h3\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is useful for ruling out malignancy and for treatment of sigmoid volvulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13928261\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of esophageal motility abnormalities includes primary idiopathic achalasia, malignancy (pseudoachalasia), amyloidosis, sarcoidosis, neurofibromatosis, and eosinophilic gastroenteritis. Chronic constipation can result from malignancy, metabolic disorders, amyloidosis, and systemic sclerosis. The diagnostic tools for these entities are the same as those used for gastrointestinal Chagas (radiography, manometry, and endoscopy); the approach for each disorder is discussed further separately (see related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302958\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data to suggest that treatment with antitrypanosomal therapy affects progression of gastrointestinal tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Management focuses on symptom amelioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302965\">",
"    <span class=\"h2\">",
"     Megaesophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of megaesophagus consists largely of supportive measures. Stage I disease may be managed with drugs to relax the lower esophageal sphincter, such as isosorbitol dinitrate (2.5 to 5.0 mg orally, five minutes before meals) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (10 mg orally, 45 minutes before meals). Stage II and III disease may warrant surgery, such as laparoscopic Heller&rsquo;s myotomy and fundoplication. Stage IV may warrant esophageal resection with cervical esophagogastric anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of other interventions is limited, including endoscopic botulin toxin injection in the sphincteric region [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/20\">",
"     20",
"    </a>",
"    ]. Endoscopic pneumatic balloon dilatation is reserved for patients with recurrence within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86302972\">",
"    <span class=\"h2\">",
"     Megacolon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early colonic dysfunction due to megacolon can be managed with a high fiber diet, abundant fluid intake, osmotic laxatives or emollients and intermittent enemas or suppositories with glycerol. As disease progresses manual disimpaction under general anesthesia may be required. Endoscopic treatment or surgical intervention may be required for patients with persistent constipation, frequent fecaloma, sigmoid volvulus, or toxic megacolon. Options for surgical intervention include rectosigmoidectomy with retrocecal interpositioning, or rectosigmoidectomy with end-to-side low colorectal anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16742/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3661108\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal manifestations of Chagas disease are the second most common cause of complications due to Chagas disease. The mortality is low, but symptoms can have a considerable impact on quality of life. The digestive form is seen more frequently in the countries of the Southern Cone (a high prevalence has been observed in the central region of Brazil) and is rare in northern South America, Central America, and Mexico. (See",
"      <a class=\"local\" href=\"#H86302849\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The digestive form of Chagas disease is characterized by alterations in the motor, secretory, and absorptive functions of the gastrointestinal tract. Uncoordinated motor activity of the sphincters occurs as a result of denervation. In the esophagus, there is hypercontractility and increased muscular tone, and often there is failure of sphincter relaxation with swallowing. In the large intestine, there is abnormal basal colonic motility and impaired relaxation of the anal sphincter. Progressive dilation of the esophagus and colon occurs, with reduction of contractility and subsequent difficulty with emptying semisolid material in these segments. (See",
"      <a class=\"local\" href=\"#H86302856\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms suggestive of upper gastrointestinal involvement include dysphagia, odynophagia, esophageal reflux, regurgitation, cough, weight loss, and aspiration. Symptoms suggestive of lower gastrointestinal involvement include prolonged constipation, fecaloma, and acute abdominal pain (volvulus and bowel ischemia). (See",
"      <a class=\"local\" href=\"#H13928168\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two steps in the diagnosis of gastrointestinal Chagas disease: laboratory confirmation of T. cruzi infection and detection of organ involvement. Laboratory evaluation for Chagas disease is discussed separately. Tools for evaluation of gastrointestinal involvement due to Chagas disease include radiography, manometry, and endoscopy. Asymptomatic patients with no gastrointestinal tract symptoms do not require further evaluation; they should be evaluated annually. (See",
"      <a class=\"local\" href=\"#H86302891\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link&amp;anchor=H541206387#H541206387\">",
"       \"Chagas disease: Natural history and diagnosis\", section on 'Laboratory diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antitrypanosomal therapy does not affect progression of gastrointestinal tract disease; management focuses on symptom amelioration. (See",
"      <a class=\"local\" href=\"#H86302958\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7650056\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge Dr. Caryn Bern, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rassi A, Rezende JM, Luquetti AO, et al. Clinical phases and forms of Chagas disease. In: American trypanosomiasis (Chagas disease): One hundred years of research, 1st ed, Telleria J, Tibayrenc M (Eds), Elsevier, Burlington, MA 2010. p.709.",
"    </li>",
"    <li>",
"     Rezende JM, Luquetti AO. Chagasic megavisceras. In: Nervous System in Chagas Disease, Pan American Health Organization, Washington 1994. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/3\">",
"      da Silveira AB, Arantes RM, Vago AR, et al. Comparative study of the presence of Trypanosoma cruzi kDNA, inflammation and denervation in chagasic patients with and without megaesophagus. Parasitology 2005; 131:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/4\">",
"      Miles MA, Feliciangeli MD, de Arias AR. American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies. BMJ 2003; 326:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/5\">",
"      Troncon LE, Oliveira RB, Romanello LM, et al. Abnormal progression of a liquid meal through the stomach and small intestine in patients with Chagas' disease. Dig Dis Sci 1993; 38:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/6\">",
"      de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998; 93:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/7\">",
"      Kamiji MM, de Oliveira RB. [Features of Chagas' disease patients with emphasis on digestive form, in a tertiary hospital of Ribeir&atilde;o Preto, SP]. Rev Soc Bras Med Trop 2005; 38:305.",
"     </a>",
"    </li>",
"    <li>",
"     Rezende JM, Moreira H. Forma digestive da Doenca de Chagas. In: Trypanosoma cruzi e Doeca de Chagas, 2nd ed, Brener Z, Andrade ZA, Barral-Neto N (Eds), Guanabara Koogan, Rio de Janeiro 2000. p.465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/9\">",
"      P&eacute;rez-Ayala A, P&eacute;rez-Molina JA, Norman F, et al. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol 2011; 105:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/10\">",
"      Kirchhoff LV. American trypanosomiasis (Chagas' disease). Gastroenterol Clin North Am 1996; 25:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/11\">",
"      Rezende Filho J, De Rezende JM, Melo JR. Electrogastrography in patients with Chagas' disease. Dig Dis Sci 2005; 50:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/12\">",
"      Meneghelli UG. Chagasic enteropathy. Rev Soc Bras Med Trop 2004; 37:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/13\">",
"      Martini AS, Lopes RA, Utrilla LS, et al. Morphological and morphometric study of the alterations on young mouse parotid gland with subpatent Chagas' disease. Angew Parasitol 1986; 27:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/14\">",
"      Mattoso LF, Reeder MM. Radiological diagnosis of Chagas' disease (American trypanosomiasis). Semin Roentgenol 1998; 33:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/15\">",
"      Rezende JM, Lauar K, Oliveira AR. Aspectos cl&iacute;nicos e radiol&oacute;gicos da aperistalsis do es&ocirc;fago. Rev Bras Gastroenterol 1960; 12:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/16\">",
"      Pinazo MJ, Ca&ntilde;as E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/17\">",
"      Hernandez EB, Rezende JM, Macedo V, Castro N. Estudo radiol&oacute;gico do c&oacute;lon em indiv&iacute;duos de &aacute;rea endemica de doenca de Chagas atraves da t&eacute;cnica simplificada de Ximenes. Rev Soc Bras Med Trop 2002; 35 Suppl III:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/18\">",
"      Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/19\">",
"      Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/20\">",
"      Brant C, Moraes-Filho JP, Siqueira E, et al. Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia. Dis Esophagus 2003; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/21\">",
"      Herbella FA, Aquino JL, Stefani-Nakano S, et al. Treatment of achalasia: lessons learned with Chagas' disease. Dis Esophagus 2008; 21:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16742/abstract/22\">",
"      Cutait DE, Cutait R. Surgery of chagasic megacolon. World J Surg 1991; 15:188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5700 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-33BC93883C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16742=[""].join("\n");
var outline_f16_22_16742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3661108\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86302849\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3660898\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86302856\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86302863\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302870\">",
"      Esophageal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302877\">",
"      Colonic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302884\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86302891\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13928168\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302898\">",
"      Esophageal involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86302907\">",
"      - Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86302914\">",
"      - Manometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86302921\">",
"      - Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302928\">",
"      Colonic involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86302937\">",
"      - Radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86302944\">",
"      - Manometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10007003\">",
"      - Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13928261\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86302958\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302965\">",
"      Megaesophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86302972\">",
"      Megacolon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3661108\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7650056\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=related_link\">",
"      Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=related_link\">",
"      Chagas disease: Natural history and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_22_16743="Angle anatomy";
var content_f16_22_16743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71234%7EPEDS%2F59454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71234%7EPEDS%2F59454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Glaucoma: Angle anatomy of the eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The angle is the recess formed by the irido-corneal juncture. The scleral spur, trabecular meshwork, and Schwalbe's line lie within this angle. The trabecular meshwork is a fenestrated structure that transmits aqueous fluid to Schlemm's canal, from which it drains into the venous system. The normal flow of aqueous is demonstrated here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Trobe JD. The Physician's Guide to Eye Care. Foundation of the American Academy of Ophthalmology, San Francisco, 2001. p.158. Copyright &copy; American Academy of Ophthalmology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute angle-closure glaucoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     The pupillary margin blocks the passage of aqueous from the posterior chamber to the anterior chamber (pupillary block), ballooning the iris forward (iris bombe), causing the iris root to occlude the trabecular meshwork and completely obstruct drainage of aqueous fluid from the anterior chamber (angle closure). The resulting rapid elevation of intraocular pressure requires urgent intervention to prevent permanent visual loss.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD. The Physician's Guide to Eye Care. Foundation of the American Academy of Ophthalmology, San Francisco, 2001. p.158. Copyright &copy; American Academy of Ophthalmology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16743=[""].join("\n");
var outline_f16_22_16743=null;
var title_f16_22_16744="Clinical manifestations, diagnosis, and treatment of nephronophthisis";
var content_f16_22_16744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16744/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/22/16744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephronophthisis (NPHP) is an autosomal recessive genetically heterogenic disorder with identified mutations in a number of genes that encode proteins involved in the function of primary cilia, basal bodies, and centrosomes.",
"   </p>",
"   <p>",
"    These gene defects result in the characteristic findings of NPHP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive inheritance",
"     </li>",
"     <li>",
"      Reduced urinary concentrating ability with a bland urinary sediment",
"     </li>",
"     <li>",
"      Chronic tubulointerstitial nephritis and progression to end-stage renal disease (ESRD), generally before the age of 20 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three clinical variants have been described based upon the median age of onset of ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infantile &mdash; one year of age",
"     </li>",
"     <li>",
"      Juvenile &mdash; 13 years of age",
"     </li>",
"     <li>",
"      Adolescent &mdash; 19 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These variants are associated with specific gene defects. In addition, several NPHP gene mutations are associated with retinal defects.",
"   </p>",
"   <p>",
"    NPHP is included in the",
"    <span class=\"nowrap\">",
"     nephronophthisis/medullary",
"    </span>",
"    cystic kidney disease complex (MCKD). In contrast to nephronophthisis, MCKD is an autosomal dominant disorder that generally progresses to ESRD later in life during adulthood.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of nephronophthisis will be reviewed here. The genetics and pathogenesis of nephronophthisis and medullary cystic kidney disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephronophthisis (NPHP) is characterized by the insidious onset of renal failure at an early age. Retinitis pigmentosa is the most common extrarenal finding and occurs in approximately 20 percent of patients. The combination of NPHP and retinitis pigmentosa is referred to as Senior-Loken syndrome.",
"   </p>",
"   <p>",
"    Other syndromes, in which NPHP can be a major clinical finding, include Joubert, Meckel-Gruber, and Cogan syndrome. These syndromes include other extrarenal manifestations, particularly neurologic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with juvenile NPHP, the most common form of the disease, symptoms generally develop after one year of age, around four to six years of age. The initial clinical renal manifestations of NPHP are due to tubular dysfunction and include reduced concentrating ability and sodium conservation. The first symptoms, polyuria and polydipsia, are related to the impairment of renal concentration. In these children, after a period of fluid restriction urinary osmolality will remain low (less than 400",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    and is not increased by the administration of vasopressin (ie, nephrogenic diabetes insipidus) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sodium-wasting can also occur. This can lead to hypovolemia, hyponatremia, and an elevation in the plasma creatinine concentration if sodium intake is diminished [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These abnormalities precede any decline in glomerular filtration rate and may also be present in asymptomatic siblings who are heterozygous carriers.",
"   </p>",
"   <p>",
"    NPHP almost uniformly progresses to ESRD, which typically develops before age 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Most studies have found a mean age of about 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/4\">",
"     4",
"    </a>",
"    ]. As in other genetic renal diseases, the rate of progression to renal failure is determined in part by the type and severity of the genetic defect. As previously mentioned, the age of ESRD in affected patients varies due to the underlying genetic defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H174931069#H174931069\">",
"     \"Genetics and pathogenesis of nephronophthisis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infantile &mdash; Infantile NPHP is characterized by mutations in the NPHP2 gene, which leads to ESRD by three years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. In these children severe blood hypertension is common. Ultrasonography usually shows moderately enlarged kidneys with cortical hyperechogenicity and no visible cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Juvenile &mdash; Most children with NPHP have the juvenile form of the disease because NPHP1 gene mutations are the most common genetic defect and occur in young and school-aged children. These patients develop ESRD by 13 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Mutations in all but the NPHP2 gene have been associated with juvenile NPHP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adolescent &mdash; Most patients with NPHP3 gene mutations develop ESRD in late adolescence and young adulthood with a reported median age of 19 years (range 4 to 37 years) at the time of ESRD [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poor growth may be initially related to chronic dehydration due to reduced urinary concentrating ability and later due to growth retardation induced by chronic kidney disease.",
"   </p>",
"   <p>",
"    Other clinical findings related to progressive chronic kidney disease include anemia, metabolic acidosis, and early uremic symptoms such as nausea, anorexia, and weakness. Proteinuria may be a late finding reflecting the development of secondary glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1\">",
"     1",
"    </a>",
"    ]. The tendency to sodium wasting probably accounts for the usual absence of hypertension in this disorder even with progressive loss of renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Retinitis pigmentosa and Senior-Loken syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Senior-Loken syndrome is characterized by the concomitant presentation of retinitis pigmentosa (also referred to as tapetoretinal degeneration (",
"    <a class=\"graphic graphic_picture graphicRef62898 \" href=\"UTD.htm?20/5/20575\">",
"     picture 1",
"    </a>",
"    )) and NPHP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It occurs in approximately 10 to 15 percent of cases of NPHP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/16\">",
"     16",
"    </a>",
"    ]. Although this syndrome is observed in association with mutations in all the NPHP genes except NPHP7, mutations of the NPHP5 and NPHP6 gene are the most common. In patients with mutations of these two genes, retinitis occurs early in life and is more severe than in patients with mutations in the other NPHP genes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NPHP5 gene &mdash; All patients with mutations of the NPHP5 gene have retinitis pigmentosa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H8#H8\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP5 gene'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NPHP6 gene &mdash; Although NPHP6 gene mutations are associated with Senior-Loken syndrome, they also are the cause of 20 percent of cases of Leber's congenital amaurosis, defined as recessive early-onset retinitis pigmentosa without renal disease. Patients with this disorder have congenital severe vision impairment or blindness due to the abnormal development of photoreceptors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H9#H9\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP6 gene'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=see_link&amp;anchor=H3#H3\">",
"       \"Retinitis pigmentosa: Clinical presentation and diagnosis\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NPHP10 gene &ndash; Mutations of the gene that encodes SDCCAG8 (serologically defined colon cancer antigen 8, also known as the centrosomal colon cancer autoantigen protein [CCCAP]) have been identified in 10 families with retinitis pigmentosa and NPHP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/19\">",
"       19",
"      </a>",
"      ]. SDCCAG8 is localized at the centrioles of both renal epithelial and retinal photoreceptor cells. This finding supports the role of the cilia-centrosome-mitotic spindle complex for single-gene disorders that affect both the kidney and retina.",
"     </li>",
"     <li>",
"      Other genes &mdash; In children with mutations in the NPHP 1, 2, 3, and 4 genes, retinitis pigmentosa occurs in approximately 10 percent of families [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1,20,21\">",
"       1,20,21",
"      </a>",
"      ]. The renal course of NPHP is not altered by the presence or absence of ocular involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H4#H4\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP1 gene'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H5#H5\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP2 gene'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H6#H6\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP3 gene'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H7#H7\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP4 gene'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In an Italian study of unrelated patients with NPHP, an allele of the AHI1 gene that encodes the protein jouberin (which interacts with nephrocystin-1) was associated with retinal disease in half of the patients with Senior-Loken syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/22\">",
"       22",
"      </a>",
"      ]. These patients did not have the other characteristic clinical manifestations of Joubert syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Joubert syndrome'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other syndromes in which NPHP can present as a main clinical finding include Joubert, Meckel-Gruber, Cogan, and Jeune syndromes. In addition to mutations of NPHP genes, these syndromes that are characterized by nonrenal symptoms including congenital neurologic abnormalities are associated with other gene mutations that affect ciliary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Joubert syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joubert syndrome is an autosomal recessive neurologic disorder characterized by cerebellar vermis hypoplasia resulting in ataxia, polydactyly, hypotonia, developmental delay, neonatal respiratory dysregulation, and abnormal eye movements [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. NPHP or cystic renal dysplasia is seen in approximately one-fourth of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/25\">",
"     25",
"    </a>",
"    ]. A pathognomonic finding on axial magnetic resonance imaging of the brain is the presence of prominent superior cerebellar peduncles, referred to as \"molar tooth sign\" of the midbrain-hindbrain junction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74695 \" href=\"UTD.htm?8/48/8975\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joubert syndrome can be associated with juvenile nephronophthisis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retinal involvement (Joubert syndrome type B). Several loci for Joubert syndrome associated with nephronophthisis have been isolated, suggesting genetic heterogeneity. These genes involve ciliary function include the following and their chromosomal loci:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      JBTS1, 2, and 3 genes at 9q34.3, 11p11.2-q12.3, and 6q23, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/11,27-29\">",
"       11,27-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CEP41 gene encodes centrosomal protein localized to the basal body and primary cilia, and is located at 7q31 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/30\">",
"       30",
"      </a>",
"      ]. This locus has also been referred to as JBTS15.",
"     </li>",
"     <li>",
"      AHI1 (Abelson helper integration site) gene that codes for the protein jouberin, which interacts with nephrocystin-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      MKS3 gene at 8q22 (also known as the TMEM67 gene) encodes meckelin, which is located at the base of primary cilia. It is also referred to as the NPHP11 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NPHP 1, 6, and 8 genes [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/21,23,24,35\">",
"       21,23,24,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      INPP5E gene, which encodes inositol polyphosphate-5-phosphatase E [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      TMEM216 gene codes for a protein that interacts with meckelin at the base of the primary cilia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CC2D2A gene, loss of function mutations of the CC2D2A gene result in clinical findings of Joubert syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/38\">",
"       38",
"      </a>",
"      ]. The CC2D2A gene product interacts with the ciliopathy-associated basal body protein CEP290.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a case series of 56 families with NPHP1 gene deletions, 9 percent of patients had a mild form of Joubert syndrome without intellectual disability (mental retardation) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/23\">",
"     23",
"    </a>",
"    ]. In another study of 28 families with NPHP and at least one Joubert-related neurologic finding, NPHP1 and NPHP6 gene mutations were found in 13 and 6 unrelated patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Meckel-Gruber syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the NPHP6, NPHP8, and MKS genes can cause Meckel-Gruber syndrome (MGS), an autosomal recessive lethal disorder characterized by central nervous system malformation (eg, occipital encephalocele), bilateral renal cystic dysplasia, cleft palate, polydactyly, ductal proliferation in the portal area of the liver, pulmonary hypoplasia and situs inversus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/27,39\">",
"     27,39",
"    </a>",
"    ]. MGS is lethal in early life.",
"   </p>",
"   <p>",
"    Mutations in the MKS1, MKS3, NPHP3, NPHP6, NPHP8, and TMEM216 genes have been found in patients with either Meckel-Gruber or Joubert syndrome suggesting that these two conditions represent a broad spectrum of the same underlying disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/31,37,40,41\">",
"     31,37,40,41",
"    </a>",
"    ]. In patients with NPHP8 gene mutations (also known as RPGRIP 1L gene), the phenotypic expression (ie, Joubert versus Meckel-Gruber syndrome) appears to be dependent upon the severity of the genetic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H174931069#H174931069\">",
"     \"Genetics and pathogenesis of nephronophthisis\", section on 'Genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cogan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cogan syndrome is defined by the association of nephronophthisis, congenital oculomotor apraxia, and hypoplasia of cerebellar vermis. Mutations of the NPHP1 and NPHP4 genes have been reported in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/1,42\">",
"     1,42",
"    </a>",
"    ]. Oculomotor apraxia has also been reported in Joubert syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18853731\">",
"    <span class=\"h3\">",
"     Jeune syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asphyxiating thoracic dystrophy (ATD, also called Jeune's syndrome) is an autosomal recessive skeletal dysplasia with multiorgan involvement. Mutations in TTC21B gene, which encodes the retrograde intraflagellar transport protein IFT139, are associated with isolated NPHP and ATD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H17#H17\">",
"     \"Diseases of the chest wall\", section on 'Asphyxiating thoracic dystrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other organs may also be affected in patients with NPHP, although the mechanism by which these changes occur is not understood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone &mdash; The association of NPHP with cone-shaped epiphyses is known as the Mainzer-Saldino syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/44\">",
"       44",
"      </a>",
"      ]. In addition to the bone anomalies, these patients may also have retinal degeneration and cerebellar ataxia.",
"     </li>",
"     <li>",
"      Liver &mdash; Hepatic involvement may be characterized by hepatosplenomegaly and portal fibrosis with no or only mild bile duct proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/12,45-47\">",
"       12,45-47",
"      </a>",
"      ]. Mutations in both alleles of the NPHP3 gene were reported in affected members of one family with hepatic fibrosis and NPHP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/12\">",
"       12",
"      </a>",
"      ]. Missense mutations in",
"      <span class=\"nowrap\">",
"       MKS3/TMEM67",
"      </span>",
"      have also been reported in patients with NPHP and associated liver fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Situs inversus &mdash; Situs inversus has been reported in a patient with infantile NPHP and mutation in the NPHP2 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H174931069#H174931069\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Septal cardiac defects have been reported in patients with NPHP2 and NPHP3 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/6,49\">",
"       6,49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of juvenile NPHP is suggested by the following clinical characteristics and confirmed by a positive genetic test (",
"    <a class=\"graphic graphic_picture graphicRef66242 \" href=\"UTD.htm?1/59/1975\">",
"     picture 2",
"    </a>",
"    ). In the absence of a positive gene test, a renal biopsy demonstrating chronic tubulointerstitial changes with a thickening of tubular basement membranes is suggestive of the diagnosis.",
"   </p>",
"   <p>",
"    NPHP should be considered in any child who presents with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyuria due to decreased concentrating ability (nephrogenic diabetes insipidus) with a relatively normal urinalysis (ie, no hematuria or proteinuria) and reduced urinary sodium conservation",
"     </li>",
"     <li>",
"      Progressive chronic kidney disease with a normal blood pressure",
"     </li>",
"     <li>",
"      Ultrasonography demonstrates normal or slightly decreased in size kidneys for age with increased echogenicity with loss of corticomedullary differentiation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/50\">",
"       50",
"      </a>",
"      ]. There is no dilation of the urinary tract, and renal cysts are not typically identified on the initial ultrasound examination but may appear at a late stage of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is also supported by the presence of associated extrarenal manifestations, especially retinitis pigmentosa, as previously described. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients in whom there is a high clinical suspicion for NPHP, screening for homozygous or heterozygous NPHP1 deletion should be performed. Homozygous deletions of about 250 kb on chromosome 2p12, the location of NPHP1 (the most common cause of NPHP), can be detected by the lack of amplification by PCR of genomic DNA markers; this test permits a quick and accurate diagnosis of the disease in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/4,52\">",
"     4,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the screen for mutation in all the other NPHP genes is not routinely performed due to the low frequency of detected mutations and the high cost of the procedure. Based upon the clinical manifestations of individual patients, testing of specific genes may be performed.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      NPHP5 gene in cases of severe retinitis pigmentosa",
"     </li>",
"     <li>",
"      NPHP6 and NPHP8 genes in patients with neurological symptoms",
"     </li>",
"     <li>",
"      NPHP2 gene in cases of early onset of CKD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Newer strategies to allow detection of additional genetic abnormalities are being developed, with newly generated multiplex marker sets enhancing the efficacy of molecular diagnostics via improved detection of heterozygous deletions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/52\">",
"     52",
"    </a>",
"    ]. Information regarding genetic testing for NPHP is available at",
"    <a class=\"external\" href=\"file://www.renalgenes.org/\">",
"     www.renalgenes.org",
"    </a>",
"    or",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    (both accessed on April 1, 2008).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders that can present with chronic kidney disease and a bland urine sediment in children and young adults include renal dysplasia, urinary tract obstruction, early onset autosomal dominant polycystic kidney disease, early onset ADPKD associated with contiguous mutations of the TSC2 and PKD1 genes, and autosomal recessive polycystic kidney disease. However, these disorders are associated with abnormalities detected on renal imaging: dysplastic kidney, hydronephrosis, and enlarged, hyperechogenic kidneys, respectively. There is no dilatation of the urinary tract in NPHP, but a large bladder may be seen because of the chronic polyuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific therapy for NPHP other than correction of water and electrolyte imbalances that may occur. Management of children in the early stage of the disease without renal impairment is focused upon replacing their ongoing water needs to prevent episodes of hypovolemia. In addition, adequate salt intake is maintained especially during intercurrent illnesses that may alter the fluid status, such as gastroenteritis.",
"   </p>",
"   <p>",
"    Patients with NPHP uniformly progress to ESRD. Renal transplantation is the preferred therapy in patients with ESRD because reported outcome is excellent as tubular injury does not recur in the transplanted kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/53\">",
"     53",
"    </a>",
"    ]. In a report from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry, the outcome of renal transplantation for patients with NPHP was better compared to the overall general pediatric transplant population, especially for patients who received living donor kidney transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16744/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephronophthisis (NPHP) is an autosomal recessive disorder that is characterized by a reduced urinary concentrating ability with a bland urinary sediment, chronic tubulointerstitial nephritis, and progression to end-stage renal disease (ESRD) at an early age (generally before the age of 20 years).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations of several genes, whose protein products are expressed in primary cilia, basal bodies, or centrosomes, have been identified in patients with NPHP. The gene products are thought to have roles in cell-cell and cell-matrix signaling, which involve sensing luminal flow rates within the renal tubules via ciliary mechanosensors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link\">",
"       \"Genetics and pathogenesis of nephronophthisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Three clinical variants have been described based upon the median age of onset of ESRD. These variants are associated with specific gene defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H174931069#H174931069\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Juvenile form (median onset of ESRD is 13 years of age) is the most common variant. It is associated with mutations in all the NPHP genes except NPHP2. In particular, patients with mutations of the NPHP1 gene, the most commonly affected gene, present with juvenile NPHP.",
"     </li>",
"     <li>",
"      The infantile form (median onset of ESRD by one year of age) is associated with mutations in the NPHP2 gene.",
"     </li>",
"     <li>",
"      The adolescent form (median onset of ESRD by 19 years of age) is associated with mutations in the NPHP3 genes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all patients with NPHP, the primary clinical finding is the insidious onset of renal failure at an early age. The most common extrarenal finding is retinitis pigmentosa, which occurs in approximately 15 percent of patients. The combination of NPHP and retinitis pigmentosa is referred to as Senior-Loken syndrome. Other syndromes in which NPHP is a major clinical finding include Joubert, Meckel-Gruber, and Cogan syndrome. These syndromes include other extrarenal manifestations including neurologic abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of NPHP is based upon a positive genetic test for mutations in one of the NPHP genes or a renal biopsy demonstrating chronic tubulointerstitial changes with a thickening of tubular basement membranes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H15#H15\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal imaging differentiates NPHP (normal or slightly decreased size and shape of the kidneys) from other disorders that can present with chronic renal failure and a bland urinalysis, which have an abnormal renal ultrasound. Other renal disorders include renal dysplasia, urinary tract obstruction, and polycystic kidney disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific treatment for NPHP. Renal transplantation is the preferred therapy in patients with ESRD because reported outcome is excellent, as tubular injury does not recur in the transplanted kidney. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/1\">",
"      Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol 2009; 20:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/2\">",
"      Bodaghi E, Honarmand MT, Ahmadi M. Infantile nephronophthisis. Int J Pediatr Nephrol 1987; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/3\">",
"      Burke JR, Inglis JA, Craswell PW, et al. Juvenile nephronophthisis and medullary cystic disease--the same disease (report of a large family with medullary cystic disease associated with gout and epilepsy). Clin Nephrol 1982; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/4\">",
"      Konrad M, Saunier S, Heidet L, et al. Large homozygous deletions of the 2q13 region are a major cause of juvenile nephronophthisis. Hum Mol Genet 1996; 5:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/5\">",
"      Haider NB, Carmi R, Shalev H, et al. A Bedouin kindred with infantile nephronophthisis demonstrates linkage to chromosome 9 by homozygosity mapping. Am J Hum Genet 1998; 63:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/6\">",
"      Otto EA, Schermer B, Obara T, et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet 2003; 34:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/7\">",
"      Gagnadoux MF, Bacri JL, Broyer M, Habib R. Infantile chronic tubulo-interstitial nephritis with cortical microcysts: variant of nephronophthisis or new disease entity? Pediatr Nephrol 1989; 3:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/8\">",
"      Hildebrandt F, Strahm B, Nothwang HG, et al. Molecular genetic identification of families with juvenile nephronophthisis type 1: rate of progression to renal failure. APN Study Group. Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Kidney Int 1997; 51:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/9\">",
"      Gretz N, Sch&auml;rer K, Waldherr R, Strauch M. Rate of deterioration of renal function in juvenile nephronophthisis. Pediatr Nephrol 1989; 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/10\">",
"      Saunier S, Calado J, Heilig R, et al. A novel gene that encodes a protein with a putative src homology 3 domain is a candidate gene for familial juvenile nephronophthisis. Hum Mol Genet 1997; 6:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/11\">",
"      Arts HH, Doherty D, van Beersum SE, et al. Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. Nat Genet 2007; 39:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/12\">",
"      Olbrich H, Fliegauf M, Hoefele J, et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 2003; 34:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/13\">",
"      Omran H, Fernandez C, Jung M, et al. Identification of a new gene locus for adolescent nephronophthisis, on chromosome 3q22 in a large Venezuelan pedigree. Am J Hum Genet 2000; 66:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/14\">",
"      SENIOR B, FRIEDMANN AI, BRAUDO JL. Juvenile familial nephropathy with tapetoretinal degeneration. A new oculorenal dystrophy. Am J Ophthalmol 1961; 52:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/15\">",
"      LOKEN AC, HANSSEN O, HALVORSEN S, JOLSTER NJ. Hereditary renal dysplasia and blindness. Acta Paediatr 1961; 50:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/16\">",
"      Otto EA, Loeys B, Khanna H, et al. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. Nat Genet 2005; 37:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/17\">",
"      Perrault I, Delphin N, Hanein S, et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum Mutat 2007; 28:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/18\">",
"      den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet 2006; 79:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/19\">",
"      Otto EA, Hurd TW, Airik R, et al. Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet 2010; 42:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/20\">",
"      Caridi G, Dagnino M, Gusmano R, et al. Clinical and molecular heterogeneity of juvenile nephronophthisis in Italy: insights from molecular screening. Am J Kidney Dis 2000; 35:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/21\">",
"      Caridi G, Murer L, Bellantuono R, et al. Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus. Am J Kidney Dis 1998; 32:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/22\">",
"      Louie CM, Caridi G, Lopes VS, et al. AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis. Nat Genet 2010; 42:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/23\">",
"      Caridi G, Dagnino M, Rossi A, et al. Nephronophthisis type 1 deletion syndrome with neurological symptoms: prevalence and significance of the association. Kidney Int 2006; 70:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/24\">",
"      Parisi MA, Bennett CL, Eckert ML, et al. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. Am J Hum Genet 2004; 75:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/25\">",
"      Tory K, Lacoste T, Burglen L, et al. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. J Am Soc Nephrol 2007; 18:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/26\">",
"      Castori M, Valente EM, Donati MA, et al. NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders. J Med Genet 2005; 42:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/27\">",
"      Delous M, Baala L, Salomon R, et al. The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. Nat Genet 2007; 39:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/28\">",
"      Lagier-Tourenne C, Boltshauser E, Breivik N, et al. Homozygosity mapping of a third Joubert syndrome locus to 6q23. J Med Genet 2004; 41:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/29\">",
"      Valente EM, Salpietro DC, Brancati F, et al. Description, nomenclature, and mapping of a novel cerebello-renal syndrome with the molar tooth malformation. Am J Hum Genet 2003; 73:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/30\">",
"      Lee JE, Silhavy JL, Zaki MS, et al. CEP41 is mutated in Joubert syndrome and is required for tubulin glutamylation at the cilium. Nat Genet 2012; 44:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/31\">",
"      Ferland RJ, Eyaid W, Collura RV, et al. Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome. Nat Genet 2004; 36:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/32\">",
"      Utsch B, Sayer JA, Attanasio M, et al. Identification of the first AHI1 gene mutations in nephronophthisis-associated Joubert syndrome. Pediatr Nephrol 2006; 21:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/33\">",
"      Dixon-Salazar T, Silhavy JL, Marsh SE, et al. Mutations in the AHI1 gene, encoding jouberin, cause Joubert syndrome with cortical polymicrogyria. Am J Hum Genet 2004; 75:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/34\">",
"      Chaki M, Hoefele J, Allen SJ, et al. Genotype-phenotype correlation in 440 patients with NPHP-related ciliopathies. Kidney Int 2011; 80:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/35\">",
"      Valente EM, Silhavy JL, Brancati F, et al. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. Nat Genet 2006; 38:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/36\">",
"      Bielas SL, Silhavy JL, Brancati F, et al. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nat Genet 2009; 41:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/37\">",
"      Valente EM, Logan CV, Mougou-Zerelli S, et al. Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. Nat Genet 2010; 42:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/38\">",
"      Gorden NT, Arts HH, Parisi MA, et al. CC2D2A is mutated in Joubert syndrome and interacts with the ciliopathy-associated basal body protein CEP290. Am J Hum Genet 2008; 83:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/39\">",
"      Baala L, Romano S, Khaddour R, et al. The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. Am J Hum Genet 2007; 80:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/40\">",
"      Kim YS, Kang HS, Herbert R, et al. Kruppel-like zinc finger protein Glis2 is essential for the maintenance of normal renal functions. Mol Cell Biol 2008; 28:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/41\">",
"      Baala L, Audollent S, Martinovic J, et al. Pleiotropic effects of CEP290 (NPHP6) mutations extend to Meckel syndrome. Am J Hum Genet 2007; 81:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/42\">",
"      Betz R, Rensing C, Otto E, et al. Children with ocular motor apraxia type Cogan carry deletions in the gene (NPHP1) for juvenile nephronophthisis. J Pediatr 2000; 136:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/43\">",
"      Davis EE, Zhang Q, Liu Q, et al. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet 2011; 43:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/44\">",
"      Mainzer F, Saldino RM, Ozonoff MB, Minagi H. Familial nephropathy associatdd with retinitis pigmentosa, cerebellar ataxia and skeletal abnormalities. Am J Med 1970; 49:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/45\">",
"      Boichis H, Passwell J, David R, Miller H. Congenital hepatic fibrosis and nephronophthisis. A family study. Q J Med 1973; 42:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/46\">",
"      Proesmans W, Van Damme B, Macken J. Nephronophthisis and tapetoretinal degeneration associated with liver fibrosis. Clin Nephrol 1975; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/47\">",
"      Witzleben CL, Sharp AR. \"Nephronophthisis-congenital hepatic fibrosis\": an additional hepatorenal disorder. Hum Pathol 1982; 13:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/48\">",
"      Otto EA, Tory K, Attanasio M, et al. Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11). J Med Genet 2009; 46:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/49\">",
"      Bergmann C, Fliegauf M, Br&uuml;chle NO, et al. Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. Am J Hum Genet 2008; 82:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/50\">",
"      Blowey DL, Querfeld U, Geary D, et al. Ultrasound findings in juvenile nephronophthisis. Pediatr Nephrol 1996; 10:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/51\">",
"      Garel LA, Habib R, Pariente D, et al. Juvenile nephronophthisis: sonographic appearance in children with severe uremia. Radiology 1984; 151:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/52\">",
"      Heninger E, Otto E, Imm A, et al. Improved strategy for molecular genetic diagnostics in juvenile nephronophthisis. Am J Kidney Dis 2001; 37:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/53\">",
"      Stavrou C, Deltas CC, Christophides TC, Pierides A. Outcome of kidney transplantation in autosomal dominant medullary cystic kidney disease type 1. Nephrol Dial Transplant 2003; 18:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16744/abstract/54\">",
"      Hamiwka LA, Midgley JP, Wade AW, et al. Outcomes of kidney transplantation in children with nephronophthisis: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry. Pediatr Transplant 2008; 12:878.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6132 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16744=[""].join("\n");
var outline_f16_22_16744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Retinitis pigmentosa and Senior-Loken syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Joubert syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Meckel-Gruber syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cogan syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18853731\">",
"      - Jeune syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6132|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/48/8975\" title=\"diagnostic image 1\">",
"      Molar tooth sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6132|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/5/20575\" title=\"picture 1\">",
"      Tapetoretinal degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/59/1975\" title=\"picture 2\">",
"      Histology of nephrophthisis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=related_link\">",
"      Retinitis pigmentosa: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_22_16745="Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology";
var content_f16_22_16745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16745/contributors\">",
"     Michael S Cooperstock, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16745/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16745/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/22/16745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiology, pathogenesis, and epidemiology of",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    infection in children will be discussed below. The clinical features, diagnosis, treatment, and prevention of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in adults also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Organism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    is an anaerobic, gram-positive, spore-forming, toxin-producing bacillus. In the environment,",
"    <em>",
"     C. difficile",
"    </em>",
"    survives in spore form; spores are resistant to heat (even ordinary cooking heat), acid, antibiotics, and most antiseptics. Once",
"    <em>",
"     C. difficile",
"    </em>",
"    spores reach the colon, they convert to the fully functional vegetative, toxin-producing form and become susceptible to killing by antimicrobial agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H9#H9\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     C. difficile",
"    </em>",
"    is widely distributed in nature and, as a spore-forming bacterium, can persist in the hospital environment for as long as several months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Toxigenic strains have been identified in healthy humans, food sources, farm animals, household pets, and hospital pet therapy dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <em>",
"     C. difficile",
"    </em>",
"    can be cultured from the environment in nursing homes, child care areas, and hospitals, particularly from the rooms of colonized or infected individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    produces toxins A and B, which account for much of its virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/5\">",
"     5",
"    </a>",
"    ]. Toxin A is an enterotoxin (active in intestinal loop models, as well as in tissue culture), whereas toxin B is a cytotoxin (active only in tissue culture). The toxins bind to proposed receptors on intestinal epithelial cells, leading to cell death, inflammation, and diarrhea. Fecal toxin levels correlate only roughly with disease severity. Toxin B appears to be the more critical of the two toxins, since occasional strains that lack toxin A can cause disease similar in severity to strains having both toxins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H10#H10\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Toxins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypervirulent strain (BI/NAP1/027)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypervirulent strain of",
"    <em>",
"     C. difficile",
"    </em>",
"    <span class=\"nowrap\">",
"     (BI/NAP1/027)",
"    </span>",
"    has been increasingly implicated in",
"    <em>",
"     C. difficile",
"    </em>",
"    infection since the early 2000s. This strain produces increased amounts of toxins A and B, possesses a third toxin called binary toxin, and is largely quinolone resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H11#H11\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Hypervirulent strain: NAP1/BI/027'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease is incompletely understood. For example, reasons for the striking differences in susceptibility or resistance to",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization and disease among individuals throughout the full age range are unclear, and the necessary and sufficient predisposing alterations in colonic flora are still unknown. However, disease expression is known to involve the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/5,9,10\">",
"     5,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alteration of the colonic microflora (usually, but not always, following antibiotic therapy)",
"     </li>",
"     <li>",
"      <em>",
"       C. difficile",
"      </em>",
"      ingestion, colonization, and overgrowth",
"     </li>",
"     <li>",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin production (necessary but not sufficient)",
"     </li>",
"     <li>",
"      Effects on intestinal epithelial cells, resulting in mucosal injury, inflammation, and diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonization with nontoxigenic strains, which may afford protection against toxigenic",
"      <em>",
"       C. difficile",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toxin A antibody production. Adults with low or undetectable levels of antibody against",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin A are more likely to develop diarrhea than those with detectable antibody against toxin A [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interleukin (IL)-8 polymorphism. Adults with the common IL-8 AA genotype polymorphism demonstrate elevated serum IL-8 levels, an impaired humoral immune response to",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin A, and increased susceptibility to",
"      <em>",
"       C. difficile",
"      </em>",
"      -associated diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variants in intestinal toxin receptors may be relevant. For example, juvenile rabbits lack intestinal receptors for toxin A and are resistant to disease, whereas juvenile pigs have receptors and are susceptible to",
"      <em>",
"       C. difficile",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H12#H12\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transmission in hospital and community",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    may be acquired from the environment or transmitted by the fecal-oral route from colonized or infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/5,17\">",
"     5,17",
"    </a>",
"    ].",
"    <em>",
"     C. difficile",
"    </em>",
"    disease commonly occurs either epidemically or endemically in hospitals. Hospital strains can be acquired from environmental surfaces and transmitted by human hands.",
"    <em>",
"     C. difficile",
"    </em>",
"    has also increasingly been acquired in the community by patients without prior healthcare exposure, antimicrobial treatment, or other established risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Domestic and food animals are frequently colonized. Toxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    may be found frequently in retail ground meat [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/18\">",
"     18",
"    </a>",
"    ]. Asymptomatically colonized infants and young children are also a potentially important source for",
"    <em>",
"     C. difficile",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise incubation period is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/17\">",
"     17",
"    </a>",
"    ]. However, symptoms of illness in antibiotic-associated colitis typically begin either during or shortly after antibiotic administration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the early 2000s, the frequency and severity of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection have increased 3- to 15-fold in adults, in part due to the emergence of hypervirulent",
"    <span class=\"nowrap\">",
"     (BI/NAP1/027)",
"    </span>",
"    strains (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    ). Smaller increases have been documented for children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/20-24\">",
"     20-24",
"    </a>",
"    ], where large national surveys found 1.8-fold increased",
"    <em>",
"     C. difficile",
"    </em>",
"    -related pediatric hospitalization between 1997 and 2006. Peak incidence was in the one- to four-year age group; notably, however, in 2006, more than 40 percent of children hospitalized with",
"    <em>",
"     C. difficile",
"    </em>",
"    illness were older than four years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/21\">",
"     21",
"    </a>",
"    ]. A similar increase has not yet been described in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether diagnosed by culture, cytotoxin assay, or enzyme immunoassay, asymptomatic intestinal colonization with toxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    is very common in infancy and early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/7-9,27\">",
"     7-9,27",
"    </a>",
"    ]. This phenomenon has two important implications: (1) Infants and young children may be an important source for",
"    <em>",
"     C. difficile",
"    </em>",
"    acquisition by adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/19\">",
"     19",
"    </a>",
"    ], and (2) since infectious diarrhea from other causes is also very common, it is likely that a finding of",
"    <em>",
"     C. difficile",
"    </em>",
"    may be incidental in most infants and young children with diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876098\">",
"    <span class=\"h4\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization is common. The cited rates range from 0 to as high as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/5,28-32\">",
"     5,28-32",
"    </a>",
"    ]. In both well-baby nurseries and neonatal intensive care units, infants are particularly vulnerable to nosocomial acquisition of toxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    from a contaminated nursery environment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/33\">",
"     33",
"    </a>",
"    ]. The risk of colonization increases with the duration of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/30\">",
"     30",
"    </a>",
"    ]. Strain typing demonstrates that a limited number of strains are shared by infants and the environment; maternal sources are rarely identified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/29,32,33\">",
"     29,32,33",
"    </a>",
"    ]. In the first few weeks of life, neither antibiotic treatment nor formula feeding appears to increase",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization.",
"    <br/>",
"    <br/>",
"    Although neonates frequently are colonized with toxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    , they rarely develop symptomatic disease, despite high levels of colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/28,29,33\">",
"     28,29,33",
"    </a>",
"    ]. The reasons for this paradox in neonates are unknown. An absence of intestinal receptors for",
"    <em>",
"     C. difficile",
"    </em>",
"    toxins has been proposed. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876105\">",
"    <span class=\"h4\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who did not acquire",
"    <em>",
"     C. difficile",
"    </em>",
"    in the newborn period frequently become colonized during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. As many as 70 percent of infants may be colonized with",
"    <em>",
"     C. difficile",
"    </em>",
"    , including toxigenic strains [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/36\">",
"     36",
"    </a>",
"    ]. Unlike neonates, exclusively breast-fed older infants are colonized much less frequently, and at lower levels, than formula-fed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. High levels of",
"    <em>",
"     C. difficile",
"    </em>",
"    organisms and toxins, similar to those in adults with pseudomembranous colitis, may be found in the stools of healthy, asymptomatic infants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/27,40\">",
"     27,40",
"    </a>",
"    ]. Colonization rates then gradually decrease with age.",
"   </p>",
"   <p>",
"    Once established, colonization persists in an individual infant for weeks or months. In one study, colonization persisted for an average of six months among infants studied during the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/40\">",
"     40",
"    </a>",
"    ]. Individual infants may demonstrate shifts between toxigenic and nontoxigenic strains over time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surveys of asymptomatic children younger than four years of age have demonstrated colonization or detectable fecal cytotoxin in 7 to 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/27,41\">",
"     27,41",
"    </a>",
"    ]. After approximately four years of age,",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization rates have decreased to &lt;5 percent, similar to rates in nonhospitalized adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypervirulent strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known yet about the prevalence or clinical severity of infection with hypervirulent strains among children. Given data in adults, both are likely to be increasing. In a pediatric study,",
"    <span class=\"nowrap\">",
"     BI/NAP1/027",
"    </span>",
"    accounted for 19 percent of 134 toxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    strains isolated from children in Philadelphia and Cleveland during 2006-2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic pretreatment appears to have little role in",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization or infection among children younger than approximately three to five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, in older children and adults, the risk of",
"    <em>",
"     C. difficile",
"    </em>",
"    acquisition is markedly increased by antimicrobial treatment, although severe",
"    <em>",
"     C. difficile",
"    </em>",
"    infection now occurs increasingly without prior antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/8\">",
"     8",
"    </a>",
"    ]. In a retrospective cohort from a tertiary-care children's hospital (2001-2006), prior antimicrobial exposure was absent in 43 percent of pediatric cases of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any antibiotic may predispose to",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/5,46\">",
"     5,46",
"    </a>",
"    ]. However, penicillins, cephalosporins,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , macrolides, and fluoroquinolones are most frequently implicated. Conversely, sulfonamides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and aminoglycosides are infrequently implicated in children. In a case-control study, exposure to multiple classes of antibiotics in the preceding 30 days was associated with severe",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/47\">",
"     47",
"    </a>",
"    ]. Resistance to fluoroquinolones has undoubtedly helped promote the current progressive worldwide distribution of",
"    <span class=\"nowrap\">",
"     BI/NAP1/027",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proton pump inhibitors have been shown to predispose to",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in adults. This has also been reported in children (odds ratio 4.5, 95% CI, 1.4-14.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/49\">",
"     49",
"    </a>",
"    ]. Other risk factors include gastrostomy or jejunostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/50\">",
"     50",
"    </a>",
"    ], elemental nutrition via gastric or small bowel tube feeding, prolonged hospitalization, the number and proximity of infected patients in the hospital environment, certain intestinal disorders, and immune compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H4#H4\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREDISPOSING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of pediatric conditions (discussed below) that seem to have unique associations with",
"    <em>",
"     C. difficile",
"    </em>",
"    . These conditions may predispose to",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, may be exacerbated by",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, or may increase the risk of severe or fatal",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/17\">",
"     17",
"    </a>",
"    ]. Conversely, however, because",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization is so frequent in children, the observed associations between fecal",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin and intestinal symptoms may be completely incidental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Occult underlying conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in previously healthy children should prompt consideration of these possible underlying conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunodeficiency &ndash; Any undiagnosed immunodeficiency is possible in children with",
"      <em>",
"       C. difficile",
"      </em>",
"      disease; for example, transient hypogammaglobulinemia of infancy and other types of hypogammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/51,52\">",
"       51,52",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"       \"Transient hypogammaglobulinemia of infancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link&amp;anchor=H2#H2\">",
"       \"Primary humoral immune deficiencies: An overview\", section on 'Presentation of humoral immune deficiency'",
"      </a>",
"      ). Interleukin-8 AA polymorphism is a reported risk factor in adults. Analogous to interleukin-8, it seems highly likely that many other susceptibility-promoting polymorphisms will be discovered among the large number of currently emerging innate defense molecules. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hirschsprung disease &ndash; Children with Hirschsprung disease may have alterations in mucosal defense, predisposing them to",
"      <em>",
"       C. difficile",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/53\">",
"       53",
"      </a>",
"      ]. However, there are few data evaluating this possibility, and it is not known definitively whether difficile contributes to Hirschsprung enterocolitis.",
"      <br/>",
"      <br/>",
"      Nonetheless, individual case reports and small case series suggest that",
"      <em>",
"       C. difficile",
"      </em>",
"      and Hirschsprung enterocolitis are often associated, suggesting the relationship could be causal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. Alternatively, since toxigenic",
"      <em>",
"       C. difficile",
"      </em>",
"      colonization is so common in young children, the association may be incidental, at least in relatively mild cases of Hirschsprung enterocolitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/56\">",
"       56",
"      </a>",
"      ]. Severe pseudomembranous colitis in children with Hirschsprung disease is perhaps more likely to be caused by",
"      <em>",
"       C. difficile",
"      </em>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link&amp;anchor=H8#H8\">",
"       \"Clostridium difficile infection in children: Clinical features\", section on 'Pseudomembranous colitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=see_link&amp;anchor=H5#H5\">",
"       \"Emergency complications of Hirschsprung disease\", section on 'Enterocolitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infant botulism &ndash;",
"      <em>",
"       C. difficile",
"      </em>",
"      may be superimposed on the intestinal immobility induced by botulinum toxin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"       \"Botulism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease &ndash;",
"      <em>",
"       C. difficile",
"      </em>",
"      infection may be the initial mode of presentation for previously unsuspected inflammatory bowel disease (IBD). At least two studies of IBD in children and adolescents demonstrate an association between IBD exacerbation and fecal",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. In the larger of these, fecal",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin was detected in 44 percent of children and adolescents with IBD exacerbation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Conditions with increased susceptibility to severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with known immune compromise, Hirschsprung disease, infant botulism, and inflammatory bowel disease have increased susceptibility to severe",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, as described above. Children with the following conditions also may develop severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer-related or solid-organ transplant-related immunosuppression &ndash; A limited number of observational studies suggest that both",
"      <em>",
"       C. difficile",
"      </em>",
"      colonization and infection are common in pediatric oncology patients and children who have undergone solid organ transplants [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/50,61-66\">",
"       50,61-66",
"      </a>",
"      ]. Although",
"      <em>",
"       C. difficile",
"      </em>",
"      may be an incidental finding,",
"      <em>",
"       C. difficile",
"      </em>",
"      should be considered in those presenting with more severe intestinal illness (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52523 \" href=\"UTD.htm?25/62/26593\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cystic fibrosis &ndash; In studies from the 1980s, asymptomatic colonization with toxigenic",
"      <em>",
"       C. difficile",
"      </em>",
"      was reported in 14 to 43 percent of pediatric and young adult patients with cystic fibrosis (CF) who had received recent or continuous antimicrobial therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/67-69\">",
"       67-69",
"      </a>",
"      ]. Fecal toxins were detectable in 0 to 14 percent. In a more recent study, using enzyme immunoassay, fecal toxins were detected in 47 percent of 30 CF patients ages 1 to 44 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/70\">",
"       70",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As with other groups of children noted to have frequent asymptomatic",
"      <em>",
"       C. difficile",
"      </em>",
"      colonization, observed associations between fecal toxin and intestinal disease in patients with CF may be incidental. However, severe",
"      <em>",
"       C. difficile",
"      </em>",
"      infection with typical findings of pseudomembranous colitis has been well-documented [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/71-74\">",
"       71-74",
"      </a>",
"      ]. Several of the cases were \"atypical\", that is, presenting without diarrhea, often with no stool for days, clinically suggesting the far more common distal intestinal obstruction syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19706?source=see_link&amp;anchor=H10#H10\">",
"       \"Cystic fibrosis: Overview of gastrointestinal disease\", section on 'Distal intestinal obstruction syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Structural or postoperative intestinal disorders &ndash; Severe",
"      <em>",
"       C. difficile",
"      </em>",
"      disease may occur in children with structural intestinal disorders and after intestinal operations, including placement of an ileostomy. Severe enteritis should prompt consideration of",
"      <em>",
"       C. difficile",
"      </em>",
"      disease in such children, whether in the immediate postoperative period or later. It is unknown whether",
"      <em>",
"       C. difficile",
"      </em>",
"      may play a role in some of the various intestinal complications that occur in children receiving parenteral nutrition for short bowel syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions linked to",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in case reports or case series include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemolytic uremic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16745/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       Clostridium difficile",
"      </em>",
"      is an anaerobic, gram-positive, spore-forming, toxin-producing bacillus. The spore form of",
"      <em>",
"       C. difficile",
"      </em>",
"      is resistant to heat, acid, antibiotics, and most antiseptics, and can persist in the hospital environment for several months. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Organism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of",
"      <em>",
"       C. difficile",
"      </em>",
"      disease involves altered colonic microflora;",
"      <em>",
"       C. difficile",
"      </em>",
"      ingestion, colonization, and overgrowth; toxin production; and toxin effects on intestinal epithelial cells, resulting in mucosal injury, inflammation, and diarrhea. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic",
"      <em>",
"       C. difficile",
"      </em>",
"      colonization is common among neonates and infants; cited rates range up to 50 percent. However, these children rarely develop symptomatic disease. The rate of colonization decreases during the preschool years to &lt;5 percent, similar to the rate in adults. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic use is a major risk factor for",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in children beyond the preschool years. The antibiotics most frequently implicated include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      , penicillins, cephalosporins, fluoroquinolones, and macrolides. However, an increasing minority of cases occur without prior antimicrobial exposure. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional risk factors for",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in children may include exposure to organisms originating from infected patients in the hospital environment, prolonged hospitalization, proton pump inhibitors, gastrostomy or jejunostomy tubes, gastric or small intestinal tube feeding, and lack of preexisting toxin-neutralizing antibodies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain medical conditions may present with",
"      <em>",
"       C. difficile",
"      </em>",
"      infection and predispose to severe infection. In the appropriate clinical setting,",
"      <em>",
"       C. difficile",
"      </em>",
"      infection should prompt consideration of such diagnoses as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immunodeficiency, including hypogammaglobulinemia",
"     </li>",
"     <li>",
"      Interleukin-8 polymorphism",
"     </li>",
"     <li>",
"      Hirschsprung disease",
"     </li>",
"     <li>",
"      Infant botulism",
"     </li>",
"     <li>",
"      Inflammatory bowel disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other conditions that may predispose to severe",
"    <em>",
"     C. difficile",
"    </em>",
"    infection include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immunosuppressive treatment",
"     </li>",
"     <li>",
"      Cystic fibrosis",
"     </li>",
"     <li>",
"      Structural or postoperative intestinal disorder",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </li>",
"     <li>",
"      Hemolytic uremic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The threshold for consideration of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in children with predisposing conditions should be lower than it is for children without these conditions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Predisposing conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author gratefully acknowledges the assistance of Caryn Scoville, librarian III and Information Services librarian, University of Missouri Libraries.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/1\">",
"      Kim KH, Fekety R, Batts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/2\">",
"      Malamou-Ladas H, O'Farrell S, Nash JQ, Tabaqchali S. Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol 1983; 36:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/3\">",
"      Fekety R, Kim KH, Brown D, et al. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med 1981; 70:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/4\">",
"      Lefebvre SL, Weese JS. Contamination of pet therapy dogs with MRSA and Clostridium difficile. J Hosp Infect 2009; 72:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/5\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/6\">",
"      McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Surveillance for community-associated Clostridium difficile--Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/9\">",
"      Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006; 73:187.",
"     </a>",
"    </li>",
"    <li>",
"     Ferry G, Versalovic J. Antibiotic-associated colitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/11\">",
"      Songer JG, Jones R, Anderson MA, et al. Prevention of porcine Clostridium difficile-associated disease by competitive exclusion with nontoxigenic organisms. Vet Microbiol 2007; 124:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/12\">",
"      Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/13\">",
"      Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/14\">",
"      Jiang ZD, Garey KW, Price M, et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 2007; 5:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/15\">",
"      Eglow R, Pothoulakis C, Itzkowitz S, et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 1992; 90:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/16\">",
"      Keel MK, Songer JG. The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs. Vet Pathol 2007; 44:814.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LJ.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/18\">",
"      Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis 2007; 13:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/19\">",
"      Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008; 62:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/20\">",
"      Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/21\">",
"      Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/22\">",
"      Baker SS, Faden H, Sayej W, et al. Increasing incidence of community-associated atypical Clostridium difficile disease in children. Clin Pediatr (Phila) 2010; 49:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/23\">",
"      Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/24\">",
"      Chen KT, Stephens DJ, Anderson E, et al. Clostridium difficile infection in the pediatric surgery population. J Pediatr Surg 2012; 47:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/25\">",
"      Lyytik&auml;inen O, Turunen H, Sund R, et al. Hospitalizations and deaths associated with Clostridium difficile infection, Finland, 1996-2004. Emerg Infect Dis 2009; 15:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/26\">",
"      Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/27\">",
"      Rousseau C, Lem&eacute;e L, Le Monnier A, et al. Prevalence and diversity of Clostridium difficile strains in infants. J Med Microbiol 2011; 60:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/28\">",
"      Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001; 7:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/29\">",
"      Larson HE, Barclay FE, Honour P, Hill ID. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/30\">",
"      Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981; 81:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/31\">",
"      Al-Jumaili IJ, Shibley M, Lishman AH, Record CO. Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol 1984; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/32\">",
"      Martirosian G, Kuipers S, Verbrugh H, et al. PCR ribotyping and arbitrarily primed PCR for typing strains of Clostridium difficile from a Polish maternity hospital. J Clin Microbiol 1995; 33:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/33\">",
"      Zedd AJ, Sell TL, Schaberg DR, et al. Nosocomial Clostridium difficile reservoir in a neonatal intensive care unit. Pediatr Infect Dis 1984; 3:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/34\">",
"      Libby JM, Donta ST, Wilkins TD. Clostridium difficile toxin A in infants. J Infect Dis 1983; 148:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/35\">",
"      M&aring;rdh PA, Helin I, Colleen I, et al. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea. Acta Paediatr Scand 1982; 71:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/36\">",
"      Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J 2009; 28:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/37\">",
"      Cooperstock MS, Steffen E, Yolken R, Onderdonk A. Clostridium difficile in normal infants and sudden infant death syndrome: an association with infant formula feeding. Pediatrics 1982; 70:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/38\">",
"      Cooperstock M, Riegle L, Woodruff CW, Onderdonk A. Influence of age, sex, and diet on asymptomatic colonization of infants with Clostridium difficile. J Clin Microbiol 1983; 17:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/39\">",
"      Euler AR, Mitchell DK, Kline R, Pickering LK. Prebiotic effect of fructo-oligosaccharide supplemented term infant formula at two concentrations compared with unsupplemented formula and human milk. J Pediatr Gastroenterol Nutr 2005; 40:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/40\">",
"      Stark PL, Lee A, Parsonage BD. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect Immun 1982; 35:895.",
"     </a>",
"    </li>",
"    <li>",
"     Cooperstock M. Clostridium difficile in infants and children. In: Clostridium Difficile Associated Intestinal Diseases, Rambaud JC, Ducluzeau R (Eds), Springer-Verlag, Paris 1990. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/42\">",
"      Vernacchio L, Vezina RM, Mitchell AA, et al. Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J 2006; 25:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/43\">",
"      Toltzis P, Kim J, Dul M, et al. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr 2009; 154:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/44\">",
"      Klein EJ, Boster DR, Stapp JR, et al. Diarrhea etiology in a Children's Hospital Emergency Department: a prospective cohort study. Clin Infect Dis 2006; 43:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/45\">",
"      Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007; 28:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/46\">",
"      Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/47\">",
"      Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/48\">",
"      P&eacute;pin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/49\">",
"      Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/50\">",
"      Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011; 30:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/51\">",
"      Gryboski JD, Pellerano R, Young N, Edberg S. Positive role of Clostridium difficile infection in diarrhea in infants and children. Am J Gastroenterol 1991; 86:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/52\">",
"      Perlmutter DH, Leichtner AM, Goldman H, Winter HS. Chronic diarrhea associated with hypogammaglobulinemia and enteropathy in infants and children. Dig Dis Sci 1985; 30:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/53\">",
"      Qualman SJ, Petric M, Karmali MA, et al. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol 1990; 94:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/54\">",
"      Thomas DF, Fernie DS, Bayston R, et al. Enterocolitis in Hirschsprung's disease: a controlled study of the etiologic role of Clostridium difficile. J Pediatr Surg 1986; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/55\">",
"      Urushihara N, Kohno S, Hasegawa S. Pseudomembranous enterocolitis and hemorrhagic necrotizing enterocolitis in Hirschsprung's disease. Surg Today 1994; 24:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/56\">",
"      Wilson-Storey D, Scobie WG, McGenity KG. Microbiological studies of the enterocolitis of Hirschsprung's disease. Arch Dis Child 1990; 65:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/57\">",
"      Thompson CM Jr, Gilligan PH, Fisher MC, Long SS. Clostridium difficile cytotoxin in a pediatric population. Am J Dis Child 1983; 137:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/58\">",
"      Schechter R, Peterson B, McGee J, et al. Clostridium difficile colitis associated with infant botulism: near-fatal case analogous to Hirschsprung's enterocolitis. Clin Infect Dis 1999; 29:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/59\">",
"      Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr 1991; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/60\">",
"      Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/61\">",
"      Burgner D, Siarakas S, Eagles G, et al. A prospective study of Clostridium difficile infection and colonization in pediatric oncology patients. Pediatr Infect Dis J 1997; 16:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/62\">",
"      Brunetto AL, Pearson AD, Craft AW, Pedler SJ. Clostridium difficile in an oncology unit. Arch Dis Child 1988; 63:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/63\">",
"      Murabata M, Kato H, Yano H, et al. [Intestinal colonization and nosocomial spread of Clostridium difficile in pediatric cancer patients under long-term hospitalization]. Kansenshogaku Zasshi 2008; 82:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/64\">",
"      Castagnola E, Battaglia T, Bandettini R, et al. Clostridium difficile-associated disease in children with solid tumors. Support Care Cancer 2009; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/65\">",
"      Simon A, Ammann RA, Bode U, et al. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 2008; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/66\">",
"      Tai E, Richardson LC, Townsend J, et al. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011; 30:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/67\">",
"      Wu TC, McCarthy VP, Gill VJ. Isolation rate and toxigenic potential of Clostridium difficile isolates from patients with cystic fibrosis. J Infect Dis 1983; 148:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/68\">",
"      Welkon CJ, Long SS, Thompson CM Jr, Gilligan PH. Clostridium difficile in patients with cystic fibrosis. Am J Dis Child 1985; 139:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/69\">",
"      Peach SL, Borriello SP, Gaya H, et al. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol 1986; 39:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/70\">",
"      Yahav J, Samra Z, Blau H, et al. Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig Dis Sci 2006; 51:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/71\">",
"      Rivlin J, Lerner A, Augarten A, et al. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis. J Pediatr 1998; 132:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/72\">",
"      Hussain SZ, Chu C, Greenberg DP, et al. Clostridium difficile colitis in children with cystic fibrosis. Dig Dis Sci 2004; 49:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/73\">",
"      Yates B, Murphy DM, Fisher AJ, et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. Thorax 2007; 62:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/74\">",
"      Theunissen C, Knoop C, Nonhoff C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis 2008; 10:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/75\">",
"      Narchi H, Beattie TJ, Taylor RG, et al. Pseudomembranous colitis in association with Henoch Schonlein purpura. Scott Med J 1988; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/76\">",
"      Boey CC, Ramanujam TM, Looi LM. Clostridium difficile-related necrotizing pseudomembranous enteritis in association with Henoch-Schonlein purpura. J Pediatr Gastroenterol Nutr 1997; 24:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/77\">",
"      Rooney N, Variend S, Taitz LS. Haemolytic uraemic syndrome and pseudomembranous colitis. Pediatr Nephrol 1988; 2:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16745/abstract/78\">",
"      Burgner DP, Rfidah H, Beattie TJ, Seal DV. Clostridium difficile after haemolytic uraemic syndrome. Arch Dis Child 1993; 69:239.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6041 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16745=[""].join("\n");
var outline_f16_22_16745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Organism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypervirulent strain (BI/NAP1/027)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transmission in hospital and community",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1876098\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1876105\">",
"      Infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypervirulent strains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREDISPOSING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Occult underlying conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Conditions with increased susceptibility to severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6041|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/62/26593\" title=\"diagnostic image 1\">",
"      C difficile sonogram",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=related_link\">",
"      Clostridium difficile infection in children: Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=related_link\">",
"      Clostridium difficile infection in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=related_link\">",
"      Clostridium difficile infection in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19706?source=related_link\">",
"      Cystic fibrosis: Overview of gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=related_link\">",
"      Emergency complications of Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_22_16746="Cytokine networks in rheumatic diseases: Implications for therapy";
var content_f16_22_16746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytokine networks in rheumatic diseases: Implications for therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16746/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16746/contributors\">",
"     Iain B McInnes, FRCP, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16746/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16746/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16746/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/22/16746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/22/16746/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/22/16746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the contribution of cytokines to the pathogenesis of rheumatic diseases offers novel and creative therapeutic options that were not previously available. This is especially true in rheumatoid arthritis (RA), in which the cytokine milieu of the joint is reasonably well-understood and in which data on human clinical trials are already available. Therapies designed to block the effects of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 receptor (IL-6R) action in this illness are effective in many patients with RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although biologic agents that regulate cytokines have met with success in the treatment of RA, small molecules that block cytokine production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signaling will likely have a competitive advantage in the coming years. An important note of caution, however, is that there is the possibility that suppressing even physiologic concentrations of some cytokines could have serious adverse effects on immune surveillance.",
"   </p>",
"   <p>",
"    This topic will review the issues relating to the manipulation of cytokine networks in patients with rheumatic disease, with an emphasis on RA. The pathogenesis of RA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INHIBITION OF CYTOKINE PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A host of small molecules with anticytokine properties are being developed or are already in clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    ), which are potent transcriptional inhibitors of production of a variety of cytokines, including interleukin (IL)-1, IL-6, and TNF, have been available for many years and have clear utility in rheumatic disorders. It is not certain whether this activity accounts for their therapeutic benefit or, more likely, whether it represents only one of many effects of glucocorticoids. Other activities that might be therapeutically important include the inhibition of adhesion molecule expression, arachidonic acid metabolism, and metalloproteinase production. These and other effects of glucocorticoids on the immune system are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other inhibitors of cytokine gene transcription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other anticytokine approaches are in earlier stages of development. As examples, transcription of cytokine genes can be reduced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , phosphodiesterase inhibition, and adenosine receptor agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    , a teratogenic sedative, decreases the transcription genes for proinflammatory cytokines and also decreases the stability of mRNA, particularly for TNF. However, adverse effects of thalidomide limit the usefulness of this agent in the treatment of rheumatic diseases. Analogues of thalidomide with greater potency in inhibiting TNF production that are not teratogenic in appropriate animal models may be candidates for study in patients with rheumatic diseases. One such analogue,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , is being studied as a potential treatment for multiple myeloma and myelodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonspecific phosphodiesterase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    (oxpentifylline), inhibits TNF transcription and abrogates experimental arthritis in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in several small, unblinded clinical trials, it produced minimal clinical benefits and was poorly tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The clinical usefulness of agents that selectively inhibit phosphodiesterase (PDE)-5 (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ) has been studied and has entered clinical practice in primary and secondary pulmonary arterial hypertension, including that associated with systemic sclerosis. Other inhibitors of PDE (eg, apremilast) are being studied in clinical trials in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\", section on 'Phosphodiesterase type 5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adenosine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of transcription of TNF is one of the properties of adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/2\">",
"     2",
"    </a>",
"    ]. Increased production of adenosine is suggested to be one of the mechanisms of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Longer-lived adenosine agonists that interact with the A3 adenosine receptor have antiinflammatory effects and reduce production of TNF when studied in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/4\">",
"     4",
"    </a>",
"    ]. Use of adenosine agonists in humans may be limited by dose-related adverse effects including flushing, tachycardia, nausea, vomiting, and leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/10\">",
"     10",
"    </a>",
"    ]. Short-term use of tolerable oral doses of one such agonist, CF101, in healthy human subjects suggested that clinical trials of this approach to treatment of inflammatory arthritis may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inhibiting posttranslational processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokine production can also be interrupted by blocking posttranslational processing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     IL-1 beta converting enzyme (ICE) inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of the IL-1 beta converting enzyme (ICE) is one example of reducing cytokine production by inhibiting posttranslational protein processing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/11\">",
"     11",
"    </a>",
"    ]. ICE is responsible for cleaving the inactive precursor of IL-1 beta into an active molecule, and an ICE inhibitor should decrease the release of biologically active IL-1. This approach might also be expected to reduce the synthesis of interleukin (IL)-18, a cytokine that is part of the IL-1 superfamily and that has pleiotropic effects, particularly stimulation of Th1 immune responses. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Interleukin-18'",
"    </a>",
"    below.) TNF is also produced though a pathway that may be amenable to a similar approach.",
"   </p>",
"   <p>",
"    A preliminary study of an oral ICE inhibitor, pralnacasan, has been conducted in humans with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/12\">",
"     12",
"    </a>",
"    ]. Antiinflammatory effects were noted, and diarrhea and nausea were the most frequently reported adverse effects. Clinical studies of this agent have been halted due to the finding of hepatotoxic effects in animals that received the drug for several months. Testing has not progressed successfully through larger controlled trials, and the drug is not being developed further for this purpose. Other caspase inhibitors have similarly been of limited success when tested in clinical trials as opposed to animal models, and this approach is deemed unlikely to succeed at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     TNF-alpha converting enzyme (TACE) inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The membrane protein, TNF-alpha converting enzyme (TACE), is a therapeutic target that is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/13\">",
"     13",
"    </a>",
"    ]. Although attractive in theory, this has a potential disadvantage in reducing secretion of TNF but not necessarily reducing membrane TNF expression. The latter may be of pathogenetic importance. Early clinical trial data have been disappointing, and future studies are awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inhibiting intracellular signaling pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of cytokine production can also be approached from the level of transcription factors and signal transduction pathways. Various kinase-dependent pathways have been targeted by kinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mitogen activated kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of the p38 mitogen-activated kinase (MAP kinase) pathway block TNF and IL-1 production [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/15\">",
"     15",
"    </a>",
"    ]. Although such agents are effective in various animal models of inflammation, many different MAP kinase inhibitors have failed in clinical trials and have been associated with significant adverse effects, particularly hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Intriguing early (two-week) beneficial effects on acute phase responses upon p38 blockade have not been sustained over the duration of three-month trials. This may reflect the combined pro- and antiinflammatory homeostatic effects of p38 in macrophages, such that inhibition leads to net neutral effects in the clinic.",
"   </p>",
"   <p>",
"    The possibility that inhibition of molecules &ldquo;upstream&rdquo; in the p38 MAP kinase signaling pathway (eg, MAP kinase kinase [MAPKK]) can reduce inflammatory cytokine production with a lower risk of toxicity is being actively investigated, as is the possibility that targeting MAPK expression in distinct tissues may offer better therapeutic utility. MAPKK3 and MAPKK6 have been implicated in the pathogenesis of inflammatory arthritis in model systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nuclear factor kappa B (NF-kB) inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;NF-kB is a ubiquitous transcription factor that regulates the expression of many proinflammatory cytokines and adhesion molecules. Gene therapy approaches that inhibit NF-kB may ameliorate joint swelling and destruction in the streptococcal cell wall arthritis model in rats [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/21\">",
"     21",
"    </a>",
"    ]. Small molecule inhibitors of the NF-kB complex are being sought.",
"   </p>",
"   <p>",
"    As an example, when NF-kB is associated with another protein (inhibitor of kappa B [IKB]), the complex is excluded from the nucleus. Phosphorylation of IKB by IKB kinase (IKK) leads to dissociation of the inhibitor from NF-kB and allows the transcription factor to pass into the nucleus, in which NF-kB dimers bind to and promote transcription of DNA. An inhibitor of IKK has antiinflammatory effects in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The broad regulatory activities of NF-kB in immune function and beyond, however, raise the possibility of unwanted adverse events upon therapeutic inhibition, and the likely toxicity to benefit ratio of novel agents is not easily predicted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INHIBITION OF CYTOKINE ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a cytokine gene has been expressed and the product has been released into the milieu, an alternative therapeutic approach is to bind or neutralize the factor. Another approach is to inhibit signal transduction by the cytokine receptors. Several different types of cytokine inhibitors have been tested in RA; the primary focus has been on the inhibition of TNF and IL-1, although several agents targeting other cytokines are in advanced trials. Increased production of these cytokines by synovial macrophages may play an important role in disease activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     TNF inhibition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anti-TNF antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most exciting advances in the therapy of RA was the demonstration of clinical efficacy of a monoclonal anti-TNF antibody. Proof of concept was obtained by administration of the mouse-human chimeric monoclonal antibody cA2 (now known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) to patients with RA resulting in rapid and impressive improvement in pain, swelling, and general sense of well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Subsequent studies have established the efficacy of anti-TNF antibodies in other rheumatic diseases including spondyloarthropathies (eg, ankylosing spondylitis, psoriatic arthritis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two fully human anti-TNF antibodies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , which are available. Similarly, polyethylene-glycolated Fab' fragment with anti-TNF reactivity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    (CDP870), has also been approved for use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of action of these antibodies is only beginning to be understood. It is likely to be multifactorial since TNF is involved in a number of processes including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endothelial cell activation",
"     </li>",
"     <li>",
"      Induction of metalloproteinases and adhesion molecules",
"     </li>",
"     <li>",
"      Growth of new blood vessels (angiogenesis)",
"     </li>",
"     <li>",
"      Regulation of other inflammatory cytokines",
"     </li>",
"     <li>",
"      Regulation of",
"      <span class=\"nowrap\">",
"       fibroblast/keratinocyte/enterocyte",
"      </span>",
"      activation",
"     </li>",
"     <li>",
"      Regulation of",
"      <span class=\"nowrap\">",
"       chondrocyte/osteoclast",
"      </span>",
"      activation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical efficacy with anti-TNF antibodies could, therefore, be a complex sum of the modulation of these activities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A synovial biopsy study found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      decreased adhesion molecule expression and cellularity, which is consistent with the many biological activities of TNF [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/28\">",
"       28",
"      </a>",
"      ]. Circulating levels of IL-1 and IL-6 are also decreased after treatment.",
"     </li>",
"     <li>",
"      Within affected joints, decreased expression of IL-8 and monocyte chemotactic protein-1 in the synovium, as well as reduced neutrophil transit (possibly due to lower levels of adhesion molecules), has been observed [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Angiogenesis is also significantly reduced, and lymphangiogenesis is increased, upon TNF blockade.",
"     </li>",
"     <li>",
"      Synovial biopsies of spondyloarthropathy patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      demonstrated reduced thickness of the synovial lining layer, reduced vascularity, and decreased vascular cell adhesion molecule 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In animal models, the destructive phase of arthritis appears to be more dependent on IL-1 than on TNF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in human studies, this has not been confirmed since TNF blockade does appear to be associated with retarding erosive progression. Several of the available TNF-blocking agents may retard or prevent articular damage even in the absence of clear clinical disease activity responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects of anti-TNF antibodies have been uncommon, but clinical experience with these agents is still progressing. It is mandatory to screen carefully for tuberculosis, and local guidelines have been produced in many countries for screening and for prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'Infliximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'Adalimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adverse effects of TNF inhibitors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Soluble TNF receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines mediate many of their activities through interactions with high-affinity surface receptors. These receptors can be shed from cell surfaces and can bind to soluble cytokines as a homeostatic mechanism to downregulate inflammation.",
"   </p>",
"   <p>",
"    Two TNF receptors have been identified (55 kD and 75 kD), and both can be released from activated cells. A form of the recombinant receptor genetically fused to the Fc portion of IgG (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ) has been used as a therapeutic agent in some rheumatic diseases, including RA, psoriatic arthritis, and ankylosing spondylitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'Etanercept'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One other TNF receptor inhibitor (p55 soluble receptor, onercept) was withdrawn from clinical development, despite efficacy, due to concerns regarding toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/33\">",
"     33",
"    </a>",
"    ]. Another soluble p55 TNFR based inhibitor, lenercept, failed in clinical trials.",
"   </p>",
"   <p>",
"    In many countries, the use of TNF blocking agents is governed by national prescribing guidelines, and the reader is referred to those for local advice and for information regarding registration of patients for safety and long-term efficacy follow-up studies. The latter are contained in national databases that have captured large numbers of patients with several rheumatic diseases and skin and inflammatory bowel disease (IBD) cohorts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other approaches to inhibition of TNF-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;A further intriguing approach is the generation of mutant forms of TNF-alpha whereby the TNF-alpha homotrimer is assembled with a mixture of native TNF-alpha monomers together with mutated TNF-alpha monomers that allow assembly of the stable TNF molecule but not subsequent functional receptor binding. This creates an effective receptor antagonist that has shown promise in preclinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/34\">",
"     34",
"    </a>",
"    ]. This approach is not thought to be under active exploration in clinical trials in rheumatic diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Interleukin-1 antagonism",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     IL-1 receptor antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to cytokine blockade involves use of a naturally occurring IL-1 antagonist. The IL-1 receptor antagonist (IL-1ra) is a glycoprotein produced by macrophages that competitively inhibits IL-1-alpha and IL-1-beta binding to IL-1 receptors (IL-1R) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/35\">",
"     35",
"    </a>",
"    ]. IL-1ra is a pure receptor antagonist since it does not induce signal transduction or internalization of the ligand-receptor complex. Although IL-1ra binds to the IL-1R with high affinity, 10- to 100-fold excess IL-1ra is needed to inhibit IL-1 activity. Human recombinant IL-1ra (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ) has received regulatory approval and is available for treatment of rheumatoid arthritis. It has not, however, proven of particular utility in the treatment of RA, and it is rarely used in RA due to its lower efficacy compared with other biologic disease-modifying antirheumatic drugs (DMARDs).",
"   </p>",
"   <p>",
"    Observational reports and controlled studies suggest it may be useful in treating other rheumatic disorders such as Still&rsquo;s disease and some of the so-called autoinflammatory conditions, such as neonatal onset multisystem inflammatory disease (NOMID) and the Muckle-Wells syndrome. Early data also suggest benefit in crystal-mediated arthropathies, particularly gout. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     IL-1 Trap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IL-1 Trap (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     rilonacept",
"    </a>",
"    ) incorporates two signaling chains of the cell surface IL-1 receptor linked by the Fc portion of IgG1 to form a soluble IL-1 binding protein with high affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/36\">",
"     36",
"    </a>",
"    ]. This agent is in clinical trials in children with juvenile idiopathic arthritis and in adults with RA. It is approved for use in NOMID in the United States.",
"   </p>",
"   <p>",
"    Anti-IL-1 monoclonal antibodies and anti-IL-1 receptor antibodies are in development. They have failed in RA but remain of interest in other IL-1-dependent conditions including the autoinflammatory disorders (see above) and gout. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link&amp;anchor=H11#H11\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Canakinumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other cytokine targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expansion of understanding of the immune pathogenesis of RA has lead to identification of a range of novel cytokine activities within the inflamed synovium. In general, the approach has been to identify the presence of a cytokine in synovial tissue, to measure its bioeffects in vitro in experimental synovial tissues, and, thereafter, to test the effect of neutralization in murine models of arthritis. This general principal was applied to the generation of TNF blocking medications. Several novel cytokine targeting agents are in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-6 is a proinflammatory cytokine originally described as B cell differentiation factor. IL-6 mediates pleiotropic functions in immunologic responses during host infection, inflammatory disease, hematopoiesis, and oncogenesis. IL-6 is expressed in RA synovial tissues and is implicated in upregulation of endothelial adhesion molecule expression, in osteoclast maturation, and in bone erosion.",
"   </p>",
"   <p>",
"    IL-6 utilizes a receptor comprising two functional chains, namely IL-6Ra and a 130 kD non-ligand binding but signal-transducing chain (gp130). IL-6 may bind",
"    <span class=\"nowrap\">",
"     IL-6R/gp130",
"    </span>",
"    complexes on target cells and may promote signals. However, expression of gp130 in the absence of IL-6Ra is widespread and confers on the expressing cell the capacity to respond to circulating",
"    <span class=\"nowrap\">",
"     IL-6/IL-6Ra",
"    </span>",
"    complex. Targeting IL-6Ra using a specific monoclonal antibody, namely a humanized anti-IL-6Ra antibody (IgG1), termed MRA (atlizumab,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ), therefore, offers a promising approach.",
"   </p>",
"   <p>",
"    Human studies in patients with RA have been performed with this agent, resulting in its approval in Europe, in Japan, in the United States, and elsewhere. Beneficial effects on disease activity, anemia, and bone erosion in RA have been demonstrated upon IL-6R blockade.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is also widely used in treatment of Still&rsquo;s disease and some forms of juvenile arthritis. Adverse events include hepatic, lipid, and hematologic events, which require further evaluation in larger safety cohorts. A range of antibodies are in development that target IL-6 directly; it remains to be seen if this offers a strategic advantage over targeting of the receptor itself.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'IL-6 inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link&amp;anchor=H5#H5\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Tocilizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Interleukin-12/interleukin-23",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-12 and interleukin (IL)-23 are members of a growing family of cytokines generated during the early phase of immune responses that regulate the type 1 and type 17 immune responses. IL-12 has been detected in RA synovial tissues but, when targeted in murine models of arthritis, has yielded somewhat contradictory results. It is not clear whether this reflects the suitability of IL-12 as a target or the lack of predictability of the model itself for subsequent utility in RA. There is also interest in the biology of IL-23 in RA pathogenesis, a cytokine that shares some structural similarities with IL-12 and that is also implicated in driving type 1 immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/37\">",
"     37",
"    </a>",
"    ]. IL-12 and IL-23 share a peptide chain (p40) that has been targeted with at least two monoclonal antibodies.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     Ustekinumab",
"    </a>",
"    <span class=\"nowrap\">",
"     (anti-IL-12/23)",
"    </span>",
"    inhibits IL-12 and IL-23 by this means and is available for use in psoriasis. Studies also suggest potential efficacy in psoriatic arthritis, although confirmatory phase III trials are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Interleukin-15",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-15 is an innate response cytokine that functions via a widely distributed heterotrimeric receptor that consists of a beta-chain (shared with IL-2) and common gamma-chain, together with a unique alpha-chain. IL-15 mediates a broad range of functional effects including activation of T cells, B cells, natural killer (NK) cells, and neutrophils. It has further effects in regulating cell survival and, in general, protects cell lineages from apoptosis (eg, T cells, NK cells, and fibroblasts).",
"   </p>",
"   <p>",
"    A fully human antibody, HuMax-IL15 (Genmab",
"    <span class=\"nowrap\">",
"     A/C/Amgen),",
"    </span>",
"    has been developed that is capable of binding not only soluble but also membrane-bound IL-15. HuMax-IL15 was effective in phase I and II clinical trials in patients with active RA providing biologic proof of concept. Larger studies, however, have not been pursued, and this should not be considered a therapeutic option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Interleukin-17",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-17 encompasses a family of homologous molecules with proinflammatory properties. Six members of the IL-17 family (IL-17A through IL-17F) have been identified. IL-17 levels are increased in synovial fluid in patients with RA, and IL-17A and IL-17F exhibit a plausible effector biologic profile. Early clinical trials in RA suggest that IL-17 blockade using monoclonal antibodies might be effective. Similarly, early studies suggest efficacy in psoriasis. Larger, appropriately controlled clinical trials are required before conclusions of practical relevance can be drawn. Soluble fusion proteins that incorporate the cognate portion of an IL-17 receptor may serve as therapeutic antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathogenesis of rheumatoid arthritis\", section on 'Cytokine networks in rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Interleukin-18",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-18 appears to be a mediator of interferon-gamma production, IL-8 release, and NF-kB mediated transcription of inflammatory cytokines; a human IL-18 binding protein was identified that effectively blocked these effects of IL-18 in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/39\">",
"     39",
"    </a>",
"    ]. Recombinant human IL-18 binding protein is being actively investigated for potential efficacy and safety in the treatment of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     GM-CSF receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a rekindling of interest in the therapeutic utility of targeting receptors of the colony stimulating factors GM-CSF. A randomized phase I study of mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-&alpha;, showed preliminary evidence of pharmacodynamic activity in patients on stable doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/41\">",
"     41",
"    </a>",
"    ]. The level of tolerability and safety was sufficient to support further clinical study. These studies are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     B cell survival cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several molecules that block the effector activities of the essential B cell survival cytokines APRIL and BAFF (BLyS) are in clinical trials in RA and in SLE. The studies in RA have been rather disappointing. However, one such agent that has received approval for use in some patients with systemic lupus is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    , an anti-BLyS monoclonal antibody. The outcome of further studies is awaited with interest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Receptor signal transduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pathways that mediate receptor signal transduction have been targeted by the use of small molecules that are kinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5878192\">",
"    <span class=\"h3\">",
"     JAK inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Janus kinases (JAK) are cytoplasmic protein tyrosine kinases that are critical for signal transduction to the nucleus from the common gamma chain of the plasma membrane receptors for interleukins-2, -4, -7, -9, -15, and -21.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"     Tofacitinib",
"    </a>",
"    (CP-690,550) is a small, orally active drug available in the US that preferentially inhibits JAK-1 and JAK-3, although it is active on all the JAK isoforms. It reduced signs and symptoms of disease activity in patients with RA in a series of phase II and phase III trials, including patients with active RA and inadequate responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), other traditional (nonbiologic) DMARDs, and TNF inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/42-47\">",
"     42-47",
"    </a>",
"    ]. The degree of benefit appeared at least comparable to the TNF inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , with which it was directly compared.",
"   </p>",
"   <p>",
"    The relative safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    appeared similar to that of biologic DMARDs, including increased risk of infections and liver function test abnormalities; additional concerns that require attention in clinical use include neutropenia, hyperlipidemia, and possible increased serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/42-44,46,47\">",
"     42-44,46,47",
"    </a>",
"    ]. The need for concurrent MTX therapy with use of tofacitinib is uncertain and requires further study.",
"   </p>",
"   <p>",
"    Two large phase III trials illustrate the clinical effects of this agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy and relative safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      monotherapy was demonstrated in a randomized trial involving 611 patients with an inadequate response to at least one nonbiologic or biologic DMARD [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/46\">",
"       46",
"      </a>",
"      ]. Either of two doses of tofacitinib (5 or 10 mg twice daily) resulted in clinically and statistically significant reductions in signs and symptoms of active RA after three months of treatment, upon assessment using the American College of Rheumatology 20 percent improvement measure (ACR20), compared with placebo (ACR20 of 60 and 66 percent versus 27 percent, respectively). Using the Disease Activity Score (DAS)-28, a combined response measure including the erythrocyte sedimentation rate (ESR), the proportion of patients achieving remission (a DAS28-4[ESR] &lt;2.6), did not differ significantly between the groups; the proportion of patients meeting criteria for low disease activity at three months was greater among the tofacitinib-treated patients (DAS28-4[ESR] &le;3.2 in 13 and 17 percent versus 5 percent, respectively). Physical function improved significantly in patients receiving tofacitinib. Serious infections were more common in the tofacitinib groups, as were increased levels of low-density lipoprotein (LDL) cholesterol and hepatic aminotransferases, mild increases in the serum creatinine, and reduced neutrophil counts.",
"     </li>",
"     <li>",
"      In a randomized trial involving 717 patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      showed similar benefit, compared with placebo, in patients with active RA and with an inadequate response to MTX who continued MTX co-therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/47\">",
"       47",
"      </a>",
"      ]. Tofacitinib (5 and 10 mg twice daily) and adalimumab (40 mg every two weeks administered subcutaneously) resulted, after six months, in clinically and statistically significant reductions in signs and symptoms of active RA, compared with placebo (ACR20 of 52, 53, and 47 percent versus 28 percent, respectively); statistically significant differences in the ACR20 and ACR50 were noted after one month. Physical function was improved, and rates of remission based upon the DAS28-4(ESR) were significantly higher after six months with the active treatments (6, 13, and 7 percent versus 1 percent, respectively).",
"      <br/>",
"      <br/>",
"      Aminotransferase elevations above the upper limit of normal were more common in patients on all active treatments compared with placebo (25 to 34 percent versus 8 to 10 percent). Neutrophil counts were decreased by 0.72 to",
"      <span class=\"nowrap\">",
"       1.25x10",
"       <sup>",
"        3",
"       </sup>",
"       /mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      with active treatments at month three but remained stable through 12 months of study. Anemia, usually mild, was also seen. There were small increases in serum creatinine and in low- and high-density lipoprotein cholesterol. Throughout the trial, serious infections occurred in 3.4, 4, and 1.5 percent of patients receiving tofacitinib (5 and 10 mg) and adalimumab, respectively; there were two cases of pulmonary tuberculosis, both in patients on tofacitinib 10 mg twice daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5878218\">",
"    <span class=\"h3\">",
"     Syk inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spleen tyrosine kinase (Syk) is an intracellular cytoplasmic tyrosine kinase that mediates immune receptor signaling in macrophages, neutrophils, mast cells, and B cells; it is important for cytokine and metalloproteinase production induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes in patients with RA. A small molecule orally administered inhibitor of Syk, R788 or fostamatinib disodium, has shown benefit in three phase II clinical trials for patients with active RA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the larger and longer phase II trial, 457 patients with active RA despite treatment with MTX were randomly assigned to receive one of two doses of R788 (100 mg",
"    <span class=\"nowrap\">",
"     twice/day",
"    </span>",
"    or 150 mg",
"    <span class=\"nowrap\">",
"     once/day)",
"    </span>",
"    or placebo, while continuing MTX. Patients receiving R788 showed significant benefit after six months (ACR20 of 67 and 57 percent versus 35 percent, respectively). Adverse events included diarrhea, neutropenia, elevated liver enzyme levels, and hypertension. Similar proportions of patients withdrew from the study due to adverse events (3, 7, and 4 percent, respectively). These benefits are similar to those observed with parenterally administered biologic agents. One study in patients who had previously failed TNF inhibitors did not show benefit with this agent; this may have reflected trial design or true biologic issues.",
"   </p>",
"   <p>",
"    Preliminary reports of aggregated data from the phase II trials confirm the observations that infections, including serious infections, appear increased in the first six months of therapy and that neutropenia and liver test abnormalities can be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/45\">",
"     45",
"    </a>",
"    ]. Diarrhea and hypertension are more common with fostamatinib compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    , while anemia, increased creatinine, and lipid elevations are less frequent. Further studies are required to adequately assess benefit and safety of this oral agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ADMINISTRATION OF INHIBITORY CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of suppressive cytokines produced in normal immune responses that limit the extent and severity of inflammation. In the absence of these factors, inflammatory processes are exaggerated and can lead to pathologic conditions. Thus, one possible approach to the treatment of rheumatic disease is to supply exogenous suppressive cytokines in an attempt to downregulate the overactive response. The following are some examples of possible cytokine activities with inhibitory potential. However, at this stage, few have shown convincing efficacy in clinical studies, and it remains unclear whether this approach can truly reestablish immune homeostasis necessary for therapeutic benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Transforming growth factor-beta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transforming growth factor (TGF)-beta is a prototypic example of a suppressive cytokine that down-regulates a variety of immunologic functions. Parenteral administration can suppress arthritis in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/51\">",
"     51",
"    </a>",
"    ]. TGF-beta is the major T-cell inhibitor in RA synovial fluid, and some animal studies suggest that systemic TGF-beta exposure can decrease synovial inflammation. One potentially confounding observation is that TGF-beta is already abundant in the joint; it is, therefore, not certain whether the administration of additional exogenous growth factor would be useful. TGF-beta may also have proinflammatory effects in RA and may actually contribute to pannus formation and to cartilage destruction. Another concern relates to profibrotic properties of TGF-beta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Interleukin-4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-4 is another cytokine that could be used to suppress synovitis. It is a T-cell product that is essentially absent from the joint, which contributes to arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/52\">",
"     52",
"    </a>",
"    ]. In vitro studies show that IL-4 inhibits cytokine and protease production by cultured synovial tissue explants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Interferon-gamma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon (IFN)-gamma is generally not thought of as a suppressive cytokine. Originally believed to be a pivotal proinflammatory factor in RA, IFN-gamma actually inhibits some aspects of cytokine-mediated synoviocyte activation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/54\">",
"     54",
"    </a>",
"    ]. The relative lack of IFN-gamma in the rheumatoid synovium may result in unopposed TNF stimulation and may contribute to disease perpetuation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of pharmacologic doses of IFN-gamma has been tested in patients with RA and appears to be of modest clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/55\">",
"     55",
"    </a>",
"    ]. This result is strikingly different from that in patients with multiple sclerosis in whom the administration of IFN-gamma increases the frequency and severity of disease flares [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/56\">",
"     56",
"    </a>",
"    ]. There is a further paradox in that IFN-gamma blockade using a neutralizing antibody may also have accrued clinical benefit in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/57\">",
"     57",
"    </a>",
"    ]. IFN-gamma does not appear to be an attractive target for modulation in RA, although further investigation in other disorders such as systemic sclerosis may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Interleukin-10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-10 has potent anticytokine activity and could be useful in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/58\">",
"     58",
"    </a>",
"    ]. However, as observed with TGF-beta, substantial amounts are already produced by the synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/59\">",
"     59",
"    </a>",
"    ]. One clinical trial with IL-10 in RA reported no improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/60\">",
"     60",
"    </a>",
"    ]; another study demonstrated improvement in psoriasis but not in psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/61\">",
"     61",
"    </a>",
"    ]. Mild anemia and thrombocytopenia were noted during treatment of patients with inflammatory bowel disease with high doses of IL-10 (eg, 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    effects that were reversible upon discontinuation of the agent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Interleukin-11",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-11, a member of the IL-6 family, has a number of activities that could be useful in treating RA. In vitro, for example, IL-11 decreases IL-1 and TNF production. It also has been shown to provide therapeutic benefit in murine collagen induced arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/63\">",
"     63",
"    </a>",
"    ]. However, in one study of patients with RA, no benefit was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     BLOCKADE OF CYTOKINE FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative strategy to decrease cytokine concentrations in the joint is the selective blockade of specific cytokine functions. If this could be accomplished, the cytokine milieu would be left intact, but the deleterious effects would be prevented. It is unclear, however, whether sufficient specificity of function can be achieved to derive therapeutic benefit.",
"   </p>",
"   <p>",
"    Several cytokine downstream actions contribute to morbidity in RA and are potential targets. Perhaps the most promising targets are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Production of metalloproteinases",
"     </li>",
"     <li>",
"      Expression of adhesion molecules",
"     </li>",
"     <li>",
"      Production and regulation of a variety of small molecule mediators, such as prostaglandins, leukotrienes, and bradykinin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Metalloproteinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone and cartilage destruction is mediated by proteolytic enzymes, including serine proteases, cysteine proteases, and, particularly, matrix metalloproteinases (MMP) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The synovial intimal lining is the primary source of these enzymes. Cytokines such as IL-1 and TNF are produced by local macrophages and induce expression of proteases (eg, collagenase and stromelysin) by synovial fibroblasts in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While suppression of MMP gene expression by inhibiting proinflammatory cytokines is possible, a more direct approach is equally plausible. One could use more traditional medicinal chemistry techniques to synthesize specific protease inhibitors. With this approach, the cytokine network would be unaffected, and the proteases would still be produced. Joint destruction, however, would be prevented by the inhibitor.",
"   </p>",
"   <p>",
"    A collagenase inhibitor has been tested in an animal model of arthritis, and joint destruction was markedly decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/68\">",
"     68",
"    </a>",
"    ]. Joint swelling was also suppressed, suggesting that metalloproteinases contribute to inflammation as well as joint destruction.",
"   </p>",
"   <p>",
"    Developers of novel metalloproteinase inhibitors have been frustrated by the frequent occurrence of musculoskeletal symptoms such as arthralgia and myalgia when nonspecific inhibitors have been used in clinical trials as cancer chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .) An agent (S-3304) which more specifically inhibits MMP-2 and MMP-9 than MMP-1 rarely produced musculoskeletal symptoms or headaches in 48 healthy volunteers but was associated with reversible elevation of serum aminotransferases in one subject [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Adhesion molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second potential target for indirect anticytokine therapy is interference with cell trafficking in the synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/70\">",
"     70",
"    </a>",
"    ]. IL-1 and TNF induce adhesion molecule expression by synovial endothelial cells; the adhesion molecules subsequently recruit cells from the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibition of cell adhesion is under active clinical investigation. The most advanced strategy is to administer anti-ICAM-1 antibody to block CD18-mediated binding of circulating leukocytes to activated endothelium. There is little published information on these approaches in chronic models of arthritis. A preliminary study of treatment with a monoclonal anti-ICAM antibody in RA suggested that some clinical improvement could be achieved concomitant with suppression of delayed type hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/71\">",
"     71",
"    </a>",
"    ]. In this study, 32 refractory patients were treated with increasing doses of antibody. Thirteen of 23 patients who received a five-day course had evidence of improvement for a period of up to one month. Peripheral lymphocytosis was observed (perhaps because cells could not enter the tissues), and several patients developed cutaneous anergy. However, toxicity occurred as the anti-ICAM-1 antibody, which is derived from the mouse, is immunogenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Small molecule mediators of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines are, in large part, responsible for regulating production of many small molecule mediators of inflammation. As examples, IL-1 and TNF increase production of prostaglandins and leukotrienes by synoviocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/72\">",
"     72",
"    </a>",
"    ]. These arachidonic acid metabolites increase vascular permeability, act as chemoattractants, and enhance nociception. As a result, suppression of arachidonic acid metabolism by enzyme inhibitors (eg, nonsteroidal antiinflammatory drugs [NSAIDs]) has proven to be an effective symptomatic approach in RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of other small molecule mediators are potential targets in RA, including neuropeptides and bradykinin. Other possible targets are important enzymes that are regulated by cytokines (eg, phospholipase A2, COX-2, and many others).",
"   </p>",
"   <p>",
"    Agents that are highly selective for the COX-2 isoform of cyclooxygenase are available for clinical use. While these drugs have largely fulfilled the promise of reduced gastroduodenal toxicity, some unanticipated adverse cardiovascular effects have been noted, particularly with two highly selective COX-2 inhibitors, rofecoxib and valdecoxib, which have been withdrawn from the market. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     RECEPTOR TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another anticytokine approach is to use specific cytokine receptors as a way to kill or inactivate cells. Cells that express the IL-2 receptor represent one potential target. High-affinity IL-2 receptors are displayed by activated T and B cells. If these cells were selectively killed, then the immune process in the synovium could theoretically be suppressed. In order to accomplish this goal, a recombinant fusion protein comprised of IL-2 and diphtheria toxin has been developed. This recombinant protein would selectively deliver the toxin to cells expressing the IL-2 receptor.",
"   </p>",
"   <p>",
"    Clinical trials have been performed in RA using this chimeric molecule, producing very little benefit despite substantial toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/22/16746/abstract/73\">",
"     73",
"    </a>",
"    ]. The lack of efficacy suggests that high-affinity IL-2 receptor-bearing cells (which are primarily lymphocytes) are not essential in RA. Alternatively, it is possible that antidiphtheria toxin antibodies could prevent the protein from expressing full activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H187421082\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several strategies are potentially effective for inhibition of cytokine production. A number of small molecules are transcriptional inhibitors of cytokine production, including some agents in clinical use, such as glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , phosphodiesterase inhibitors, and adenosine receptor agonists. Additional agents block posttranslational processing, for example, by inhibition of interleukin (IL)-1 beta or tumor necrosis factor (TNF)-alpha converting enzymes. Other agents inhibit intracellular signalling, such as mitogen activated kinase inhibitors and nuclear factor kappa B inhibitors; most approaches of this nature, however, have been disappointing in clinic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inhibition of cytokine production'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Other inhibitors of cytokine gene transcription'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Inhibiting posttranslational processing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Inhibiting intracellular signaling pathways'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another therapeutic approach is the inhibition of cytokine action. Agents in clinical use include inhibitors of TNF, such as anti-TNF antibodies and soluble TNF receptors; IL-1 antagonists, including the IL-1 receptor antagonist, IL-1 trap, and monoclonal antibodies against IL-1; anti-IL-6 receptor monoclonal antibody; a monoclonal antibody against IL-12 and IL-23; and an anti-B lymphocyte stimulator monoclonal antibody. Biologics in development target IL-15, IL-17, IL-18, and the GM-CSF receptor. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Inhibition of cytokine action'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'TNF inhibition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Interleukin-1 antagonism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Other cytokine targets'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'GM-CSF receptor'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'B cell survival cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small molecule inhibitors of receptor signal transduction in development include inhibitors of the Janus kinase family and spleen tyrosine kinase. Of these,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      is in the most advanced stage of development. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inhibiting intracellular signaling pathways'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another possible approach to the treatment of rheumatic disease is to supply exogenous suppressive cytokines in an attempt to downregulate the overactive immune response. Few therapies under consideration have shown convincing efficacy in clinical studies, and it remains unclear whether this approach can truly reestablish immune homeostasis necessary for therapeutic benefits. Such agents include transforming growth factor-beta, IL-4, interferon-gamma, IL-10, and IL-11. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Administration of inhibitory cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative strategy to decrease cytokine concentrations in the joint is the selective blockade of specific cytokine functions. It is unclear whether sufficient specificity of function can be achieved to derive therapeutic benefit. Agents under study include inhibitors of metalloproteinases, adhesion molecules, and novel small molecule mediators of inflammation. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Blockade of cytokine function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38\">",
"       'Metalloproteinases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H39\">",
"       'Adhesion molecules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Small molecule mediators of inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another anticytokine approach, which has not shown significant benefit, is the targeting of specific cytokine receptors as a way to kill or inactivate potentially pathogenic cells. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Receptor targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/1\">",
"      Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/2\">",
"      Sajjadi FG, Takabayashi K, Foster AC, et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996; 156:3435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/3\">",
"      Huizinga TW, Dijkmans BA, van der Velde EA, et al. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996; 55:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/4\">",
"      Baharav E, Bar-Yehuda S, Madi L, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005; 32:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/5\">",
"      Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005; 32:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/6\">",
"      Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol 1995; 25:2899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/7\">",
"      Kiely PD, Johnson D, Bourke BE. An open study of oxpentifylline in early rheumatoid arthritis. Br J Rheumatol 1998; 37:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/8\">",
"      Dubost JJ, Soubrier M, Ristori JM, et al. An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis. Rev Rhum Engl Ed 1997; 64:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/9\">",
"      Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/10\">",
"      van Troostenburg AR, Clark EV, Carey WD, et al. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004; 42:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/11\">",
"      Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/12\">",
"      Pavelka K, Kuba V, Moeller J, et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin -1beta converting enzyme (ICE) inhibitor, in a 285 patient PhII trial in rheumatoid arthritis (abstract). Arthritis Rheum 2002; 46:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/13\">",
"      Zhang Y, Xu J, Levin J, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 2004; 309:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/14\">",
"      Bonilla-Hern&aacute;n MG, Miranda-Car&uacute;s ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford) 2011; 50:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/15\">",
"      Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999; 42:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/16\">",
"      Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/17\">",
"      Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/18\">",
"      Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/19\">",
"      Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009; 60:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/20\">",
"      Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010; 69:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/21\">",
"      Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 1998; 95:13859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/22\">",
"      Okazaki Y, Sawada T, Nagatani K, et al. Effect of nuclear factor-kappaB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. J Rheumatol 2005; 32:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/23\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/24\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/25\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/26\">",
"      Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/27\">",
"      Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/28\">",
"      Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/29\">",
"      Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/30\">",
"      Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/31\">",
"      van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/32\">",
"      Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/33\">",
"      Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs 2003; 4:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/34\">",
"      Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003; 301:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/35\">",
"      Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/36\">",
"      Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/37\">",
"      Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/38\">",
"      Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007; 179:5462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/39\">",
"      Gracie JA, Forsey RJ, Chan WL, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/40\">",
"      Dinarello CA. Interleukin-18 and the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/41\">",
"      Burmester GR, Feist E, Sleeman MA, et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-&alpha;, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011; 70:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/42\">",
"      Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/43\">",
"      Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/44\">",
"      Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/45\">",
"      Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/46\">",
"      Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/47\">",
"      van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/48\">",
"      Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58:3309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/49\">",
"      Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/50\">",
"      Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/51\">",
"      Brandes ME, Allen JB, Ogawa Y, Wahl SM. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/52\">",
"      Miossec P, Naviliat M, Dupuy d'Angeac A, et al. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum 1990; 33:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/53\">",
"      Miossec P, Briolay J, Dechanet J, et al. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum 1992; 35:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/54\">",
"      Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990; 86:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/55\">",
"      Cannon GW, Emkey RD, Denes A, et al. Prospective two-year followup of recombinant interferon-gamma in rheumatoid arthritis. J Rheumatol 1990; 17:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/56\">",
"      Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/57\">",
"      Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001; 30:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/58\">",
"      Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993; 11:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/59\">",
"      Cush JJ, Splawski JB, Thomas R, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/60\">",
"      Maini RN, Paulus H, Breedveld FC, et al. rhuIL-10 in subjects with active rheumatoid arthritis (RA): a Phase I and cytokine response study (abstract). Arthritis Rheum 1997; 40:S224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/61\">",
"      McInnes IB, Illei GG, Danning CL, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001; 167:4075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/62\">",
"      Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/63\">",
"      Walmsley M, Butler DM, Marinova-Mutafchieva L, Feldmann M. An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology 1998; 95:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/64\">",
"      Moreland LW, Chase W, Fife R, et al. Phase I/II study evaluating the safety and potential efficacy of recombinant interleukin-11 in patients with refractory rheumatoid arthritis (abstract). Arthritis Rheum 1999; 42:S171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/65\">",
"      Firestein GS. Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis. Curr Opin Rheumatol 1992; 4:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/66\">",
"      Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/67\">",
"      Firestein GS, Paine MM. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 1992; 140:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/68\">",
"      Conway JG, Wakefield JA, Brown RH, et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995; 182:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/69\">",
"      van Marle S, van Vliet A, Sollie F, et al. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther 2005; 43:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/70\">",
"      Cronstein BN, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993; 36:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/71\">",
"      Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/72\">",
"      Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/22/16746/abstract/73\">",
"      Moreland LW, Sewell KL, Trentham DE, et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum 1995; 38:1177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7982 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16746=[""].join("\n");
var outline_f16_22_16746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H187421082\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INHIBITION OF CYTOKINE PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other inhibitors of cytokine gene transcription",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adenosine agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inhibiting posttranslational processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - IL-1 beta converting enzyme (ICE) inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - TNF-alpha converting enzyme (TACE) inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inhibiting intracellular signaling pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mitogen activated kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nuclear factor kappa B (NF-kB) inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INHIBITION OF CYTOKINE ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TNF inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anti-TNF antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Soluble TNF receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other approaches to inhibition of TNF-alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Interleukin-1 antagonism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - IL-1 receptor antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - IL-1 Trap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other cytokine targets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Interleukin-12/interleukin-23",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Interleukin-15",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Interleukin-17",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Interleukin-18",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      GM-CSF receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      B cell survival cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Receptor signal transduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5878192\">",
"      - JAK inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5878218\">",
"      - Syk inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ADMINISTRATION OF INHIBITORY CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Transforming growth factor-beta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Interleukin-4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Interferon-gamma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Interleukin-10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Interleukin-11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      BLOCKADE OF CYTOKINE FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Metalloproteinases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Adhesion molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Small molecule mediators of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      RECEPTOR TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H187421082\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_22_16747="Anomalies with malrotation";
var content_f16_22_16747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anomalies associated with intestinal malrotation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Congenital diaphragmatic hernia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal wall defects (omphalocele and gastroschisis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duodenal atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jejunoileal atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meckel diverticulum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duodenal web or stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hirschsprung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imperforate anus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal atresia with tracheoesophageal fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prune belly syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Situs inversus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right isomerism syndromes (polysplenia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left isomerism syndromes (asplenia)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16747=[""].join("\n");
var outline_f16_22_16747=null;
var title_f16_22_16748="Lab diagnosis fibrinolysis";
var content_f16_22_16748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory diagnosis of abnormal fibrinolysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary hyperfibrinolysis",
"       </td>",
"       <td class=\"subtitle1\">",
"        DIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        TTP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet count",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrinogen",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FDP",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D-dimer",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithrombin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistocytes",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma clotting times",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Euglobulin lysis time",
"       </td>",
"       <td>",
"        Shortened",
"       </td>",
"       <td>",
"        Shortened",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADAMTS13 level",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal*",
"       </td>",
"       <td>",
"        Low (usually &lt;10 percent)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DIC: disseminated intravascular coagulation; TTP: thrombotic thrombocytopenic purpura; FDP: fibrinogen degradation products; ADAMTS13: von Willebrand factor-cleaving protease (A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).&nbsp;",
"     <br>",
"      * May be reduced when bacterial sepsis is present.",
"      <br>",
"       &bull; A normal plasma ADAMTS13 level does not&nbsp;exclude the diagnosis of TTP.&nbsp;",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rocha E, Paramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management. Haematologica 1998; 83:1024. Copyright &copy; 1998 Ferrata Storti Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16748=[""].join("\n");
var outline_f16_22_16748=null;
var title_f16_22_16749="Risk of intracranial bleed with thrombolytic therapy";
var content_f16_22_16749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of intracranial hemorrhage from thrombolytic therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 163px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the GUSTO-I trial, increasing age and systolic pressure and, not shown, increasing diastolic pressure and decreasing body weight were associated with an increased probability of intracranial hemorrhage in patients who received thrombolytic therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gore JM, Granger CB, Simoons ML, et al for the GUSTO-I Investigators. Circulation 1995; 92:2811.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16749=[""].join("\n");
var outline_f16_22_16749=null;
var title_f16_22_16750="Transplant vasculopathy and age";
var content_f16_22_16750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Donor age and preexisting coronary artery disease predict transplant vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence of allograft coronary artery disease (TxCAD) is greater in those who receive a heart from a donor with CAD (left panel). New TxCAD is less frequent during the first three years and occurs later in patients receiving a donor heart from younger (&lt;40 years) compared to older donors (right panel). However, at five years there is no significant difference between older and younger donors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gao, SZ, Hunt, SA, Alderman, EL, et al, J Am Coll Cardiol 1997; 29:623.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16750=[""].join("\n");
var outline_f16_22_16750=null;
var title_f16_22_16751="Ultrasound ulnar nerve at the elbow";
var content_f16_22_16751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/64956/US_ulnar_ner_elbow_upd_conv.mp4?title=Ultrasound+ulnar+nerve+at+the+elbow\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound ulnar nerve at the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an axial view of the left elbow in a patient with subluxation of the ulnar nerve. At the beginning of the video, the medial epicondyle is between the two arrows; the ulnar nerve (right arrow) is in its normal position just lateral to the medial epicondyle. As the elbow is flexed from 70 to 130 degrees, the ulnar nerve pops out of the ulnar groove to a position just medial to the medial epicondyle (left arrow). As the elbow re-extends, the ulnar nerve pops back into the groove. The patient reports a slightly uncomfortable sensation with sudden translocation of the nerve each time the elbow flexion/extension movement is repeated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_22_16751=[""].join("\n");
var outline_f16_22_16751=null;
